BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
b cell diffuse large cell lymphoma of the mediastinum 2005:2010[pubdate] *count=100
130 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
b cell diffuse large cell lymphoma of the mediastinum
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 130
1.
Wessendorf S, Barth TF, Viardot A, Mueller A, Kestler HA, Kohlhammer H, Lichter P, Bentz M, Döhner H, Möller P, Schwaenen C:
Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).
Leukemia
; 2007 Dec;21(12):2463-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Further delineation of chromosomal consensus regions in
primary mediastinal
B-
cell
lymphomas
: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).
Primary mediastinal
B-
cell lymphoma
(
PMBL
) is an aggressive extranodal B-
cell
non-Hodgkin's
lymphoma
with specific clinical, histopathological and genomic features.
To characterize further the genotype of
PMBL
, we analyzed 37 tumor samples and
PMBL
cell
lines Med-B1 and Karpas1106P using array-based comparative genomic hybridization (matrix- or array-CGH) to a 2.8k genomic microarray.
[MeSH-major]
Chromosome Aberrations. Consensus Sequence. Gene Expression Profiling / methods.
Lymphoma
, B-
Cell
/ genetics.
Mediastinal
Neoplasms / genetics
[MeSH-minor]
Adult. Apoptosis / genetics.
Cell
Line, Tumor / metabolism. Chromosome Deletion. Female. Gene Amplification. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Janus Kinases / genetics. Janus Kinases / metabolism. Male. Middle Aged. NF-kappa B / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. STAT Transcription Factors / genetics. STAT Transcription Factors / metabolism
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17728785.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / STAT Transcription Factors; EC 2.7.10.2 / Janus Kinases
2.
Weniger MA, Pulford K, Gesk S, Ehrlich S, Banham AH, Lyne L, Martin-Subero JI, Siebert R, Dyer MJ, Möller P, Barth TF:
Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.
Leukemia
; 2006 Oct;20(10):1880-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in
primary mediastinal
B-
cell lymphoma
.
[MeSH-major]
Carrier Proteins / genetics. Carrier Proteins / metabolism. Gene Expression Regulation, Neoplastic.
Lymphoma
, B-
Cell
/ genetics.
Mediastinal
Neoplasms / genetics. Nuclear Proteins / genetics. Nuclear Proteins / metabolism
[MeSH-minor]
Cell
Nucleus / metabolism. Humans
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16871282.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / MC/ U132670597
[Publication-type]
Letter; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / BCL11A protein, human; 0 / Carrier Proteins; 0 / Nuclear Proteins
3.
Rodríguez J, Gutiérrez A, Piris M:
Primary mediastinal B-cell lymphoma: treatment and therapeutic targets.
Leuk Lymphoma
; 2008 Jun;49(6):1050-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
B-
cell lymphoma
: treatment and therapeutic targets.
Primary mediastinal
B-
cell lymphoma
(PMBCL) is a recognised
subtype
of diffuse large B
-
cell lymphoma
according to the WHO classification that represents approximately 5% of aggressive
lymphomas
, and 2% of all cases of
lymphomas
.
It presents with unique clinical,
morphologic
and immunophenotypic characteristics that define the disease.
[MeSH-major]
Lymphoma
, B-
Cell
/ therapy.
Mediastinal
Neoplasms / therapy
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18452109.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
[Number-of-references]
78
Advertisement
4.
Andriamparany J, Margery J, Grand B, Saint-Blancard P:
[Primary mediastinal large B-cell lymphoma: histopathologic features. A specific tumour].
Rev Pneumol Clin
; 2010 Jun;66(3):191-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Primary mediastinal
large B
-
cell lymphoma
: histopathologic features. A specific tumour].
[Transliterated title]
Le
lymphome
B à
grandes cellules primitif du mediastin
, une tumeur particulière. Aspects anatomopathologiques.
The diffuse large B
-
cell
lymphomas
of the
mediastinum
were long considered to be a variant of the classic forms
of large
B-
cell
lymphomas
.
However, their clinical and radiological features and especially their histopathological variants point to other lymphoid tumours such as Hodgkin's disease or anaplastic
lymphomas
,
thymic
tumours, germ
cell
tumours or metastatic tumors.
The immunohistochemical findings are of prime importance in the
diagnosis
.
Currently, they represent a distinct entity among
the large
B-
cell
lymphomas
, due to their clinical, pathological and molecular features as well as the outcome.
[MeSH-major]
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Elsevier Masson SAS. All rights reserved.
(PMID = 20561485.001).
[ISSN]
0761-8417
[Journal-full-title]
Revue de pneumologie clinique
[ISO-abbreviation]
Rev Pneumol Clin
[Language]
fre
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
France
5.
Eberle FC, Mani H, Jaffe ES:
Histopathology of Hodgkin's lymphoma.
Cancer J
; 2009 Mar-Apr;15(2):129-37
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Histopathology of Hodgkin's
lymphoma
.
In the last few years, there has been a greater understanding of the spectrum and biology of Hodgkin's
lymphoma
.
In standard texts, Hodgkin's
lymphoma
is classified as 2 distinct entities, namely nodular lymphocyte predominant Hodgkin's
lymphoma
and classical Hodgkin's
lymphoma
.
However, recent evidence suggests that classical Hodgkin's
lymphoma
is not a single disease.
Although the mixed cellularity and lymphocyte-depleted subtypes may be part of a biologic continuum, the nodular sclerosis
subtype
has a distinct epidemiology, clinical presentation, and histology.
Nodular sclerosis Hodgkin's
lymphoma
, particularly those cases presenting with
mediastinal
disease, also seems related to
primary mediastinal
B-
cell lymphoma
.
As Hodgkin's
lymphoma
is a B-
cell
neoplasm, there is also a better appreciation today of cases that may be borderline with conventional B-
cell
lymphomas
.
We present an update on the histopathological features of Hodgkin's
lymphoma
and the immunohistochemical tools available for
diagnosis
in the clinical setting.
[MeSH-minor]
History, 19th Century. History, 20th Century. Humans. Immunohistochemistry. Lymphocytes / pathology.
Lymphoma
, B-
Cell
/ classification.
Lymphoma
, B-
Cell
/ history.
Lymphoma
, B-
Cell
/ pathology
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19390308.001).
[ISSN]
1528-9117
[Journal-full-title]
Cancer journal (Sudbury, Mass.)
[ISO-abbreviation]
Cancer J
[Language]
eng
[Publication-type]
Historical Article; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
118
6.
Noguchi T, Nohara J, Sakaguchi Y, Kono T, Terada Y:
[Case of malignant lymphoma associated with rheumatoid arthritis].
Nihon Kokyuki Gakkai Zasshi
; 2008 Feb;46(2):131-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Case of
malignant
lymphoma
associated with rheumatoid arthritis].
Chest radiograph and chest CT revealed marked
mediastinal
and right axillary lymph node swelling, interstitial shadows and bilateral pleural effusion.
A biopsy of the right axillary lymph node for histopathological examination revealed
diffuse large B cell lymphoma
.
As RA is associated with an increased risk of developing
lymphoma
,
malignant
lymphoma
must be considered as a possible cause of the
mediastinal
swelling in a patient with RA.
[MeSH-major]
Arthritis, Rheumatoid / complications.
Lymphoma
, B-
Cell
/ drug therapy.
Lymphoma
, B-
Cell
/ etiology
[MeSH-minor]
Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage.
Diagnosis
, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / radiography.
Mediastinum
. Methotrexate / therapeutic use. Prednisolone / administration & dosage. Remission Induction. Rituximab. Tomography, X-Ray Computed. Vincristine / administration & dosage
Genetic Alliance.
consumer health - Arthritis
.
Genetic Alliance.
consumer health - Rheumatoid arthritis
.
MedlinePlus Health Information.
consumer health - Rheumatoid Arthritis
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18318257.001).
[ISSN]
1343-3490
[Journal-full-title]
Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
[ISO-abbreviation]
Nihon Kokyuki Gakkai Zasshi
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
7.
Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA:
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
Blood
; 2005 Aug 15;106(4):1392-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
NFkappaB activity, function, and target-gene signatures in
primary mediastinal
large B
-
cell lymphoma
and
diffuse large
B-
cell lymphoma
subtypes.
Primary mediastinal
large B
-
cell lymphoma
(MLBCL) shares important clinical and molecular features with classic Hodgkin
lymphoma
, including nuclear localization of the nuclear factor kappaB (NFkappaB) subunit c-REL (reticuloendotheliosis viral oncogene homolog) in a pilot series.
Herein, we analyzed c-REL subcellular localization in additional
primary
MLBCLs and characterized NFkappaB activity and function in a MLBCL
cell
line.
The new
primary
MLBCLs had prominent c-REL nuclear staining, and the MLBCL
cell
line exhibited high levels of NFkappaB binding activity.
MLBCL cells expressing a superrepressor form of inhibitor of kappa B alpha signaling (IkappaB alpha) had a markedly higher rate of apoptosis, implicating constitutive NFkappaB activity in MLBCL
cell
survival.
The transcriptional profiles of newly diagnosed
primary
MLBCLs and
diffuse large
B-
cell
lymphomas
(DLBCLs) were then used to characterize the NFkappaB target gene signatures of MLBCL and specific DLBCL subtypes.
MLBCLs expressed increased levels of NFkappaB targets that promote
cell
survival and favor antiapoptotic tumor necrosis factor alpha (TNFalpha) signaling.
In contrast, activated
B cell
(ABC)-like DLBCLs had a more restricted, potentially developmentally regulated, NFkappaB target gene signature.
Of interest, the newly characterized host response DLBCL
subtype
had a robust NFkappaB target gene signature that partially overlapped that of
primary
MLBCL.
In this
large
series of
primary
MLBCLs and DLBCLs, NFkappaB activation was not associated with amplification of the cREL locus, suggesting alternative pathogenetic mechanisms.
[MeSH-major]
Gene Expression Regulation, Neoplastic.
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / pathology. NF-kappa B / physiology. Proto-Oncogene Proteins c-rel / genetics
[MeSH-minor]
Apoptosis.
Cell
Line, Tumor. Gene Expression Profiling. Humans
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15870177.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-rel
8.
Rehm A, Anagnostopoulos I, Gerlach K, Broemer M, Scheidereit C, Jöhrens K, Hübler M, Hetzer R, Stein H, Lipp M, Dörken B, Höpken UE:
Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma.
Int J Cancer
; 2009 Nov 15;125(10):2367-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of a chemokine receptor profile characteristic for
mediastinal
large B
-
cell lymphoma
.
Mediastinal
large B
-
cell
lymphomas
(MLBCLs) are considered as
a subtype
of diffuse large B
-
cell lymphoma
; however, they exhibit completely different patterns of dissemination.
Since they share a number of surface markers with
thymic
B cells, a close relationship was assumed.
MLBCLs arise extranodally within the anterior
mediastinum
and have a low propensity to metastasize.
To address the preferential positioning of MLBCL, we focused on homeostatic chemokines involved in B-
cell
compartmental homing in secondary lymphoid organs, which are also capable of shaping lymphoid niches in ectopic sites.
Flow cytometry was used to identify the chemokine receptor profile on an MLBCL-derived
cell
line, Karpas1106 and on
thymic
B cells.
Using immunohistochemistry, we obtained an unexpectedly low-expression frequency for the chemokine receptors CXCR5 and CCR7 in
primary
lesions.
Although the mature B-
cell
marker CCR6 was absent in most cases, the lineage aberrant marker CCR9 emerged in the majority of MLBCL cases.
MLBCLs exhibit a diagnostic chemokine receptor profile that is instrumental in the discrimination from
diffuse large
B-
cell lymphoma
not otherwise specified and classical Hodgkin
lymphoma
.
Furthermore, we suggest that low-abundance expression of CCR7 and CXCR5 may hinder
lymphoma
cells from nodal dissemination.
[MeSH-major]
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ metabolism.
Mediastinal
Neoplasms / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR5 / metabolism
[MeSH-minor]
Adolescent. B-Lymphocytes / metabolism.
Cell
Movement. Cells, Cultured. Chemotaxis. Child. Child, Preschool. Electrophoretic Mobility Shift Assay. Flow Cytometry. Humans. Immunoenzyme Techniques. Infant. NF-kappa B / metabolism.
Thymus
Gland / cytology.
Thymus
Gland / metabolism. Young Adult
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19536742.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CCR7 protein, human; 0 / CXCR5 protein, human; 0 / NF-kappa B; 0 / Receptors, CCR7; 0 / Receptors, CXCR5
9.
Miles RR, Mankey CC, Seiler CE 3rd, Smith LB, Teruya-Feldstein J, Hsi ED, Elenitoba-Johnson KS, Lim MS:
Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
Hum Pathol
; 2009 Dec;40(12):1731-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of Grb2 distinguishes classical Hodgkin
lymphomas
from
primary mediastinal
B-
cell
lymphomas
and other
diffuse large
B-
cell
lymphomas
.
Growth factor receptor-bound protein 2 is an adaptor molecule that mediates B-
cell
receptor (BCR) signaling pathways, but the expression of growth factor receptor-bound protein 2 in
lymphoma
tissues has not been reported.
We sought to characterize growth factor receptor-bound protein 2 protein expression in reactive tonsillar tissues and
lymphoma
tissues obtained from diagnostic biopsies of classical Hodgkin
lymphoma
,
primary mediastinal
large B
-
cell lymphoma
,
diffuse large
B-
cell lymphoma
, nodular lymphocyte predominant Hodgkin
lymphoma
, and 20 low-grade B-
cell
lymphomas
.
Growth factor receptor-bound protein 2 expression was assessed in tissues by immunohistochemistry and in
lymphoma cell
lines by immunoblotting.
In reactive lymphoid tissues, growth factor receptor-bound protein 2 was expressed in the cytoplasm
of B
-cells and histiocytes but not T-cells.
Strong, cytoplasmic growth factor receptor-bound protein 2 expression was seen in the neoplastic cells of follicular
lymphoma
, chronic lymphocytic leukemia/small lymphocytic
lymphoma
, splenic marginal zone
lymphoma
,
primary mediastinal
large B
-
cell lymphoma
,
diffuse large
B-
cell lymphoma
, and nodular lymphocyte predominant Hodgkin
lymphoma
.
In contrast, only 10% of the classical Hodgkin
lymphomas
showed growth factor receptor-bound protein 2 expression in the neoplastic cells.
Growth factor receptor-bound protein 2 protein expression was detected by Western blotting in all
lymphoma cell
lines tested with higher levels in
primary mediastinal
large B
-
cell lymphoma
compared with classical Hodgkin
lymphoma cell
lines.
These findings support a role for growth factor receptor-bound protein 2 in the diagnostically challenging workup of classical Hodgkin
lymphoma
versus
primary mediastinal
large B
-
cell lymphoma
and warrant further studies to evaluate the biologic significance of growth factor receptor-bound protein 2 in the pathogenesis of classical Hodgkin
lymphoma
.
[MeSH-major]
Biomarkers, Tumor / analysis. GRB2 Adaptor Protein / biosynthesis. Hodgkin Disease /
diagnosis
.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
.
Mediastinal
Neoplasms /
diagnosis
[MeSH-minor]
Blotting, Western.
Diagnosis
, Differential. Humans. Immunohistochemistry. Tissue Array Analysis
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19716163.001).
[ISSN]
1532-8392
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / GRB2 Adaptor Protein; 0 / GRB2 protein, human
10.
Dunphy CH, O'Malley DP, Cheng L, Fodrie TY, Perkins SL, Kaiser-Rogers K:
Primary mediastinal B-cell lymphoma: detection of BCL2 gene rearrangements by PCR analysis and FISH.
J Hematop
; 2008 Sep;1(2):77-84
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
B-
cell lymphoma
: detection of BCL2 gene rearrangements by PCR analysis and FISH.
Primary mediastinal
large B
-
cell lymphoma
(PMBCL) has a characteristic clinical presentation, morphology, and immunophenotype, representing a clinically favorable subgroup
of diffuse large B
-
cell lymphoma
(DLBCL).
By gene expression profiling (GEP), PMBCL shares features with classical Hodgkin
lymphoma
(cHL).
Of further interest, BCL6 gene mutations and BCL6 and/or MUM1 expression in a number of PMBCLs have supported an activated B-
cell
(ABC) origin.
Of the five with cytogenetics, two had
a t
(14;.
BCL2 protein expression by IHC analysis was variably detected in 21 out of 24 (strongly, uniformly expressed: 6, including all with
a t
(14;.
18) or a BCL2 gene rearrangement; moderately weakly expressed in a subset of the
malignant
cells: 15).
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Haematol. 1999 Oct;107(1):106-13
[
10520030.001
]
[Cites]
Mod Pathol. 2002 Nov;15(11):1172-80
[
12429796.001
]
[Cites]
Histopathology. 1986 Apr;10(4):379-90
[
2423430.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001
[
3494249.001
]
[Cites]
Cancer. 1981 Feb 15;47(4):748-56
[
6784911.001
]
[Cites]
Leuk Lymphoma. 2003;44 Suppl 3:S21-6
[
15202521.001
]
[Cites]
Am J Surg Pathol. 2004 Apr;28(4):464-70
[
15087665.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Feb;33(2):114-22
[
11793437.001
]
[Cites]
Leuk Lymphoma. 2001 Mar;41(1-2):47-53
[
11342356.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Jun;31(2):191-5
[
11319807.001
]
[Cites]
Nature. 2000 Feb 3;403(6769):503-11
[
10676951.001
]
[Cites]
Blood. 2000 Jan 15;95(2):651-9
[
10627476.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):243-53
[
12507907.001
]
[Cites]
Am J Pathol. 1996 Jun;148(6):2017-25
[
8669486.001
]
(PMID = 19669206.001).
[ISSN]
1868-9256
[Journal-full-title]
Journal of hematopathology
[ISO-abbreviation]
J Hematop
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC2713480
11.
Zinzani PL, Martelli M, Poletti V, Vitolo U, Gobbi PG, Chisesi T, Barosi G, Ferreri AJ, Marchetti M, Pimpinelli N, Tura S, Italian Society of Hematology, Italian Society of Experimental Hematology, Italian Group for Bone Marrow Transplantation:
Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Haematologica
; 2008 Sep;93(9):1364-71
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Practice guidelines for the management of extranodal non-Hodgkin's
lymphomas
of adult non-immunodeficient patients. Part I:
primary
lung and
mediastinal lymphomas
. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Extranodal non-Hodgkin's
lymphomas
constitute 20-25% of overall non-Hodgkin's
lymphomas
cases and can be managed with very different therapeutic strategies.
Primary
lung and
mediastinal lymphomas
were the objective of this part of the project.
The first-line therapy for non-MALT
primary
lung non-Hodgkin's
lymphomas
should include anthracycline-based chemotherapy with CHOP or CHOP-like, MACOP-B or MACOP-B-like regimens (grade D).
Second-line therapy with high-dose chemotherapy and autologous stem
cell
transplantation is recommended (grade B).
In patients with MALT
primary
lung non-Hodgkin's
lymphomas
, the recommended first-line therapy should include chlorambucil, CHOP, CHOP-like or fludarabine-containing regimens (grade B).
For treatment of
primary mediastinal
large B
-
cell
lymphomas
, the recommended first-line therapy is a chemotherapy and radiotherapy association (grade B).
Patients with refractory or relapsed disease should undergo rescue programs including intensive, non-cross-resistant debulking treatment followed, in chemosensitive patients, by high-dose chemotherapy and autologous stem
cell
transplantation (grade B).
[MeSH-major]
Bone Marrow Transplantation. Lung Neoplasms / therapy.
Lymphoma
, Non-Hodgkin / therapy.
Mediastinal
Neoplasms / therapy. Practice Guidelines as Topic / standards
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18603558.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
12.
Ortonne N, Copie-Bergman C, Remy P, Delfau-Larue MH, Alonso MA, Mariette X, Dierlamm J, Leroy K, Gaulard P:
Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement.
Virchows Arch
; 2005 Feb;446(2):189-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mucosa-associated lymphoid tissue
lymphoma of
the
thymus
: a case report with no evidence of MALT1 rearrangement.
We report a case of
thymic
mucosa-associated lymphoid tissue (MALT)
lymphoma
(TML) that presented as an asymptomatic
mediastinal
mass in a 40-year-old woman with a past history of Sjögren syndrome.
This case had the characteristic clinical and pathological features of TML, as found in most of the 24 previously reported cases, i.e., autoimmune context, especially Sjögren syndrome, IgA secretion,
large
epithelial cysts, lymphoepithelial lesions involving residual Hassal's corpuscles, epithelial cysts, and a marked plasmacytic differentiation with IgA expression.
Neoplastic cells were negative for MAL, a marker of
primary mediastinal
large B cell lymphoma
(
PMBL
).
Altogether, these findings further support that among MALT
lymphomas
, TML have peculiar clinical and morphological characteristics and appear not to involve MALT1 rearrangement.
They also suggest the absence of a relationship between TML and
PMBL
.
[MeSH-major]
Lymphoma
, B-
Cell
, Marginal Zone / genetics.
Lymphoma
, B-
Cell
, Marginal Zone / pathology. Neoplasm Proteins / genetics.
Thymus
Neoplasms / genetics.
Thymus
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Diagn Cytopathol. 1993 Dec;9(6):665-7
[
8143541.001
]
[Cites]
Cancer. 1992 Mar 15;69(6):1347-55
[
1540872.001
]
[Cites]
Hum Pathol. 2000 Feb;31(2):255-9
[
10685645.001
]
[Cites]
Hum Pathol. 1998 Sep;29(9):1021-4
[
9744322.001
]
[Cites]
Pathol Int. 1998 Jan;48(1):74-81
[
9589469.001
]
[Cites]
Am J Pathol. 2002 Apr;160(4):1435-43
[
11943727.001
]
[Cites]
Blood. 2001 Aug 15;98(4):1182-7
[
11493468.001
]
[Cites]
Blood. 2003 Mar 15;101(6):2335-9
[
12406890.001
]
[Cites]
Am J Clin Pathol. 2002 Jan;117(1):51-6
[
11789730.001
]
[Cites]
Jpn J Clin Oncol. 2000 Aug;30(8):349-53
[
11059340.001
]
[Cites]
Mod Pathol. 2002 Nov;15(11):1172-80
[
12429796.001
]
[Cites]
Arch Pathol Lab Med. 2001 Sep;125(9):1246-8
[
11520284.001
]
[Cites]
J Clin Pathol. 1996 Jul;49(7):595-7
[
8813963.001
]
[Cites]
Blood. 1999 Nov 15;94(10):3567-75
[
10552968.001
]
[Cites]
Arch Pathol Lab Med. 2000 May;124(5):770-3
[
10782167.001
]
[Cites]
Am J Surg Pathol. 1990 Apr;14(4):342-51
[
1690952.001
]
[Cites]
Cell. 1999 Jan 8;96(1):35-45
[
9989495.001
]
[Cites]
Am J Clin Pathol. 2000 Jun;113(6):784-91
[
10874878.001
]
[Cites]
Am J Surg Pathol. 1996 Jul;20(7):877-88
[
8669537.001
]
[Cites]
Histopathology. 2002 Mar;40(3):294-6
[
11895498.001
]
[Cites]
Hematol Oncol. 2000 Mar;18(1):1-13
[
10797525.001
]
(PMID = 15650839.001).
[ISSN]
0945-6317
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Immunoglobulin A; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
13.
Assaad MW, Pantanowitz L, Otis CN:
Diagnostic accuracy of image-guided percutaneous fine needle aspiration biopsy of the mediastinum.
Diagn Cytopathol
; 2007 Nov;35(11):705-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnostic accuracy of image-guided percutaneous fine needle aspiration biopsy of the
mediastinum
.
Interpreting a fine needle aspiration biopsy (FNAB) from
the mediastinum
is challenging as this location may harbor many lesions, including
primary
and metastatic tumors.
The aim of this study was to determine the diagnostic accuracy of FNAB performed percutaneously for evaluating
mediastinal
lesions.A retrospective study of 157 consecutive CT-guided transthoracic FNAB of the
mediastinum
was performed (1988-2004).
Direct smears (N = 145; average 13 slides/case), ThinPrep slides (N = 25), and adequate
cell
blocks (N = 131) were prepared from procured cytologic material.
A definitive
diagnosis
was rendered in 128 (82%) cases.
Primary
neoplasms (N = 38) included 24
lymphomas
(6 Hodgkin and 18 non-Hodgkin), 7 thymomas, 1
thymic
carcinoma, and 6 peripheral nerve sheath tumors.
There were 4 non-neoplastic lesions (1 granulomatous process; 2 bronchogenic and 1 pericardial cyst), 1 case of undifferentiated
malignant
large cell
neoplasm, 13 cases negative for malignancy, and 29 (18%) that were indeterminate, due largely to insufficient cellularity.
There were 6 discordant cases, including 5 FNAB that were of adequate cellularity but interpreted as negative for
malignant
cells (on subsequent histology 2 turned out to be Hodgkin
lymphoma
, 2 carcinomas, and 1
diffuse large cell lymphoma
), and 1 diagnosed as thymoma that on histologic evaluation was
a thymic
large cell lymphoma
.
Adequate diagnostic cytologic material was obtained by image-guided percutaneous FNAB of
mediastinal
lesions in 82% of our cases.
Sufficient material was available to make
cell
blocks and perform ancillary studies when necessary.
These data also show a high proportion of agreement (78%) between FNAB and subsequent histologic diagnoses for a wide variety of
mediastinal
lesions.
The majority of discordant cases were primarily interpretive, with a final cytologic
diagnosis
negative for malignancy.
Only one problematic case misdiagnosed on FNAB as thymoma was found on subsequent surgical excision to be
a thymic
large B cell lymphoma
.
Therefore, percutaneous FNAB of the
mediastinum
is a diagnostically helpful, minimally invasive procedure that can be performed in patients of all ages as part of the evaluation of
a mediastinal
mass lesion.
[MeSH-major]
Biopsy, Fine-Needle.
Mediastinal
Neoplasms /
diagnosis
.
Mediastinum
/ pathology. Surgery, Computer-Assisted
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley-Liss, Inc.
(PMID = 17924408.001).
[ISSN]
8755-1039
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
14.
Turk HM, Ozet A, Ozturk M, Komurcu S, Kuzhan O, Arpaci F, Ozturk B, Safali M:
Isolated renal relapse of a case with non-Hodgkin's lymphoma.
Med Oncol
; 2010 Jun;27(2):434-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Isolated renal relapse of a case with non-Hodgkin's
lymphoma
.
A 29-year-old woman with left pleural effusion and a mass in anterior
mediastinum
was admitted.
The patient was in remission after six cycles of ABVD followed by
mediastinal
radiotherapy.
Ultrasound guided renal biopsy revealed
diffuse large B cell lymphoma
.
Retrospective re-evaluation of the archival specimens of the
mediastinal
mass was also consistent with
diffuse large B cell lymphoma
.
After induction chemotherapy (four cycles of DHAP) she underwent high dose chemotherapy (BEAM) and autologous peripheral blood stem
cell
transplantation.
In conclusion, renal involvement during advanced
lymphoma
is quite common but isolated renal relapse in NHL is a rare situation.
Although renal infiltration generally shows a poor prognosis, long-term survival may be achieved with high dose chemotherapy and autologous peripheral blood stem
cell
transplantation.
[MeSH-major]
Kidney Neoplasms /
diagnosis
. Kidney Neoplasms / therapy.
Lymphoma
, Non-Hodgkin /
diagnosis
.
Lymphoma
, Non-Hodgkin / therapy. Neoplasm Recurrence, Local /
diagnosis
. Neoplasm Recurrence, Local / therapy
[MeSH-minor]
Adult. Female. Humans. Peripheral Blood Stem
Cell
Transplantation. Secondary Prevention
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Urol. 2005 Jan;173(1):239
[
15592087.001
]
[Cites]
Am J Surg Pathol. 1995 Feb;19(2):134-44
[
7832273.001
]
[Cites]
Nephron Clin Pract. 2005;100(3):c86-91
[
15824512.001
]
[Cites]
Urology. 1993 Sep;42(3):331-5
[
8379037.001
]
[Cites]
Leuk Lymphoma. 2003 Oct;44(10):1733-8
[
14692526.001
]
[Cites]
Hematol Oncol. 1990 Mar-Apr;8(2):105-10
[
2344997.001
]
[Cites]
Cancer. 1996 Jun 1;77(11):2325-31
[
8635103.001
]
[Cites]
J Clin Oncol. 2007 Aug 20;25(24):3783-5
[
17704429.001
]
[Cites]
Turk J Pediatr. 1989 Jan-Mar;31(1):71-7
[
2692261.001
]
[Cites]
Eur Urol. 1986;12(5):352-4
[
3780803.001
]
[Cites]
Cancer. 1987 Aug 1;60(3):386-91
[
3594375.001
]
[Cites]
Saudi J Kidney Dis Transpl. 2006 Sep;17(3):395-8
[
16970262.001
]
[Cites]
Int Braz J Urol. 2006 Mar-Apr;32(2):190-2
[
16650297.001
]
[Cites]
Clin Adv Hematol Oncol. 2008 Jul;6(7):527-31
[
18654120.001
]
[Cites]
Tumour Biol. 2003 Aug-Sep;24(4):172-5
[
14654710.001
]
[Cites]
Am J Nephrol. 1994;14(2):148-53
[
8080008.001
]
[Cites]
Oncology. 1998 Sep-Oct;55(5):482-6
[
9732229.001
]
[Cites]
Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92
[
4007017.001
]
[Cites]
Gen Diagn Pathol. 1997 Feb;142(3-4):147-53
[
9065578.001
]
[Cites]
Eur J Haematol. 2001 Sep;67(3):158-64
[
11737248.001
]
[Cites]
Am J Kidney Dis. 1994 Oct;24(4):586-9
[
7942815.001
]
[Cites]
J Natl Med Assoc. 2003 Mar;95(3):220-4
[
12749682.001
]
[Cites]
J Surg Oncol. 1997 Mar;64(3):207-11
[
9121151.001
]
[Cites]
Br J Cancer. 1994 Jul;70(1):154-9
[
7517172.001
]
(PMID = 19437146.001).
[ISSN]
1559-131X
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
15.
Milling DL, Lazarchick J, Chaudhary UB:
Primary mediastinal large B-cell lymphoma in an HIV-infected patient.
Am J Med Sci
; 2005 Mar;329(3):136-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell lymphoma
in an HIV-infected patient.
HIV-related non-Hodgkin
lymphoma
is well documented in the literature.
We report a case of an HIV-infected patient who presents with
primary mediastinal
large B
-
cell lymphoma
.
On review of the literature, this appears to be the first documented case of this
subtype
of large
B-
cell
non-Hodgkin
lymphoma
seen in an HIV-infected patient.
[MeSH-major]
Lymphoma
, AIDS-Related /
diagnosis
.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
.
Mediastinal
Neoplasms /
diagnosis
Genetic Alliance.
consumer health - HIV
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15767818.001).
[ISSN]
0002-9629
[Journal-full-title]
The American journal of the medical sciences
[ISO-abbreviation]
Am. J. Med. Sci.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
16.
Wang E, Stoecker M:
Primary mediastinal (thymic) large B cell lymphoma with aberrant expression of CD3: a case report with review of the literature.
Int J Hematol
; 2010 Apr;91(3):509-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
(
thymic
)
large B cell lymphoma
with aberrant expression of CD3: a case report with review of the literature.
We report the first case of
primary mediastinal
large B cell lymphoma
(
PMBL
) with aberrant expression of CD3.
PMBL
is
a subtype
of diffuse large B cell lymphoma
(DLBCL) and usually presents with bulky
mediastinal
lesions.
Of the 14 total cases, 6 are pyothorax-associated
lymphoma
, 4 are conventional DLBCL, 2 are plasmablastic
lymphoma
, one is
primary
effusion
lymphoma
and one is
PMBL
.
[MeSH-major]
Antigens, CD3 / metabolism.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ metabolism.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / metabolism.
Mediastinal
Neoplasms / pathology
[MeSH-minor]
Adult. Biopsy. Female. Humans. Radiography.
Thymus
Neoplasms / diagnostic imaging.
Thymus
Neoplasms / metabolism.
Thymus
Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Surg Pathol. 1994 Nov;18(11):1092-101
[
7943530.001
]
[Cites]
Haematologica. 1997 Jan-Feb;82(1):64-6
[
9107085.001
]
[Cites]
Blood. 1992 Jul 1;80(1):209-16
[
1319235.001
]
[Cites]
Am J Surg Pathol. 1996 Jun;20(6):760-6
[
8651357.001
]
[Cites]
J Pediatr Hematol Oncol. 2009 Feb;31(2):124-7
[
19194198.001
]
[Cites]
J Mol Diagn. 2006 Sep;8(4):426-9; quiz 526-7
[
16931581.001
]
[Cites]
Am J Surg Pathol. 2002 Jun;26(6):724-32
[
12023576.001
]
[Cites]
Clin Lymphoma Myeloma. 2009 Apr;9(2):133-7
[
19406723.001
]
[Cites]
Lancet Oncol. 2002 Apr;3(4):229-34
[
12067685.001
]
[Cites]
Am J Surg Pathol. 1999 Aug;23(8):992-4
[
10435572.001
]
[Cites]
Hematol J. 2000;1(1):53-66
[
11920170.001
]
[Cites]
Am J Surg Pathol. 2009 Apr;33(4):505-12
[
19011566.001
]
[Cites]
Blood. 2005 Sep 1;106(5):1770-7
[
15886317.001
]
[Cites]
Am J Surg Pathol. 1996 Jul;20(7):877-88
[
8669537.001
]
(PMID = 20131102.001).
[ISSN]
1865-3774
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antigens, CD3
[Number-of-references]
15
17.
Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA:
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Blood
; 2010 Oct 28;116(17):3268-77
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin
lymphoma
and
primary mediastinal
large B
-
cell lymphoma
.
Classical Hodgkin
lymphoma
(cHL) and
mediastinal
large B
-
cell lymphoma
(MLBCL) are lymphoid malignancies with certain shared clinical, histologic, and molecular features.
Primary
cHLs and MLBCLs include variable numbers of
malignant
cells within an inflammatory infiltrate, suggesting that these tumors escape immune surveillance.
Herein, we integrate high-resolution copy number data with transcriptional profiles and identify the immunoregulatory genes, PD-L1 and PD-L2, as key targets at the 9p24.1 amplification peak in HL and MLBCL
cell
lines.
We extend these findings to laser-capture microdissected
primary
Hodgkin Reed-Sternberg cells and
primary
MLBCLs and find that programmed
cell
death-1 (PD-1) ligand/9p24.1 amplification is restricted to nodular sclerosing HL, the cHL
subtype
most closely related to MLBCL.
Using quantitative immunohistochemical methods, we document the association between 9p24.1 copy number and PD-1 ligand expression in
primary
tumors.
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
SciCrunch.
ArrayExpress: Data: Microarray
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2004 Jul 15;64(14):4965-72
[
15256470.001
]
[Cites]
Nature. 2008 Oct 23;455(7216):1061-8
[
18772890.001
]
[Cites]
Nucleic Acids Res. 1995 Oct 25;23(20):4097-103
[
7479071.001
]
[Cites]
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W393-6
[
15980497.001
]
[Cites]
J Leukoc Biol. 2005 Nov;78(5):1043-51
[
16204623.001
]
[Cites]
FEBS Lett. 2006 Feb 6;580(3):755-62
[
16413538.001
]
[Cites]
Oncogene. 2006 Apr 27;25(18):2679-84
[
16532038.001
]
[Cites]
Clin Cancer Res. 2006 Nov 15;12(22):6844-52
[
17121906.001
]
[Cites]
Nat Med. 2007 Jan;13(1):84-8
[
17159987.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
[
17360651.001
]
[Cites]
Clin Cancer Res. 2007 Apr 1;13(7):2151-7
[
17404099.001
]
[Cites]
Bioinformatics. 2007 Mar 15;23(6):657-63
[
17234643.001
]
[Cites]
Blood. 2007 Jul 1;110(1):296-304
[
17363736.001
]
[Cites]
Immunity. 2007 Jul;27(1):111-22
[
17629517.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9
[
17670934.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3226-33
[
17644739.001
]
[Cites]
J Immunol. 2007 Dec 1;179(11):7466-77
[
18025191.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12
[
18077431.001
]
[Cites]
Oncogene. 2008 Jan 10;27(3):318-22
[
17637749.001
]
[Cites]
Blood. 2008 Mar 15;111(6):3220-4
[
18203952.001
]
[Cites]
Annu Rev Immunol. 2008;26:677-704
[
18173375.001
]
[Cites]
Clin Cancer Res. 2008 May 15;14(10):3044-51
[
18483370.001
]
[Cites]
Nat Protoc. 2008;3(6):1101-8
[
18546601.001
]
[Cites]
Cancer Lett. 2008 Sep 8;268(1):98-109
[
18486325.001
]
[Cites]
J Cancer Res Clin Oncol. 2008 Sep;134(9):1021-7
[
18347814.001
]
[Cites]
Nat Rev Cancer. 2009 Jan;9(1):15-27
[
19078975.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20428-33
[
19075244.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7
[
19088198.001
]
[Cites]
Clin Cancer Res. 2009 Feb 1;15(3):971-9
[
19188168.001
]
[Cites]
Immunol Rev. 2009 Jul;230(1):144-59
[
19594634.001
]
[Cites]
Blood. 2009 Oct 1;114(14):2945-51
[
19666866.001
]
[Cites]
Hum Pathol. 2009 Dec;40(12):1715-22
[
19695683.001
]
[Cites]
Blood. 2009 Nov 12;114(20):4503-6
[
19734449.001
]
[Cites]
J Exp Med. 2009 Dec 21;206(13):3015-29
[
20008522.001
]
[Cites]
Cancer. 2010 Apr 1;116(7):1757-66
[
20143437.001
]
[Cites]
Clin Cancer Res. 2010 Apr 1;16(7):1988-96
[
20215535.001
]
[Cites]
Blood. 2010 Jul 22;116(3):418-27
[
20339089.001
]
[Cites]
Cancer Res. 2000 Feb 1;60(3):549-52
[
10676635.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Apr;30(4):393-401
[
11241792.001
]
[Cites]
Immunol Lett. 2002 Oct 21;84(1):57-62
[
12161284.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
[
12218188.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Eur J Immunol. 2003 Oct;33(10):2706-16
[
14515254.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Blood. 2004 Jul 15;104(2):543-9
[
15044251.001
]
[Cites]
Mol Cancer Ther. 2008 Aug;7(8):2308-18
[
18723478.001
]
[Cites]
Biostatistics. 2004 Oct;5(4):557-72
[
15475419.001
]
(PMID = 20628145.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA092625
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / PDCD1LG2 protein, human; 0 / Programmed Cell Death 1 Ligand 2 Protein; EC 2.7.10.2 / Janus Kinase 2
[Other-IDs]
NLM/ PMC2995356
18.
Oberson M, Zucca E, Mazzucchelli L, Menafoglio A, Guerra A, Gallino A:
Extrinsic compression of the pulmonary artery by primary mediastinal large B-cell lymphoma.
Br J Haematol
; 2009 Feb;144(3):277
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extrinsic compression of the pulmonary artery by
primary mediastinal
large B
-
cell lymphoma
.
[MeSH-major]
Lymphoma
, B-
Cell
/ ultrasonography. Pulmonary Artery / ultrasonography.
Thymus
Neoplasms / ultrasonography
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19149803.001).
[ISSN]
1365-2141
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
19.
Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K, Mattfeldt T, Barth TF, Möller P:
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.
Oncogene
; 2006 Apr 27;25(18):2679-84
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin
lymphoma
are frequent and associated with nuclear phospho-STAT5 accumulation.
SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-
cell
neoplasias and carcinomas.
Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of
primary mediastinal
B-
cell lymphoma
(
PMBL
) and in the
PMBL
line MedB-1, and a biallelic SOCS-1 deletion in
PMBL
line Karpas1106P.
For both
cell
lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5.
Here, we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin
lymphoma
(cHL).
We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin
lymphoma
(HL)-derived
cell
lines by sequencing analysis.
Collectively, these findings support the concept that
PMBL
and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both
lymphomas
.
[MeSH-major]
Cell
Nucleus / metabolism. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Hodgkin Disease / genetics. Intracellular Signaling Peptides and Proteins / genetics. Mutation. Repressor Proteins / genetics. STAT5 Transcription Factor / metabolism. Suppressor of Cytokine Signaling Proteins / genetics
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16532038.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Intracellular Signaling Peptides and Proteins; 0 / Repressor Proteins; 0 / SOCS1 protein, human; 0 / STAT5 Transcription Factor; 0 / Suppressor of Cytokine Signaling Proteins
20.
Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, Jaffe ES:
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
Am J Surg Pathol
; 2005 Nov;29(11):1411-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mediastinal
gray zone
lymphoma
: the missing link between classic Hodgkin's
lymphoma
and
mediastinal
large B
-
cell lymphoma
.
In recent years, overlap in biologic and
morphologic
features has been identified between classic Hodgkin
lymphoma
(cHL) and B-
cell
non-Hodgkin
lymphoma
.
We undertook a study of "
mediastinal
gray zone
lymphomas
" (MGZL), with features transitional between cHL nodular sclerosis (NS) and
primary mediastinal
large B
-
cell lymphoma
(MLBCL) to better understand the
morphologic
and immunophenotypic spectrum of such cases.
We also studied 6 cases of composite or synchronous
lymphoma
with two distinct components at the same time (cHL-NS and MLBCL) and 9 sequential cases with MLBCL and cHL-NS at different times.
All patients had a
large
mediastinal
mass.
Immunohistochemical studies focused on markers known to discriminate between cHL and MLBCL, including B-
cell
transcription factors.
Of the gray zone cases, 11 had morphology reminiscent of cHL-NS, but with unusual features, including a
large
number of mononuclear variants, diminished inflammatory background, absence of classic Hodgkin phenotype, and strong CD20 expression (11 of 11).
B-
cell
transcription factor expression in the gray zone cases more closely resembled MLBCL than cHL with expression of Pax5, Oct2, and BOB.1 in all but 1 case studied (14 of 15).
Two cases of sequential
lymphoma
showed rearrangements of the IgH gene of identical size: one in which MLBCL was the first
diagnosis
and one in which MLBCL was diagnosed at relapse, indicating clonal identity for the two components of cHL and MLBCL.
Further support for a relationship between MLBCL and cHL-NS is provided by composite and metachronous
lymphomas
in the same patient, as well as the existence of MGZL with transitional morphology and phenotype.
[MeSH-major]
Hodgkin Disease / pathology.
Lymphoma
, B-
Cell
/ pathology.
Mediastinal
Neoplasms / pathology
Genetic Alliance.
consumer health - Gray zone lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16224207.001).
[ISSN]
0147-5185
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
21.
García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, Pérez-Seoane C, Rivera T, Ortega P, Piris MA:
Large B-cell lymphoma with Hodgkin's features.
Histopathology
; 2005 Jul;47(1):101-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Large B
-
cell lymphoma
with Hodgkin's features.
AIMS: To describe the features of a series of nine cases
of diffuse large B
-
cell lymphoma
(DLBCL) showing morphological and immunophenotypic features that are intermediate with Hodgkin's
lymphoma
(HL).
METHODS AND RESULTS: Most cases (6/9) presented as
mediastinal
tumours affecting young males, while the other three cases arose in extramediastinal locations.
Histopathologically, tumours showed
diffuse large cell
areas in a polymorphous background, with pleomorphic cytology and the common presence of Hodgkin's and Reed-Sternberg cells.
Immunophenotypically, tumours shared features of DLBCL and classical HL, with expression of CD30, CD15 (6/9), and a full B-
cell
profile including CD45RB, CD20, CD79a and OCT2.
CONCLUSIONS: These findings suggest that DLBCLs with HL features constitute a distinctive subgroup of aggressive
lymphomas
whose neoplastic growth and peculiar characteristics could be facilitated by a particular microenvironment found in
the mediastinum
.
[MeSH-major]
Hodgkin Disease / pathology.
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology
[MeSH-minor]
Adult. Aged. Antigens, CD / analysis. DNA-Binding Proteins / analysis. DNA-Binding Proteins / genetics.
Diagnosis
, Differential. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. Male. Middle Aged. Mutation. Neoplasm Staging. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Transcription Factors / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15982329.001).
[ISSN]
0309-0167
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
22.
Massoud M, Koscielny S, Lapusan S, Bosq J, Ribrag V:
Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy.
Leuk Lymphoma
; 2008 Aug;49(8):1510-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell
lymphomas
treated with dose-intensified CHOP alone or CHOP combined with radiotherapy.
We retrospectively reviewed 105 cases of
primary mediastinal
large B
-
cell lymphoma
(PMLBL).
Radiotherapy was delivered to patients with a
lymphoma
proven sensitive to CHOP who could receive irradiation for localised disease.
[MeSH-minor]
Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ drug therapy.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ radiotherapy.
Mediastinal
Neoplasms / drug therapy.
Mediastinal
Neoplasms / radiotherapy. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18766963.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
England
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
23.
Melzner I, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Barth TF, Leithäuser F, Möller P:
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
Blood
; 2005 Mar 15;105(6):2535-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1
mediastinal
lymphoma
line.
Primary mediastinal
B-
cell lymphoma
(
PMBL
) is a well-defined
subtype
of diffuse large B
-
cell lymphoma
.
JAK2, mapping in this region, is presently regarded as a candidate oncogene because expression profiling showed high Janus kinase-2 (JAK2) transcript levels and JAK2 was found to be constitutively phosphorylated in
mediastinal
B-
cell
lymphomas
.
We confirm that in the MedB-1
mediastinal
B-
cell
line, harboring a trisomy 9, JAK2 transcription is elevated and the product is highly phosphorylated.
This unexpected finding coincides with a biallelic mutation of the suppressor of cytokine signaling-1 (SOCS-1) gene in this
cell
, which abrogates SOCS box function of the protein.
Ectopic expression of wild-
type
(wt) SOCS-1 in MedB-1 leads to growth arrest and dramatic reduction of phospho-JAK2 and its downstream partner phospho-signal transducer and activator of transcription-5 (phospho-STAT5).
Of note, SOCS-1 mutations are also present in the parental tumor of MedB-1 and were detected in 9 of 20
PMBLs
.
[MeSH-major]
Intracellular Signaling Peptides and Proteins / genetics.
Lymphoma
, B-
Cell
/ metabolism.
Mediastinal
Neoplasms / metabolism. Mutation. Protein Processing, Post-Translational / genetics. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / genetics. Suppressor of Cytokine Signaling Proteins / genetics. Tumor Suppressor Proteins / genetics
[MeSH-minor]
Alleles.
Cell
Line, Tumor. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / metabolism. Cyclin D1 / genetics. Cyclin D1 / metabolism. Gene Expression Regulation, Leukemic / genetics. Humans. Janus Kinase 2. Phosphorylation. Retinoblastoma Protein / genetics. Retinoblastoma Protein / metabolism. STAT5 Transcription Factor / genetics. STAT5 Transcription Factor / metabolism. Signal Transduction / genetics. Trisomy / genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15572583.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / Retinoblastoma Protein; 0 / SOCS1 protein, human; 0 / STAT5 Transcription Factor; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
24.
Martelli M, Ferreri AJ, Johnson P:
Primary mediastinal large B-cell lymphoma.
Crit Rev Oncol Hematol
; 2008 Dec;68(3):256-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell lymphoma
.
Primary mediastinal
large B
-
cell lymphoma
(PMLBCL) is a unique
type
of B
-
cell lymphoma
probably arising from a putative
thymic
medulla B-
cell
.
It constitutes 6-10% of all
diffuse large
B-
cell
lymphomas
(DLBCL), occurring more often in young females.
PMLBCL is characterized by a
diffuse
proliferation of medium to
large B
-cells associated with sclerosis and a degree of compartmentalisation.
The gene expression signature of PMLBCL seems to be much closer to classic Hodgkin
lymphoma
than to DLBCL.
PMLBCL is characterized by a locally invasive anterior
mediastinal
mass, often producing cough, chest pain, dyspnea, and superior vena cava syndrome.
Features associated with poor prognosis are poor performance status, pericardial effusion, bulky disease, high serum LDH at
diagnosis
, and a compromised dose-intensity of anthracycline and cyclophosphamide.
[MeSH-major]
Lymphoma
, B-
Cell
.
Mediastinal
Neoplasms
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18774728.001).
[ISSN]
1040-8428
[Journal-full-title]
Critical reviews in oncology/hematology
[ISO-abbreviation]
Crit. Rev. Oncol. Hematol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Neoplasm Proteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
[Number-of-references]
75
25.
Clarke JR, Brglevska S, Lau EW, Ramdave S, Hicks RJ:
Atypical brown fat distribution in young males demonstrated on PET/CT.
Clin Nucl Med
; 2007 Sep;32(9):679-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Other described sites of uptake include
the mediastinum
and retroperitoneum.
We present examples of 2 cases of atypical
diffuse
brown fat uptake seen in the subcutaneous fat of the thighs, abdomen, and pelvis.
Although rare in our experience, knowledge of this condition may prevent misinterpretation of this finding as an infiltrative condition of the skin, such as
lymphoma
.
[MeSH-minor]
Adolescent. False Positive Reactions. Humans.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
. Male. Middle Aged. Rhabdomyosarcoma, Alveolar /
diagnosis
MedlinePlus Health Information.
consumer health - CT Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17710017.001).
[ISSN]
0363-9762
[Journal-full-title]
Clinical nuclear medicine
[ISO-abbreviation]
Clin Nucl Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
26.
Zamò A, Malpeli G, Scarpa A, Doglioni C, Chilosi M, Menestrina F:
Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas.
Mod Pathol
; 2005 Nov;18(11):1448-53
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of TP73L is a helpful diagnostic marker of
primary mediastinal
large B
-
cell
lymphomas
.
Primary mediastinal
large B
-
cell lymphoma
is a well-defined
lymphoma
entity whose molecular pathogenesis is incompletely understood and also lacking well-established diagnostic markers.
Recently, the presence of overlapping features between classical Hodgkin's
lymphoma
and
primary mediastinal
large B
-
cell lymphoma
was highlighted by gene expression profiling as well as morphological studies.
We investigated the expression of TP73L (commonly known as p63) isoforms in
primary mediastinal
large B
-
cell lymphoma
at both protein and mRNA level, and demonstrated the exclusive presence of transactivating (TA) isoforms in all cases.
We also demonstrated that TP73L is expressed in a subset of germinal center B-cells, as well as in some
diffuse large
B-
cell
lymphomas
, but it is never present in classical Hodgkin
lymphoma
.
Nodular lymphocyte predominant Hodgkin's
lymphoma
also showed TP73L positivity by immunohistochemistry.
Isoform analysis by real-time PCR showed that TA-TP73Lalpha is the most represented in
primary mediastinal
large B
-
cell lymphoma
, but TA-TP73Lgamma is the most differentially expressed in comparison to both germinal center B-cells and
diffuse large
B-
cell
lymphomas
.
TP73L expression proved a useful diagnostic marker of
primary mediastinal
large B
-
cell lymphoma
, and gave new insights in to the molecular pathways playing a role in this
lymphoma
.
[MeSH-major]
Hodgkin Disease /
diagnosis
.
Lymphoma
, B-
Cell
/
diagnosis
.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
.
Mediastinal
Neoplasms /
diagnosis
. Phosphoproteins / biosynthesis. Trans-Activators / biosynthesis
[MeSH-minor]
Biomarkers, Tumor / analysis. DNA-Binding Proteins.
Diagnosis
, Differential. Gene Expression. Gene Expression Profiling. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Protein Isoforms / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors. Tumor Suppressor Proteins
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Modern Pathology (2005) 18, 1448-1453. doi:10.1038/modpathol.3800440; published online 13 May 2005.
(PMID = 15920542.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
27.
Popov SW, Moldenhauer G, Wotschke B, Brüderlein S, Barth TF, Dorsch K, Ritz O, Möller P, Leithäuser F:
Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphoma.
Cancer Res
; 2007 Jul 15;67(14):6555-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Target sequence accessibility limits activation-induced cytidine deaminase activity in
primary mediastinal
B-
cell lymphoma
.
Activation-induced cytidine deaminase (AID) initiates somatic hypermutation (SHM) and class switch recombination (CSR) in activated B lymphocytes and is potentially implicated in genomic instability
of B
-
cell
malignancies.
For unknown reasons, B-
cell
neoplasms often lack SHM and CSR in spite of high AID expression.
Here, we show that
primary mediastinal
B-
cell lymphoma
(
PMBL
), an immunoglobulin (Ig)-negative
lymphoma
that possesses hypermutated, class-switched Ig genes, expresses high levels of AID with an intact
primary
structure but does not do CSR in 14 of 16 cases analyzed.
Interleukin-4/CD40L costimulation induced CSR and a marked up-regulation of germ-line transcription in the
PMBL
-derived
cell
line MedB-1.
In the
PMBL
cell
line Karpas 1106P, CSR was not inducible and germ-line transcription remained low on stimulation.
Thus, accessibility of the target sequences seems to be a major limiting factor for AID-dependent somatic gene diversification in
PMBL
.
[MeSH-major]
Cytidine Deaminase / biosynthesis. Cytidine Deaminase / chemistry. Gene Expression Regulation, Neoplastic.
Lymphoma
, B-
Cell
/ metabolism
[MeSH-minor]
Cell
Line, Tumor. Cloning, Molecular. Cyclic AMP-Dependent Protein Kinases / metabolism. Genes, Immunoglobulin. Humans. Immunoglobulin Class Switching.
Mediastinal
Neoplasms / metabolism. RNA, Messenger / metabolism. Transcription, Genetic. Transfection. Up-Regulation
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17638864.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
28.
Inoue H, Yasu T, Kawahito K, Kubo N, Nishida J, Kawakami M, Saito M:
Successfully treated massive pulmonary thromboembolism and thrombus in the right atrium due to diffuse malignant lymphoma: a case report.
J Cardiol
; 2006 Sep;48(3):159-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Successfully treated massive pulmonary thromboembolism and thrombus in the right atrium due to
diffuse
malignant
lymphoma
: a case report.
A 40-year-old man presented with massive pulmonary embolism related to
diffuse large B cell lymphoma
.
Echocardiography and thoracic computed tomography indicated pulmonary thromboembolism due to deep venous thromboembolism, associated with a mass in the anterior
mediastinum
and a 5 x 8 cm mass in the left pelvis compressing the left femoral vein.
Soon after this surgery, his hemodynamic state recovered and excision of the left cervical lymph node revealed
diffuse large B cell lymphoma
.
Venous compression by
the lymphoma
mass had caused hemostasis and thrombus formation in the present case.
[MeSH-major]
Lymphoma
, B-
Cell
/ complications.
Lymphoma
, Non-Hodgkin / complications. Pulmonary Embolism / etiology. Pulmonary Embolism / surgery
MedlinePlus Health Information.
consumer health - Pulmonary Embolism
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17007241.001).
[ISSN]
0914-5087
[Journal-full-title]
Journal of cardiology
[ISO-abbreviation]
J Cardiol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
29.
Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R, Möller P, Barth TF:
Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein.
Genes Chromosomes Cancer
; 2007 Apr;46(4):406-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gains of REL in
primary mediastinal
B-
cell lymphoma
coincide with nuclear accumulation of REL protein.
Gains or amplifications of the REL locus are frequently seen in
primary mediastinal
B-
cell lymphoma
(
PMBL
).
In classical Hodgkin's
lymphoma
, genomic overrepresentation of REL correlated with nuclear REL protein accumulation.
To investigate the correlation between REL gene copies and its RNA and protein expression in
PMBL
, we analyzed genomic, transcriptional, and protein levels in 20
PMBLs
and the
PMBL
derived
cell
lines MedB-1 and Karpas1106P.
We found gains/amplifications in 75% of the
PMBLs
by fluorescence in situ hybridization (FISH) and genomic REL overrepresentation in the
PMBL
lines.
Three of the five
PMBLs
with amplifications displayed elevated REL transcripts, while only 3/10
PMBLs
with gains showed increased REL transcripts by real-time PCR.
One
PMBL
without gains displayed increased REL transcription.
REL protein expression exhibited a variable pattern across the
PMBLs
except for a single case that was completely negative by immunohistochemistry despite having gained REL.
Although transcript levels were generally low and nuclear REL staining was weak in
the lymphoma cell
lines, these nevertheless exhibited high NF-kappaB activation.
In conclusion, the frequent genomic overrepresentation of REL in
PMBL
does not necessarily trigger an increased transcription/translation of REL.
However, combined genomic and protein analysis revealed a significant association of gained REL and nuclear REL accumulation at the single
cell
level.
[MeSH-major]
Cell
Nucleus / metabolism.
Lymphoma
, B-
Cell
/ metabolism.
Mediastinal
Neoplasms / metabolism. Proto-Oncogene Proteins c-rel / metabolism
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley-Liss, Inc.
(PMID = 17243160.001).
[ISSN]
1045-2257
[Journal-full-title]
Genes, chromosomes & cancer
[ISO-abbreviation]
Genes Chromosomes Cancer
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / MC/ U132670597
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Proto-Oncogene Proteins c-rel
30.
Barth TF, Melzner I, Wegener S, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Leithäuser F, Möller P:
[Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line].
Verh Dtsch Ges Pathol
; 2005;89:234-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1
mediastinal
lymphoma
line].
[Transliterated title]
Die biallelische Mutation von SOCS-1 verhindert den Abbau von JAK2 und prolongiert die Wirkung von phospho-JAK2 in der mediastinalen B-
Zell
Lymphomlinie MedB-1.
Primary mediastinal
B-
cell lymphoma
(
PMBL
) is a well-defined
subtype
of diffuse large B
-
cell lymphoma
.
JAK2, mapping in this region, is presently regarded as a candidate oncogene since expression profiling showed high JAK2 transcript levels and JAK2 was found to be constitutively phosphorylated in
mediastinal
B-
cell
lymphomas
.
We confirm that in the MedB-1
mediastinal
B-
cell
line, harbouring a trisomy 9, JAK2 transcription is elevated and the product is highly phosphorylated.
This unexpected finding coincides with a biallelic mutation of the SOCS-1 gene in this
cell
, which abrogates SOCS box function of the protein.
Of note, the SOCS-1 mutations are also present in the parental tumor of MedB-1 and were detected in 9 of 20
PMBL
.
[MeSH-major]
Janus Kinase 2 / metabolism.
Lymphoma
, B-
Cell
/ genetics.
Mediastinal
Neoplasms / genetics. Mutation. Suppressor of Cytokine Signaling Proteins / genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18035697.001).
[ISSN]
0070-4113
[Journal-full-title]
Verhandlungen der Deutschen Gesellschaft für Pathologie
[ISO-abbreviation]
Verh Dtsch Ges Pathol
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
31.
Hoda RS, Picklesimer L, Green KM, Self S:
Fine-needle aspiration of a primary mediastinal large B-cell lymphoma: a case report with cytologic, histologic, and flow cytometric considerations.
Diagn Cytopathol
; 2005 Jun;32(6):370-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fine-needle aspiration of
a primary mediastinal
large B
-
cell lymphoma
: a case report with cytologic, histologic, and flow cytometric considerations.
Fine-needle aspiration (FNA) cytology and immunophenotyping by flow cytometry (FCM) are increasingly being used for diagnosing and subclassifying
lymphoma
in the REAL/WHO classification.
Herein, we report a case of
primary mediastinal
large B
-
cell lymphoma
(
PMBL
),
a subtype
of diffuse large B
-
cell lymphoma
in the WHO classification, diagnosed by FNA cytology in conjunction with FCM.
CT scan revealed a 5-cm anterior
mediastinal
mass and
mediastinal
lymphadenopathy.
Endoscopic ultrasound-guided FNA of a 4.5-cm subcarinal lymph node showed medium to
large
atypical lymphocytes with scant to moderate finely vacuolated cytoplasm.
Malignant
large cell lymphoma
was cytologically diagnosed.
FCM, performed on a portion of the FNA specimen, demonstrated
large B
cells devoid of surface immunoglobulin expression, the characteristic immunophenotype of
PMBL
.
The histologic
diagnosis
was
PMBL
.
Touch-imprint cytology of the histologic specimen showed
large
cells with a narrow rim of clear cytoplasm and prominent outer
cell
border.
In the presence of
a mediastinal
mass, FNA cytology in conjunction with FCM can effectively diagnose
PMBL
in the appropriate clinical setting.
[MeSH-major]
Lymphoma
, B-
Cell
/ pathology.
Mediastinal
Neoplasms / pathology
[MeSH-minor]
Antigens, CD / analysis. Biopsy, Fine-Needle. Female. Flow Cytometry. Humans.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology. Middle Aged
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15880713.001).
[ISSN]
8755-1039
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD
32.
Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A:
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
J Pathol
; 2005 Oct;207(2):243-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
BIC and miR-155 are highly expressed in Hodgkin,
primary mediastinal
and
diffuse large B cell
lymphomas
.
In a previous study we demonstrated high expression of the non-coding BIC gene in the vast majority of Hodgkin's
lymphomas
(HLs).
Evidence suggesting that BIC is
a primary
microRNA transcript containing the mature microRNA-155 (miR-155) as part of a RNA hairpin is now accumulating.
We therefore analysed HL
cell
lines and tissue samples to determine whether miR-155 is also expressed in HL.
However, in
diffuse large B cell lymphoma
(DLBCL) and
primary mediastinal
B cell lymphoma
(
PMBL
), significant percentages of positive tumour cells were observed in 12/18 and 8/8 cases.
A higher proportion of tumour cells were positive for BIC in DLBCL with activated
B cell
-like phenotype than in DLBCL with germinal centre
B cell
-like phenotype.
Northern blot analysis showed expression of miR-155 in all DLBCL and
PMBL
derived
cell
lines and tissue samples analysed.
In summary, we demonstrate expression of
primary
microRNA BIC and its derivative miR-155 in HL,
PMBL
and DLBCL.
[MeSH-major]
Lymphoma
/ genetics.
Mediastinal
Neoplasms / genetics. MicroRNAs / genetics. Receptors, Antigen, B-
Cell
/ genetics
[MeSH-minor]
Cell
Line, Tumor. Hodgkin Disease / genetics. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods.
Lymphoma
, B-
Cell
/ genetics.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
(PMID = 16041695.001).
[ISSN]
0022-3417
[Journal-full-title]
The Journal of pathology
[ISO-abbreviation]
J. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / MicroRNAs; 0 / RNA, Neoplasm; 0 / Receptors, Antigen, B-Cell
33.
Vides Almonacid G, García A, Denninghoff V, Avagnina A, Castiglioni T, Elsner B:
[Flow cytometry for the study of mediastinal tumors with abundant lymphoid elements].
Medicina (B Aires)
; 2008;68(1):43-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Flow cytometry for the study of
mediastinal
tumors with abundant lymphoid elements].
[Transliterated title]
La citometría
de
flujo en el estudio
de
tumores
mediastinales
ricos en elementos linfoides.
The anterior
mediastinum
is a common site of tumors with abundant lymphoid elements.
Flow cytometry is a useful complementary technique to analyze this
type
of tumors, which provides qualitative and quantitative information.
A differential
diagnosis
can be sometimes made between thymoma and precursor T-lymphoblastic
lymphoma
(T-LBL).
A total of 38
mediastinal
tumors were analyzed, and samples were separated for flow cytometry.
Flow cytometry data from thymomas and normal
thymic
tissue were compared with 42 cases of T-LBL from other anatomical locations.
Among 38
mediastinal
tumors, we found 6 benign lesions, 9
diffuse large
B-
cell
lymphomas
(DLBCL), 10 Hodgkin
lymphomas
(HL), 11 thymomas and 2 T-LL.
Flow cytometry helped differentiate 10 cases of HL and 4 benign lesions from other
lymphomas
(DLBCL, T-LBL, etc.).
CD3, CD4 and CD8 expressions were most useful for the differential
diagnosis
of thymomas and T-LL.
To conclude, flow cytometry is a valid complementary technique, which promptly provides information on
mediastinal
lesions, requiring small quantities of tissue for both early
diagnosis
and follow up of these diseases.
[MeSH-major]
Antigens, CD / analysis. Biomarkers, Tumor. Flow Cytometry.
Mediastinal
Neoplasms / pathology. Thymoma / pathology.
Thymus
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18416319.001).
[ISSN]
0025-7680
[Journal-full-title]
Medicina
[ISO-abbreviation]
Medicina (B Aires)
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Argentina
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Biomarkers, Tumor
34.
Johnson PW, Davies AJ:
Primary mediastinal B-cell lymphoma.
Hematology Am Soc Hematol Educ Program
; 2008;:349-58
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
B-
cell lymphoma
.
Primary mediastinal
B-
cell lymphoma
is a discrete clinicopathologic entity.
Molecular analysis reveals it to be distinct from other types
of large
B-
cell lymphoma
, and retrospective analysis suggests that it may respond better to multi-agent chemotherapy regimens than to the more commonly used CHOP.
The addition of rituximab may mitigate such differences, and may also diminish the role of consolidation radiotherapy, which is often used to treat residual
mediastinal
masses.
For the future the role of FDG-PET scanning requires prospective examination, and it is hoped that this may allow the
de
-escalation of treatment if it can be shown to yield reliable prognostic information.
The relative rarity of this
type
of lymphoma
necessitates international collaboration in clinical trials, with a prospective clinicopathologic study, IELSG 26, already underway.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19074109.001).
[ISSN]
1520-4391
[Journal-full-title]
Hematology. American Society of Hematology. Education Program
[ISO-abbreviation]
Hematology Am Soc Hematol Educ Program
[Language]
ENG
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
[Number-of-references]
77
35.
Sambade C, Berglund M, Lagercrantz S, Sällström J, Reis RM, Enblad G, Glimelius B, Sundström C:
U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma.
Int J Cancer
; 2006 Feb 1;118(3):555-63
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
U-2940, a human B-
cell
line derived from a
diffuse large cell lymphoma
sequential to Hodgkin
lymphoma
.
Several patterns of association between Hodgkin and non-Hodgkin
lymphomas
are recognized, some of which support a common cellular origin or shared transformation events for both malignancies.
We describe the U-2940
cell
line derived from a
diffuse large
B-
cell lymphoma
with some features consistent with
mediastinal
large B
-
cell lymphoma
, clinically apparent 1 month after the initial course of chemotherapy for Hodgkin's disease, fulfilling the criteria for composite malignancies.
The cell
line is negative for Epstein-Barr virus and no evidence of t(14;18) was found.
U-2940 cells display multiple chromosomal rearrangements similar to recurrent aberrations described in both Hodgkin and non-Hodgkin
lymphomas
, also partially shared by U-2932 derived from a B-
cell lymphoma
sequential to Hodgkin's disease.
The original
large B
-
cell lymphoma
and the U-2940
cell
line bear microsatellite instability, an
abnormality
associated with particular subtypes of non-Hodgkin
lymphomas
and found in tissues involved by Hodgkin
lymphoma
.
Therefore, U-2940 cells bear several features known to occur in Hodgkin and in non-Hodgkin
lymphomas
, leading to the assumption that this
cell
line may constitute a useful tool to address elective pathways of lymphomagenesis and eventually the Hodgkin and non-Hodgkin
lymphoma
association.
[MeSH-major]
Hodgkin Disease / pathology.
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / pathology. Neoplasms, Second
Primary
/ pathology
[MeSH-minor]
Adolescent. Animals.
Cell
Line, Tumor. Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Colony-Forming Units Assay. DNA, Neoplasm / analysis. Epstein-Barr Virus Infections / etiology. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement. Herpesvirus 4, Human / pathogenicity. Humans. Immunoglobulin Heavy Chains / genetics. Mice. Mice, Nude. Spectral Karyotyping. Translocation, Genetic
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Genetic Alliance.
consumer health - Lymphoma, large-cell
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Cellosaurus - a cell line knowledge resource.
culture/stock collections - Cellosaurus - a cell line knowledge resource
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 Wiley-Liss, Inc.
(PMID = 16106419.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains
36.
Kolonić SO, Dzebro S, Kusec R, Planinc-Peraica A, Dominis M, Jaksić B:
Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics.
Int J Hematol
; 2006 May;83(4):331-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell lymphoma
: a single-center study of clinicopathologic characteristics.
Primary mediastinal
large B
-
cell lymphoma
(PMLBCL) is a subset of LBCL with unique clinicopathologic features.
[MeSH-major]
Lymphoma
, B-
Cell
/ blood.
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ blood.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / blood.
Mediastinal
Neoplasms / pathology
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 1993 Sep 30;329(14 ):987-94
[
8141877.001
]
[Cites]
Leuk Lymphoma. 1999 Sep;35(1-2):139-46
[
10512171.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
Br J Haematol. 1995 Apr;89(4):780-9
[
7539625.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Leuk Lymphoma. 1998 Jan;28(3-4):295-306
[
9517501.001
]
[Cites]
Int J Hematol. 2004 Jun;79(5):465-71
[
15239397.001
]
[Cites]
Am J Surg Pathol. 2001 Oct;25(10):1277-82
[
11688462.001
]
[Cites]
J Clin Oncol. 1993 Dec;11(12):2306-13
[
8246020.001
]
[Cites]
Br J Haematol. 2005 Sep;130(5):691-9
[
16115124.001
]
[Cites]
J Clin Oncol. 2001 Mar 15;19(6):1855-64
[
11251018.001
]
[Cites]
Am J Pathol. 1996 Jun;148(6):2017-25
[
8669486.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):243-53
[
12507907.001
]
[Cites]
Blood. 1994 Sep 1;84(5):1361-92
[
8068936.001
]
[Cites]
Ann Oncol. 1998 Jul;9(7):717-20
[
9739436.001
]
[Cites]
Ann Oncol. 1998 Sep;9(9):1027-9
[
9818079.001
]
[Cites]
Am J Clin Oncol. 2004 Jun;27(3):312-6
[
15170155.001
]
[Cites]
Leuk Lymphoma. 2000 Apr;37(3-4):361-5
[
10752987.001
]
[Cites]
J Clin Oncol. 1999 Mar;17(3):784-90
[
10071267.001
]
[Cites]
Br J Haematol. 2002 May;117(2):322-32
[
11972514.001
]
[Cites]
Blood. 1999 Nov 15;94(10):3567-75
[
10552968.001
]
[Cites]
Am J Surg Pathol. 1989 Sep;13(9):730-9
[
2788371.001
]
[Cites]
J Clin Oncol. 1990 May;8(5):804-8
[
1692089.001
]
[Cites]
Am J Surg Pathol. 1996 Jul;20(7):877-88
[
8669537.001
]
[Cites]
Br J Cancer. 2004 Jan 26;90(2):372-6
[
14735179.001
]
[Cites]
Cancer Res. 1971 Nov;31(11):1860-1
[
5121694.001
]
[Cites]
Am J Clin Pathol. 1999 Aug;112(2):241-7
[
10439805.001
]
(PMID = 16757434.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antigens, CD30; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-6; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
37.
Stefoni V, Broccoli A, Pellegrini C, Derenzini E, Fina M, Zinzani PL:
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission.
J Neurooncol
; 2009 Oct;95(1):135-139
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CNS recurrence of
primary mediastinal
large b
-
cell lymphoma
after complete remission.
[MeSH-major]
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Oncol. 2007 Jan;18(1):149-57
[
17018708.001
]
[Cites]
Ann Oncol. 2000 Jun;11(6):685-90
[
10942056.001
]
[Cites]
Ann Intern Med. 1985 May;102(5):596-602
[
2580468.001
]
[Cites]
Cancer. 2002 Aug 1;95(3):576-80
[
12209750.001
]
[Cites]
Leuk Lymphoma. 1996 Jul;22(3-4):361-3
[
8819088.001
]
[Cites]
Curr Treat Options Neurol. 2006 Jul;8(4):335-45
[
16942676.001
]
[Cites]
Oncologist. 2006 May;11(5):488-95
[
16720849.001
]
[Cites]
J Clin Oncol. 1993 Dec;11(12):2306-13
[
8246020.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2002;:283-96
[
12446428.001
]
[Cites]
Blood Rev. 2006 Nov;20(6):319-32
[
16884838.001
]
[Cites]
Ann Hematol. 1998 Nov;77(5):239-42
[
9858151.001
]
[Cites]
Ann Hematol. 2000 Dec;79(12):696-9
[
11195008.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2479-85
[
10561312.001
]
[Cites]
Ann Oncol. 1998 Sep;9(9):1027-9
[
9818079.001
]
[Cites]
Leuk Lymphoma. 1999 Feb;32(5-6):571-6
[
10048430.001
]
[Cites]
Cancer. 1994 Dec 1;74(11):3034-41
[
7954266.001
]
[Cites]
Cancer. 1982 Dec 1;50(11):2486-92
[
7139540.001
]
[Cites]
Ann Hematol. 2003 Apr;82(4):241-3
[
12707728.001
]
[Cites]
Ann Oncol. 2002 Jul;13(7):1099-107
[
12176790.001
]
[Cites]
Leuk Lymphoma. 2008;49 Suppl 1:52-8
[
18821433.001
]
[Cites]
Haematologica. 2008 Sep;93(9):1364-71
[
18603558.001
]
[Cites]
Haematologica. 2001 Feb;86(2):187-91
[
11224489.001
]
[Cites]
Leuk Lymphoma. 2002 Sep;43(9):1783-8
[
12685832.001
]
[Cites]
Blood. 1998 Feb 15;91(4):1178-84
[
9454747.001
]
[Cites]
Haematologica. 2006 Jan;91(1):96-103
[
16434377.001
]
(PMID = 19381440.001).
[ISSN]
1573-7373
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Complement 3d; EC 2.3.2.27 / MIB1 ligase, human; EC 2.3.2.27 / Ubiquitin-Protein Ligases
38.
Bödör C, Bognár A, Reiniger L, Szepesi A, Tóth E, Kopper L, Matolcsy A:
Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma.
Br J Haematol
; 2005 May;129(3):373-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in
mediastinal
large B
-
cell lymphoma
.
To determine the possible role of aberrant somatic hypermutation (ASHM) and activation-induced cytidine deaminase (AID) expression in the pathogenesis of
mediastinal
large B
-
cell lymphoma
(MBL), the mutational status of genes affected by ASHM, including c-MYC, PAX-5 and RhoH, was analysed, and the expression level of AID mRNA in tumour specimens from six patients with MBL was determined.
[MeSH-major]
Cytidine Deaminase / genetics.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ genetics.
Mediastinal
Neoplasms / genetics. Somatic Hypermutation, Immunoglobulin
[MeSH-minor]
B-
Cell
-Specific Activator Protein. DNA Mutational Analysis. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Gene Expression. Genes, myc / genetics. Humans. Neoplasm Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Transcription Factors / genetics. rho GTP-Binding Proteins / genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15842661.001).
[ISSN]
0007-1048
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / B-Cell-Specific Activator Protein; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / PAX5 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RhoH protein, human; 0 / Transcription Factors; EC 3.5.4.5 / Cytidine Deaminase; EC 3.6.5.2 / rho GTP-Binding Proteins
39.
Tsai HW, Yen YS, Chang KC:
Mediastinal large B-cell lymphoma with rosette formation mimicking thymoma and thymic carcinoid.
Histopathology
; 2006 Jul;49(1):93-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mediastinal
large B
-
cell lymphoma
with rosette formation mimicking thymoma and
thymic
carcinoid.
[MeSH-major]
Lymphoma
, B-
Cell
/
diagnosis
.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
.
Mediastinal
Neoplasms /
diagnosis
[MeSH-minor]
Adult. Carcinoid Tumor /
diagnosis
.
Diagnosis
, Differential. Female. Humans. Rosette Formation. Thymoma /
diagnosis
.
Thymus
Neoplasms /
diagnosis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16842255.001).
[ISSN]
0309-0167
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
40.
Juul-Madsen HR, Krogh-Meibom T, Henryon M, Palaniyar N, Heegaard PM, Purup S, Willis AC, Tornøe I, Ingvartsen KL, Hansen S, Holmskov U:
Identification and characterization of porcine mannan-binding lectin A (pMBL-A), and determination of serum concentration heritability.
Immunogenetics
; 2006 Apr;58(2-3):129-37
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification and characterization of porcine mannan-binding lectin A (
pMBL
-A), and determination of serum concentration heritability.
Although two MBLs (MBL-A and MBL-C) have been characterized in various species, the identity of porcine MBL (
pMBL
) was not clearly defined.
Based on the N-terminal sequence, multiple sequence alignment, and relative affinities to various carbohydrate ligands, we propose that the MBL purified in this study is
pMBL
-A.
We have generated antibodies to this protein and established an immunoassay to quantify
pMBL
-A in serum.
Using this assay, we found breed differences in
pMBL
-A concentration distributions and heritability estimates.
In the Duroc breed (n=588),
pMBL
-A concentrations show a unimodal distribution with a mean of 9,125 ng/ml.
In contrast, the
pMBL
-A concentration distributions in the Landrace breed (n=533) show three distinct mean values: 301, 2,385, and 11,507 ng/ml.
Furthermore, heritability calculations based on an additive genetic variance model with no fixed effects indicate that serum
pMBL
-A concentration is highly heritable in the Landrace (h (2)=0.8) but not in the Duroc breed (h (2)=0.15).
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2004 Jul 30;279(31):32728-36
[
15145932.001
]
[Cites]
Immunology. 2001 Mar;102(3):338-43
[
11298833.001
]
[Cites]
Mol Immunol. 2003 Sep;40(2-4):73-84
[
12914814.001
]
[Cites]
Immunopharmacology. 1992 Sep-Oct;24(2):91-9
[
1473968.001
]
[Cites]
Biochem Soc Trans. 2003 Aug;31(Pt 4):753-7
[
12887297.001
]
[Cites]
Annu Rev Immunol. 2002;20:197-216
[
11861602.001
]
[Cites]
J Immunol. 2000 Jul 15;165(2):878-87
[
10878362.001
]
[Cites]
J Exp Med. 1992 Dec 1;176(6):1497-502
[
1460414.001
]
[Cites]
J Immunol. 1995 Sep 15;155(6):3013-20
[
7673719.001
]
[Cites]
Scand J Immunol. 1996 Mar;43(3):289-96
[
8602463.001
]
[Cites]
J Immunol. 1993 Jan 15;150(2):571-8
[
8419490.001
]
[Cites]
Immunity. 2001 Jul;15(1):127-35
[
11485744.001
]
[Cites]
Immunol Rev. 2001 Apr;180:86-99
[
11414367.001
]
[Cites]
Nature. 1997 Apr 3;386(6624):506-10
[
9087411.001
]
[Cites]
FEBS Lett. 1975 Sep 15;57(2):187-91
[
1175787.001
]
[Cites]
Immunobiology. 1998 Aug;199(2):165-89
[
9777404.001
]
[Cites]
Nature. 1992 Nov 12;360(6400):183-6
[
1279438.001
]
[Cites]
Nature. 1992 Nov 12;360(6400):127-34
[
1436090.001
]
[Cites]
Scand J Immunol. 2001 May;53(5):489-97
[
11309157.001
]
[Cites]
Immunol Today. 1996 Nov;17(11):532-40
[
8961631.001
]
[Cites]
FEBS Lett. 1994 May 16;344(2-3):191-5
[
8187882.001
]
[Cites]
Biochem J. 1996 Oct 15;319 ( Pt 2):329-32
[
8912663.001
]
[Cites]
Mol Immunol. 2003 Nov;40(7):423-9
[
14568388.001
]
[Cites]
J Immunol. 2000 Mar 1;164(5):2610-8
[
10679100.001
]
(PMID = 16518621.001).
[ISSN]
0093-7711
[Journal-full-title]
Immunogenetics
[ISO-abbreviation]
Immunogenetics
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies; 0 / Mannose-Binding Lectin; 0 / Monosaccharides
41.
Miyake GM, Newton SE, Mariott WR, Chen EY:
Coordination polymerization of renewable butyrolactone-based vinyl monomers by lanthanide and early metal catalysts.
Dalton Trans
; 2010 Aug 7;39(29):6710-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The resulting atactic
PMBL
and PMMBL have high T(g)'s of 194 degrees C and 227 degrees C, respectively; when compared to atactic PMMA having comparable MW, the T(g) and onset decomposition temperatures of the PMMBL produced are substantially higher (by approximately 120 degrees C and 40 degrees C, respectively).
In comparison, the polymerizations by non-lanthanocene(III) silylamides,
Ln
[N(SiMe(3))(2)](3) (
Ln
= La, Nd, Sm, Er), and by cationic group 4 metallocene and half-metallocene catalysts incorporating C(2) and C(s) symmetric ligands are much slower and less effective.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20631950.001).
[ISSN]
1477-9234
[Journal-full-title]
Dalton transactions (Cambridge, England : 2003)
[ISO-abbreviation]
Dalton Trans
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
42.
Konety SH, Wooldridge JE, Kerber RE:
Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography.
Echocardiography
; 2006 Feb;23(2):147-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary
cardiac non-Hodgkin's
lymphoma
diagnosed by transthoracic echocardiography.
Primary
cardiac
lymphomas
are extremely rare and can be diagnosed by echocardiography.
We present the case of a 79-year-old man with an intracardiac mass, shown to be an aggressive
large B
-
cell lymphoma
by
mediastinal
aspiration, who had rapid regression of the tumor following one cycle of chemotherapy.
[MeSH-major]
Heart Neoplasms / ultrasonography.
Lymphoma
, Non-Hodgkin / ultrasonography
[MeSH-minor]
Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Diagnosis
, Differential. Humans. Male
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16445735.001).
[ISSN]
0742-2822
[Journal-full-title]
Echocardiography (Mount Kisco, N.Y.)
[ISO-abbreviation]
Echocardiography
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
43.
Gualco G, Weiss LM, Barber GN, Bacchi CE:
T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Hum Pathol
; 2010 Sep;41(9):1238-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
T-
cell
leukemia 1 expression in nodal Epstein-Barr virus-negative
diffuse large
B-
cell lymphoma
and
primary mediastinal
B-
cell lymphoma
.
The physiologic expression of the product of the proto-oncogene TCL1 (T-
cell
leukemia 1) is primarily restricted to early embryonic cells.
It has been shown that TCL1 is a powerful B-
cell
oncogene, which has been implicated in the pathogenesis of various types of mature B-
cell
lymphomas
.
There is no comparative information in the literature addressing the expression of TCL1 in pediatric and adult nodal
diffuse large
B-
cell lymphoma
or
primary mediastinal
large B
-
cell lymphoma
.
We studied 55 cases of adult and pediatric
diffuse large
B-
cell lymphoma
and
primary mediastinal
large B
-
cell lymphoma
to analyze the phenotypic profile of these
lymphomas
, including TCL1 expression, and its relationship with clinical outcome in different age groups.
TCL1 was observed in 11 cases, 5 pediatric and 6 adult cases, all but one
diffuse large
B-
cell lymphoma
.
TCL1 positivity was predominantly found in germinal center phenotype
diffuse large
B-
cell lymphoma
.
Primary mediastinal
large B
-
cell
lymphomas
infrequently expressed TCL1 in both age groups.
[MeSH-major]
Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / isolation & purification.
Lymphoma
, B-
Cell
/ metabolism.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ metabolism.
Mediastinal
Neoplasms / metabolism. Proto-Oncogene Proteins / metabolism
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Inc. All rights reserved.
(PMID = 20382409.001).
[ISSN]
1532-8392
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / TCL1A protein, human
44.
Mazzarotto R, Boso C, Vianello F, Aversa MS, Chiarion-Sileni V, Trentin L, Zambello R, Muzzio PC, Fiore D, Sotti G:
Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
Int J Radiat Oncol Biol Phys
; 2007 Jul 1;68(3):823-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell lymphoma
: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
PURPOSE: The optimal therapy for
primary mediastinal
large B
-
cell lymphoma
(PMLBCL) remains undefined.
In the absence of randomized trials, we report clinical findings and treatment response in 53 consecutive patients treated with intensive chemotherapy and
mediastinal
involved-field radiation therapy (IFRT).
CONCLUSIONS: Our report confirms the efficacy of intensive chemotherapy plus
mediastinal
IFRT.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Lymphoma
, B-
Cell
/ mortality.
Lymphoma
, B-
Cell
/ therapy. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality
[MeSH-minor]
Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Incidence. Italy / epidemiology. Male.
Mediastinum
. Middle Aged. Prognosis. Risk Assessment / methods. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17379431.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Controlled Clinical Trial; Journal Article
[Publication-country]
United States
45.
Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, Fujioka T, Masuda T, Kawase I, Ogawa H:
HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimaerism.
Clin Lab Haematol
; 2005 Apr;27(2):139-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HLA-haploidentical nonmyeloablative stem
cell
transplantation: induction to tolerance without passing through mixed chimaerism.
There are few reports of unmanipulated HLA-haploidentical nonmyeloablative stem
cell
transplantation (NST) using only pharmacological acute graft-vs.-host disease (GVHD) prophylaxis.
We present here a successful case of unmanipulated HLA-haploidentical NST for
mediastinal
large B cell lymphoma
that was resistant to autologous peripheral blood stem
cell
transplantation (PBSCT).
[MeSH-major]
Hematopoietic Stem
Cell
Transplantation / methods. Histocompatibility Testing
[MeSH-minor]
Adult. Female. Graft Survival. Graft vs Host Disease / prevention & control. Haplotypes. Humans. Immunosuppression / methods.
Lymphoma
, B-
Cell
/ therapy.
Mediastinal
Neoplasms / therapy. Transplantation Chimera. Transplantation Conditioning / methods
Genetic Alliance.
consumer health - Transplantation
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15784130.001).
[ISSN]
0141-9854
[Journal-full-title]
Clinical and laboratory haematology
[ISO-abbreviation]
Clin Lab Haematol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
46.
Mottok A, Renné C, Seifert M, Oppermann E, Bechstein W, Hansmann ML, Küppers R, Bräuninger A:
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.
Blood
; 2009 Nov 12;114(20):4503-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset
of B
-
cell lymphoma
entities.
In
primary mediastinal
large B
-
cell lymphoma
and Hodgkin
lymphoma
(HL), inactivating mutations in SOCS1, an inhibitor of JAK/STAT signaling, contribute to deregulated STAT activity.
Based on indications that the SOCS1 mutations are caused by
the B cell
-specific somatic hypermutation (SHM) process, we analyzed B-
cell
non-HL and normal B cells for mutations in SOCS1.
One-fourth
of diffuse large B
-
cell lymphoma
and follicular
lymphomas
carried SOCS1 mutations, which were preferentially targeted to SHM hotspot motifs and frequently obviously inactivating.
Rare mutations were observed in Burkitt
lymphoma
, plasmacytoma, and mantle
cell lymphoma
but not in tumors of a non-B-
cell
origin.
Mutations in single-sorted germinal center B cells were infrequent relative to other genes mutated as byproducts of normal SHM, indicating that SOCS1 inactivation in
primary mediastinal
large B
-
cell lymphoma
, HL,
diffuse large
B-
cell lymphoma
, and follicular
lymphoma
is frequently the result of aberrant SHM.
[MeSH-major]
Lymphoma
, B-
Cell
/ genetics. Somatic Hypermutation, Immunoglobulin / genetics. Suppressor of Cytokine Signaling Proteins / genetics
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19734449.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins
47.
Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C:
Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling.
J Pathol
; 2006 Oct;210(2):155-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Relationship between classic Hodgkin
lymphoma
and overlapping
large cell lymphoma
investigated by comparative expressed sequence hybridization expression profiling.
There is a diagnostic grey zone between classic Hodgkin
lymphoma
(cHL) and some non-Hodgkin
lymphoma
(NHL), including
primary mediastinal
B cell lymphoma
,
diffuse large B cell lymphoma
, and anaplastic
large cell lymphoma
.
To investigate this, we undertook an expression profiling study of these
lymphomas
using comparative expressed sequence hybridization.
Using this approach, we identified a unique expression profile for all
lymphoma
types investigated.
Moreover, anaplastic
lymphoma
kinase (ALK)-negative ALCL clustered in a separate branch together with ALCL-like HL.
Thus, analysing the neoplastic cells concurrently with their microenvironment, ALK-negative ALCL and ALCL-like HL seem to be related to each other, while cHL constitutes a separate
lymphoma
entity.
[MeSH-major]
Hodgkin Disease / genetics.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ genetics
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Child. Cluster Analysis. DNA, Neoplasm / genetics.
Diagnosis
, Differential. Female. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization / methods
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Lymphoma, large-cell
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16874743.001).
[ISSN]
0022-3417
[Journal-full-title]
The Journal of pathology
[ISO-abbreviation]
J. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Neoplasm
48.
Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH:
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
Br J Haematol
; 2005 Sep;130(5):691-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell lymphoma
: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
Primary mediastinal
large B
-
cell lymphoma
(PMLBL) is a distinct clinicopathological entity with unclear prognostic factors and optimal treatment approach.
Patients received cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone (CHOP)-like therapy, the non-Hodgkin
lymphoma
(NHL)-15 regimen or upfront autologous stem
cell
transplantation (ASCT) on Institutional Review Board approved trials or according to the institutional guidelines.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ drug therapy.
Mediastinal
Neoplasms / drug therapy
[MeSH-minor]
Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Factor Analysis, Statistical. Female. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. Stem
Cell
Transplantation. Survival Analysis. Transplantation, Autologous
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16115124.001).
[ISSN]
0007-1048
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / 5901CA05826-34
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
England
49.
Hasserjian RP, Ströbel P, Marx A:
Pathology of thymic tumors.
Semin Thorac Cardiovasc Surg
; 2005;17(1):2-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pathology of
thymic
tumors.
As the
thymus
is composed of heterogeneous admixture of lymphoid and epithelial elements, tumors originating in the
thymus
may be of varied histologic types.
Thymomas are the most common
thymic
tumor in adults.
In addition to histologic
subtype
, tumor stage and resection status are important factors in determining outcome in thymomas.
Thymic lymphomas
typically occur in younger patients than thymomas.
The most common
thymic lymphomas
are precursor T-lymphoblastic
lymphoma
, Hodgkin
lymphoma
, and
primary mediastinal
large B
-
cell lymphoma
.
Thorough histologic sampling and, in some cases, the appropriate use of ancillary studies such as immunohistochemistry, flow cytometry, and molecular studies, are important in proper pathologic evaluation of
thymic
tumors.
[MeSH-major]
Carcinoma / pathology. Hodgkin Disease / pathology. Thymoma / pathology.
Thymus
Gland / pathology.
Thymus
Neoplasms / classification.
Thymus
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16104355.001).
[ISSN]
1043-0679
[Journal-full-title]
Seminars in thoracic and cardiovascular surgery
[ISO-abbreviation]
Semin. Thorac. Cardiovasc. Surg.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
69
50.
Rodríguez J, Conde E, Gutiérrez A, García JC, Lahuerta JJ, Varela MR, Pérez C, Albo C, Caballero MD:
Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience.
Hematol Oncol
; 2008 Sep;26(3):171-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large cell lymphoma
(
PMBL
): frontline treatment with autologous stem
cell
transplantation (ASCT). The GEL-TAMO experience.
Given the excellent results obtained with present new induction regimens in
PMBL
, the role of frontline ASCT is controversial.
We present 71 patients with
PMBL
receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry.
With a median follow-up of 52.5 months, the OS, PFS and DFS at 4 years from
diagnosis
were, respectively, 84%, 81% and 81% for the first CR patients and 49%, 42% and 82% for the induction failure (PR and refractory) patients.
Our experience, with a prolonged follow-up, shows that patients with
PMBL
presenting at
diagnosis
with high-risk features or PR response to induction therapy have an encouraging survival with frontline ASCT.
[MeSH-major]
Hematopoietic Stem
Cell
Transplantation.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ therapy.
Mediastinal
Neoplasms / therapy
Genetic Alliance.
consumer health - Lymphoma, large-cell
.
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2008 John Wiley & Sons, Ltd.
[CommentIn]
Expert Rev Hematol. 2009 Feb;2(1):31-6
[
21082992.001
]
(PMID = 18432630.001).
[ISSN]
0278-0232
[Journal-full-title]
Hematological oncology
[ISO-abbreviation]
Hematol Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
51.
Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, Dubois G, Gaulard P, Möller P, Leroy K:
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Blood
; 2009 Aug 6;114(6):1236-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recurrent mutations of the STAT6 DNA binding domain in
primary mediastinal
B-
cell lymphoma
.
Primary mediastinal
B-
cell lymphoma
(
PMBL
) is a separate entity of aggressive B-
cell lymphoma
, characterized by a constitutive activation of janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, also observed in Hodgkin
lymphoma
.
Here, we show that MedB-1
PMBL
-derived and L1236 Hodgkin-derived
cell
lines and 20 of 55 (36%)
PMBL
cases harbor heterozygous missense mutations in STAT6 DNA binding domain, whereas no mutation was found in 25
diffuse large
B-
cell lymphoma
samples.
The mutant STAT6 proteins showed a decreased DNA binding ability in transfected HEK cells, but no decrease in expression of STAT6 canonical target genes was observed in
PMBL
cases with a mutated STAT6 gene.
Although the oncogenic properties of STAT6 mutant proteins remain to be determined, their recurrent selection in
PMBL
strongly argues for their involvement in the pathogenesis of this aggressive B-
cell lymphoma
.
[MeSH-major]
Gene Expression Regulation, Neoplastic / genetics.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ genetics.
Mediastinal
Neoplasms / genetics. Mutation / genetics. Neoplasm Proteins / genetics. STAT6 Transcription Factor / genetics
[MeSH-minor]
Cell
Line, Tumor. Female. Humans. Male. Protein Structure, Tertiary / genetics. Signal Transduction / genetics
HAL archives ouvertes.
Full text from
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Genes Chromosomes Cancer. 2001 Apr;30(4):393-401
[
11241792.001
]
[Cites]
Blood. 2001 Jan 1;97(1):250-5
[
11133768.001
]
[Cites]
Blood. 2002 Jan 15;99(2):618-26
[
11781246.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
Lancet Oncol. 2002 Apr;3(4):229-34
[
12067685.001
]
[Cites]
Int J Cancer. 2003 Feb 10;103(4):489-95
[
12478664.001
]
[Cites]
Blood. 2003 Apr 1;101(7):2756-61
[
12446450.001
]
[Cites]
J Immunol. 2003 Apr 1;170(7):3478-87
[
12646608.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Cancer Res. 2004 May 1;64(9):3271-5
[
15126369.001
]
[Cites]
Blood. 2004 Jul 15;104(2):543-9
[
15044251.001
]
[Cites]
Haematologica. 2004 Sep;89(9):1091-9
[
15377470.001
]
[Cites]
Blood. 1996 Feb 15;87(4):1571-8
[
8608249.001
]
[Cites]
Cell. 1998 May 29;93(5):827-39
[
9630226.001
]
[Cites]
Nature. 1998 Jul 9;394(6689):145-51
[
9671298.001
]
[Cites]
Hum Pathol. 1999 Feb;30(2):178-87
[
10029446.001
]
[Cites]
J Exp Med. 1999 Jun 21;189(12):1939-46
[
10377189.001
]
[Cites]
Blood. 2005 Mar 15;105(6):2535-42
[
15572583.001
]
[Cites]
Leukemia. 2005 Dec;19(12):2363-6
[
16208407.001
]
[Cites]
Blood. 2006 Mar 15;107(6):2470-3
[
16269615.001
]
[Cites]
Oncogene. 2006 Apr 27;25(18):2679-84
[
16532038.001
]
[Cites]
Cytokine Growth Factor Rev. 2006 Jun;17(3):173-88
[
16540365.001
]
[Cites]
Nat Rev Immunol. 2006 Aug;6(8):573-83
[
16868548.001
]
[Cites]
PLoS Genet. 2006 Aug 18;2(8):e131
[
16934001.001
]
[Cites]
Haematologica. 2007 Jul;92(7):913-20
[
17606441.001
]
[Cites]
Nature. 2007 Aug 30;448(7157):1058-62
[
17676033.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3387-90
[
17652621.001
]
[Cites]
Blood. 2007 Dec 15;110(13):4367-9
[
17878403.001
]
[Cites]
Trends Biochem Sci. 2008 Mar;33(3):122-31
[
18291658.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5
[
18765795.001
]
[Cites]
Leukemia. 2008 Nov;22(11):2106-10
[
18401415.001
]
[Cites]
J Biol Chem. 2000 May 12;275(19):14255-9
[
10747856.001
]
[Cites]
Int J Cancer. 2001 May 1;92(3):348-53
[
11291070.001
]
[CommentIn]
Blood. 2009 Aug 6;114(6):1133-4
[
19661272.001
]
(PMID = 19423726.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Neoplasm Proteins; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human
[Other-IDs]
NLM/ HALMS411059; NLM/ PMC2824656
52.
Coso D, Rey J, Bouabdallah R:
[Primary mediastinal B-cell lymphoma].
Rev Pneumol Clin
; 2010 Feb;66(1):32-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Primary mediastinal
B-
cell lymphoma
].
[Transliterated title]
Lymphomes
B
primitifs du
médiastin: aspect clinique.
Primary mediastinal
B-
cell lymphoma
(
PMBL
) is a clinicopathological entity among the world health organization classification of lymphoid neoplasms.
PMBL
often concerns young adults, and the disease remains a localized disease in the majority of cases.
The outcome of patients with
PMBL
is variable and unlike
diffuse large cell
lymphomas
, the international prognostic index seems to be less applicable to such disease.
However, high-dose chemotherapy supported by peripheral blood stem
cell
support is often warranted in poor-prognosis patients.
[MeSH-major]
Lymphoma
, B-
Cell
/
diagnosis
.
Mediastinal
Neoplasms /
diagnosis
[MeSH-minor]
Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fluorodeoxyglucose F18. Hematopoietic Stem
Cell
Transplantation. Humans. Positron-Emission Tomography. Prognosis. Radiotherapy, Adjuvant. Rituximab. Young Adult
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2010. Published by Elsevier Masson SAS.
(PMID = 20207294.001).
[ISSN]
0761-8417
[Journal-full-title]
Revue de pneumologie clinique
[ISO-abbreviation]
Rev Pneumol Clin
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
[Number-of-references]
32
53.
Banche G, Allizond V, Mandras N, Garzaro M, Cavallo GP, Baldi C, Scutera S, Musso T, Roana J, Tullio V, Carlone NA, Cuffini AM:
Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: in vivo immunological effects.
Int J Immunopathol Pharmacol
; 2007 Jan-Mar;20(1):129-38
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The aim of the present trial is to evaluate the efficacy of the treatment with an immunostimulating vaccine consisting of a polyvalent mechanical bacterial lysate (
PMBL
) in the prophylaxis of allergic rhinitis and subsequently to analyze its in vivo effects on immune responses.
41 allergic rhinitis patients were enrolled: 26 patients were randomly assigned to the group for
PMBL
sublingual treatment and 15 others to the group for placebo treatment.
For all 26 patients blood samples were drawn just before (T0) and after 3 months of
PMBL
treatment (T3) to evaluate plasma IgE levels (total and allergen-specific) and the cytokine production involved in the allergic response (IL-4, IFN-gamma).
The results of our study indicate that
PMBL
is effective in vivo in the reduction or in the elimination of the symptoms in rhinitis subjects during the treatment period in comparison to a non-immunostimulating treatment.
PMBL
treatment did not affect the serum IgE levels (either total or allergen-specific) and did not induce significant changes in IFN-gamma concentration.
In contrast,
PMBL
therapy may be accompanied, in some patients, by a potential immunomodulating activity by decreasing IL-4 cytokine expression.
Genetic Alliance.
consumer health - Allergic rhinitis
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17346436.001).
[ISSN]
0394-6320
[Journal-full-title]
International journal of immunopathology and pharmacology
[ISO-abbreviation]
Int J Immunopathol Pharmacol
[Language]
eng
[Publication-type]
Journal Article; Randomized Controlled Trial
[Publication-country]
England
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Bacterial Vaccines; 0 / Cytokines; 0 / RNA, Messenger; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E
54.
Frank DA:
STAT6 in PMBL: pathogenic or passenger?
Blood
; 2009 Aug 6;114(6):1133-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
STAT6 in
PMBL
: pathogenic or passenger?
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Blood. 2009 Aug 6;114(6):1236-42
[
19423726.001
]
(PMID = 19661272.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Comment; Journal Article
[Publication-country]
United States
55.
Barth TF, Möller P:
[Mediastinal large B-cell lymphoma].
Pathologe
; 2007 Feb;28(1):36-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Mediastinal
large B
-
cell lymphoma
].
[Transliterated title]
Das
mediastinale
(thymische)
grosszellige
B-
Zell
-
Lymphom
.
Mediastinal
B-
cell lymphoma
is a locally highly aggressive tumour which was first described in the early 1980s.
The incidence is about 2-3% of all non-Hodgkin's
lymphomas
.
The conceptional evolution of this
lymphoma
entity was hampered by its low incidence and the broad spectrum of morphological variants present.
However, since
mediastinal
B-
cell lymphoma
has distinct morphological, immunological, genetic, and clinical features, it has been listed in the revised European-American Classification of Lymphoid Neoplasms (REAL-Classification) since 1994 as a variant
of diffuse large B
-
cell lymphoma
.
In the World Health Organization classification of
malignant lymphomas
,
mediastinal
B-
cell lymphoma
is now listed with an own disease code (ICD-9679/3).
[MeSH-major]
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / pathology
[MeSH-minor]
Humans. Immunophenotyping. Incidence.
Lymphoma
, Non-Hodgkin / epidemiology.
Lymphoma
, Non-Hodgkin / pathology. Neoplasm Staging
SciCrunch.
The Antibody Registry: Reagent: Antibodies
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1986;409(1):79-92
[
3085342.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Am J Pathol. 1995 Mar;146(3):735-41
[
7887454.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Int J Cancer. 1989 Jan 15;43(1):10-6
[
2783413.001
]
[Cites]
Leukemia. 2006 Oct;20(10):1880-2
[
16871282.001
]
[Cites]
Histopathology. 1986 Jun;10(6):589-600
[
3525372.001
]
[Cites]
Am J Surg Pathol. 2001 Oct;25(10):1277-82
[
11688462.001
]
[Cites]
Am J Pathol. 1996 Jun;148(6):2017-25
[
8669486.001
]
[Cites]
Am J Clin Pathol. 1985 Jun;83(6):676-80
[
3923821.001
]
[Cites]
Genes Chromosomes Cancer. 1999 Nov;26(3):203-9
[
10502317.001
]
[Cites]
Nature. 1997 Jun 26;387(6636):921-4
[
9202126.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):243-53
[
12507907.001
]
[Cites]
Blood. 1994 Sep 1;84(5):1361-92
[
8068936.001
]
[Cites]
Ann Oncol. 1998;9 Suppl 5:S31-8
[
9926235.001
]
[Cites]
Hum Pathol. 1988 Nov;19(11):1280-7
[
3263309.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Apr;30(4):393-401
[
11241792.001
]
[Cites]
EMBO J. 1999 Mar 1;18(5):1309-20
[
10064597.001
]
[Cites]
Blood. 2003 Oct 15;102(8):2868-76
[
12829584.001
]
[Cites]
Blood. 1987 Apr;69(4):1087-95
[
3103712.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2479-85
[
10561312.001
]
[Cites]
Oncogene. 2006 Apr 27;25(18):2679-84
[
16532038.001
]
[Cites]
Blood. 2004 Jul 15;104(2):543-9
[
15044251.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1987;412(1):17-21
[
2825402.001
]
[Cites]
Blood. 1995 Oct 15;86(8):3072-82
[
7579401.001
]
[Cites]
Cancer. 1982 Dec 1;50(11):2486-92
[
7139540.001
]
[Cites]
Blood. 2002 Feb 15;99(4):1381-7
[
11830490.001
]
[Cites]
Blood. 1999 Nov 15;94(10):3567-75
[
10552968.001
]
[Cites]
J Clin Oncol. 1997 Apr;15(4):1646-53
[
9193365.001
]
[Cites]
Immunology. 1986 Nov;59(3):411-7
[
3491784.001
]
[Cites]
Blood. 1996 Feb 15;87(4):1571-8
[
8608249.001
]
[Cites]
Hum Pathol. 1999 Feb;30(2):178-87
[
10029446.001
]
[Cites]
Br J Haematol. 1999 Oct;107(1):106-13
[
10520030.001
]
[Cites]
Blood. 2006 Jul 1;108(1):311-8
[
16543468.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3909-18
[
9166827.001
]
[Cites]
J Pathol. 2005 Feb;205(3):336-48
[
15682441.001
]
[Cites]
Am J Surg Pathol. 1996 Jul;20(7):877-88
[
8669537.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Jun;31(2):191-5
[
11319807.001
]
[Cites]
Eur J Immunol. 1997 Jun;27(6):1398-405
[
9209491.001
]
[Cites]
Histopathology. 1986 Apr;10(4):379-90
[
2423430.001
]
[Cites]
Blood. 1991 Aug 1;78(3):780-8
[
1713514.001
]
[Cites]
Int J Cancer. 2001 May 1;92(3):348-53
[
11291070.001
]
[Cites]
Am J Clin Pathol. 1999 Aug;112(2):241-7
[
10439805.001
]
[Cites]
Blood. 2005 Mar 15;105(6):2535-42
[
15572583.001
]
(PMID = 17195039.001).
[ISSN]
0172-8113
[Journal-full-title]
Der Pathologe
[ISO-abbreviation]
Pathologe
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
56.
Iwasaki Y, Takami U, Shinohara Y, Kurita K, Akiyoshi K:
Selective biorecognition and preservation of cell function on carbohydrate-immobilized phosphorylcholine polymers.
Biomacromolecules
; 2007 Sep;8(9):2788-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Selective biorecognition and preservation
of cell
function on carbohydrate-immobilized phosphorylcholine polymers.
Poly[2-methacryloyloxyethyl phosphorylcholine (MPC)-co-n-butyl methacrylate (BMA)-co-2-lactobionamidoethyl methacrylate (LAMA)] (
PMBL
) was synthesized and coated on substrates by solvent evaporation.
Selective binding of galactose-recognized lectin, RCA120, to
a PMBL
surface was investigated by measurement of surface plasmon resonance.
The binding of RCA120 to the
PMBL
surface was confirmed by a remarkable change in resonance angle.
When a glucose-recognized lectin, concanavalin A, was in contact with
PMBL
, no change in the resonance angle was observed, and any nonspecific fouling of protein on
PMBL
was effectively reduced.
Cells of the human hepatocellular liver carcinoma
cell
line (HepG2) having asialoglycoprotein receptors (ASGPRs) were seeded on polymer surfaces.
On poly(BMA) (PBMA), many adherent cells were observed and were well-spread with monolayer adhesion, but
cell
adhesion was reduced on poly(MPC-co-BMA) (PMB).
HepG2 adhesion was observed on
PMBL
because
the cell
has ASGPRs; the number of cells adhering to the
PMBL
polymer surfaces increased with an increase in the density of galactose residues on the surface.
In contrast, adhesion of NIH-3T3 cells to
PMBL
was reduced in a manner similar to that on PMB because the NIH-3T3 cells did not have ASGPRs.
Cell
adhesion to the
PMBL
surface was well-regulated by ligand-receptor interactions.
Furthermore, some of the cells adhering to the
PMBL
surface had a spheroid form, and similarly shaped spheroids were scattered on the surface.
The MPC units in
PMBL
contribute to make a spheroid formation of HepG2 cells.
The amount of albumin secreted from a
cell
was compared with the chemical structure of the substrate.
The spheroid shaped cells cultured on the
PMBL
surface secreted much more albumin than did the spreading cells that adhered to the PBMA.
In conclusion, the biomembrane mimetic carbohydrate-immobilized phosphorylcholine polymers produced a suitable surface for biorecognition and preservation
of cell
function.
[MeSH-minor]
Albumins / metabolism. Animals.
Cell
Culture Techniques.
Cell
Line.
Cell
Line, Tumor. Hepatocytes / physiology. Humans. Lectins / chemistry. Mice. NIH 3T3 Cells. Protein Binding
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17663529.001).
[ISSN]
1525-7797
[Journal-full-title]
Biomacromolecules
[ISO-abbreviation]
Biomacromolecules
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Albumins; 0 / Carbohydrates; 0 / Lectins; 0 / Polymers; 107-73-3 / Phosphorylcholine
57.
Staudt LM, Dave S:
The biology of human lymphoid malignancies revealed by gene expression profiling.
Adv Immunol
; 2005;87:163-208
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Gene expression profiling provides a quantitative molecular framework for the study of human
lymphomas
.
Diffuse large
B-
cell lymphoma
(DLBCL), for example, consists of three gene expression subgroups, termed germinal center B-
cell
-like (GCB) DLBCL, activated B-
cell
-like (ABC) DLBCL, and
primary mediastinal
B-
cell lymphoma
(
PMBL
).
These DLBCL subgroups arise from different stages of normal B-
cell
differentiation, utilize distinct oncogenic mechanisms, and differ in their ability to be cured by chemotherapy.
ABC DLBCL and
PMBL
depend upon constitutive activation of the NF-kappaB pathway for their survival but GCB DLBCL does not, demonstrating that this pathway is a potential therapeutic target for certain DLBCL subgroups.
In DLBCL, mantle
cell lymphoma
, and follicular
lymphoma
, gene expression profiling has also been used to create gene expression-based models of survival, which have identified the biological characteristics of the tumors that influence their clinical behavior.
In mantle
cell lymphoma
, the length of survival following
diagnosis
is primarily influenced by the tumor proliferation rate, which can be quantitatively measured by a proliferation gene expression "signature."
Based on this accurate measure, the proliferation rate can now be viewed as an integration of several oncogenic lesions that each increase progression from the G1 to the S phase of the
cell
cycle.
In DLBCL and follicular
lymphoma
, gene expression profiling has revealed that the molecular characteristics of non-
malignant
tumor-infiltrating immune cells have a major influence on the length of survival.
The implications of these insights for the
diagnosis
and treatment of non-Hodgkin
lymphomas
are discussed.
MedlinePlus Health Information.
consumer health - Lymphoma
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1999 Nov 1;94(9):3129-34
[
10556199.001
]
[Cites]
Nat Med. 1999 Dec;5(12):1365-9
[
10581077.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
[Cites]
Cancer Res. 2000 Feb 1;60(3):549-52
[
10676635.001
]
[Cites]
Nature. 2000 Feb 3;403(6769):503-11
[
10676951.001
]
[Cites]
Ann Oncol. 2000;11 Suppl 1:23-7
[
10707774.001
]
[Cites]
Blood. 2000 Mar 15;95(6):2084-92
[
10706878.001
]
[Cites]
J Immunol. 2000 Jun 1;164(11):5998-6004
[
10820283.001
]
[Cites]
Am J Pathol. 2000 Jun;156(6):1987-96
[
10854221.001
]
[Cites]
Genes Dev. 2000 Jul 15;14(14):1810-23
[
10898795.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10209-13
[
10954754.001
]
[Cites]
Immunity. 2000 Aug;13(2):199-212
[
10981963.001
]
[Cites]
J Exp Med. 2000 Oct 2;192(7):1027-34
[
11015443.001
]
[Cites]
Mol Cell Biol. 2000 Nov;20(21):7903-13
[
11027261.001
]
[Cites]
J Immunol. 2000 Nov 15;165(10):5462-71
[
11067898.001
]
[Cites]
Semin Cancer Biol. 2000 Oct;10(5):331-40
[
11100880.001
]
[Cites]
Blood. 2001 Jan 1;97(1):101-6
[
11133748.001
]
[Cites]
Blood. 2001 Jan 1;97(1):250-5
[
11133768.001
]
[Cites]
Cold Spring Harb Symp Quant Biol. 1999;64:71-8
[
11232339.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Apr;30(4):393-401
[
11241792.001
]
[Cites]
Nat Immunol. 2001 Mar;2(3):261-8
[
11224527.001
]
[Cites]
Nat Immunol. 2000 Dec;1(6):526-32
[
11101876.001
]
[Cites]
Cancer Res. 2001 Mar 15;61(6):2409-12
[
11289106.001
]
[Cites]
Nature. 2001 Apr 26;410(6832):1099-103
[
11323673.001
]
[Cites]
Am J Surg Pathol. 2001 Jul;25(7):925-9
[
11420464.001
]
[Cites]
Nature. 2001 Jul 19;412(6844):300-7
[
11460154.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9654-9
[
11481442.001
]
[Cites]
Hum Pathol. 2001 Sep;32(9):926-34
[
11567221.001
]
[Cites]
Immunity. 2001 Sep;15(3):375-85
[
11567628.001
]
[Cites]
Blood. 2001 Nov 1;98(9):2762-70
[
11675349.001
]
[Cites]
J Exp Med. 2001 Dec 17;194(12):1861-74
[
11748286.001
]
[Cites]
Nat Med. 2002 Jan;8(1):68-74
[
11786909.001
]
[Cites]
Blood. 2002 Mar 1;99(5):1517-26
[
11861263.001
]
[Cites]
Immunity. 2002 Jul;17(1):51-62
[
12150891.001
]
[Cites]
Nat Med. 2002 Aug;8(8):793-800
[
12091876.001
]
[Cites]
Nature. 2002 Aug 22;418(6900):823
[
12192390.001
]
[Cites]
Cancer Cell. 2002 Aug;2(2):103-12
[
12204530.001
]
[Cites]
Eur J Haematol. 2002 Jul;69(1):11-20
[
12270057.001
]
[Cites]
J Mol Med (Berl). 2003 May;81(5):281-7
[
12721664.001
]
[Cites]
J Exp Med. 2003 Jun 16;197(12):1721-30
[
12810690.001
]
[Cites]
Am J Pathol. 2003 Jul;163(1):135-44
[
12819018.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
[
12829800.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
[
12900505.001
]
[Cites]
Semin Cancer Biol. 2003 Jun;13(3):191-202
[
12959350.001
]
[Cites]
Am J Surg Pathol. 2003 Sep;27(9):1269-77
[
12960812.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
J Biol Chem. 2003 Oct 3;278(40):38980-90
[
12860980.001
]
[Cites]
J Clin Pathol. 2003 Oct;56(10):747-52
[
14514777.001
]
[Cites]
Genome Biol. 2003;4(10):R69
[
14519204.001
]
[Cites]
Immunity. 2003 Oct;19(4):607-20
[
14563324.001
]
[Cites]
Nucleic Acids Res. 2003 Nov 1;31(21):6148-56
[
14576301.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Blood. 2004 Jan 1;103(1):275-82
[
14504078.001
]
[Cites]
Cancer Cell. 2004 Feb;5(2):191-9
[
14998494.001
]
[Cites]
Nat Rev Cancer. 2004 Apr;4(4):309-14
[
15057290.001
]
[Cites]
Am J Surg Pathol. 2004 Apr;28(4):464-70
[
15087665.001
]
[Cites]
N Engl J Med. 2004 Apr 29;350(18):1828-37
[
15115829.001
]
[Cites]
Blood. 2004 Jun 1;103(11):4251-8
[
14976040.001
]
[Cites]
Leuk Lymphoma. 2003;44 Suppl 3:S5-12
[
15202519.001
]
[Cites]
Blood. 2004 Jul 15;104(2):543-9
[
15044251.001
]
[Cites]
J Immunol. 2004 Jul 15;173(2):1158-65
[
15240705.001
]
[Cites]
Cell. 2004 Aug 20;118(4):477-91
[
15315760.001
]
[Cites]
J Biol Chem. 2004 Aug 27;279(35):36698-707
[
15199070.001
]
[Cites]
Immunity. 2004 Jul;21(1):81-93
[
15345222.001
]
[Cites]
Leuk Lymphoma. 2004 Oct;45(10):2105-10
[
15370257.001
]
[Cites]
Nature. 2004 Oct 7;431(7009):712-7
[
15361884.001
]
[Cites]
Nature. 1982 Sep 2;299(5878):65-7
[
7110326.001
]
[Cites]
N Engl J Med. 1984 Dec 6;311(23):1471-5
[
6548796.001
]
[Cites]
Histopathology. 1986 Apr;10(4):379-90
[
2423430.001
]
[Cites]
Mod Pathol. 2002 Nov;15(11):1172-80
[
12429796.001
]
[Cites]
Nat Genet. 2002 Dec;32(4):606-13
[
12402037.001
]
[Cites]
Am J Clin Pathol. 1991 Jul;96(1):81-9
[
2069139.001
]
[Cites]
Mol Cell Biol. 1991 Oct;11(10):4846-53
[
1833629.001
]
[Cites]
Oncogene. 1992 Jul;7(7):1401-6
[
1535701.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4
[
1495966.001
]
[Cites]
N Engl J Med. 1992 Oct 22;327(17):1209-15
[
1406793.001
]
[Cites]
Am J Surg Pathol. 1992 Sep;16(9):885-95
[
1415907.001
]
[Cites]
Immunology. 1992 Dec;77(4):621-3
[
1337336.001
]
[Cites]
Leukemia. 1993 Mar;7(3):398-403
[
7680400.001
]
[Cites]
N Engl J Med. 1993 Sep 30;329(14):987-94
[
8141877.001
]
[Cites]
Immunol Res. 1993;12(3):213-32
[
8288943.001
]
[Cites]
Blood. 1994 Jun 15;83(12):3689-96
[
8204893.001
]
[Cites]
Oncogene. 1994 Jul;9(7):1925-9
[
8208539.001
]
[Cites]
Int Immunol. 1994 Aug;6(8):1203-11
[
7981148.001
]
[Cites]
Oncogene. 1995 May 4;10(9):1833-40
[
7753558.001
]
[Cites]
Blood. 1995 Jul 1;86(1):28-37
[
7795234.001
]
[Cites]
Blood. 1995 Jul 1;86(1):45-53
[
7795255.001
]
[Cites]
Am J Pathol. 1995 Aug;147(2):405-11
[
7639334.001
]
[Cites]
Cell. 1995 Aug 25;82(4):621-30
[
7664341.001
]
[Cites]
Biochim Biophys Acta. 1996 Feb 7;1305(1-2):39-43
[
8605247.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7
[
9653180.001
]
[Cites]
Mol Cell Biol. 1998 Sep;18(9):5500-10
[
9710634.001
]
[Cites]
Oncogene. 1999 Jan 28;18(4):943-53
[
10023670.001
]
[Cites]
Oncogene. 1999 May 20;18(20):3063-70
[
10340377.001
]
[Cites]
J Clin Oncol. 1999 Jan;17(1):268-76
[
10458242.001
]
[Cites]
Nat Med. 1999 Oct;5(10):1171-7
[
10502821.001
]
[Cites]
Cold Spring Harb Symp Quant Biol. 1961;26:389-401
[
14475415.001
]
[Cites]
N Engl J Med. 2004 Nov 18;351(21):2159-69
[
15548776.001
]
[Cites]
Blood. 2005 Nov 1;106(9):3183-90
[
16046532.001
]
[Cites]
Biochem Biophys Res Commun. 1996 Mar 27;220(3):911-5
[
8607866.001
]
[Cites]
Blood. 1996 Feb 15;87(4):1571-8
[
8608249.001
]
[Cites]
J Exp Med. 1996 Feb 1;183(2):393-401
[
8627152.001
]
[Cites]
Blood. 1996 May 15;87(10):4340-7
[
8639794.001
]
[Cites]
J Exp Med. 1996 Mar 1;183(3):971-7
[
8642300.001
]
[Cites]
Oncogene. 1996 Jun 6;12(11):2331-42
[
8649773.001
]
[Cites]
J Clin Oncol. 1996 Apr;14(4):1269-74
[
8648383.001
]
[Cites]
Blood. 1996 Jun 15;87(12):5257-68
[
8652841.001
]
[Cites]
J Immunol. 1996 Jul 1;157(1):81-6
[
8683159.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6947-52
[
8692924.001
]
[Cites]
Blood. 1996 Aug 15;88(4):1359-64
[
8695854.001
]
[Cites]
J Exp Med. 1996 Aug 1;184(2):627-37
[
8760816.001
]
[Cites]
J Biol Chem. 1996 Aug 23;271(34):20231-4
[
8702752.001
]
[Cites]
Blood. 1997 Jan 1;89(1):272-80
[
8978301.001
]
[Cites]
Blood. 1997 Mar 15;89(6):2067-78
[
9058729.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2507-12
[
9122225.001
]
[Cites]
Int Immunol. 1997 Mar;9(3):407-14
[
9088979.001
]
[Cites]
Science. 1997 Apr 25;276(5312):589-92
[
9110977.001
]
[Cites]
Science. 1997 Apr 25;276(5312):596-9
[
9110979.001
]
[Cites]
Nat Genet. 1997 Jun;16(2):161-70
[
9171827.001
]
[Cites]
Eur J Immunol. 1997 Jun;27(6):1398-405
[
9209491.001
]
[Cites]
Blood. 1997 Sep 15;90(6):2188-95
[
9310469.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10762-7
[
9380707.001
]
[Cites]
Cancer Res. 1997 Oct 15;57(20):4608-14
[
9377576.001
]
[Cites]
J Clin Invest. 1997 Dec 15;100(12):2961-9
[
9399941.001
]
[Cites]
Cancer. 1998 Feb 1;82(3):567-75
[
9452276.001
]
[Cites]
Blood. 1998 Apr 15;91(8):2977-84
[
9531609.001
]
[Cites]
Oncogene. 1998 Apr 23;16(16):2131-9
[
9572494.001
]
[Cites]
Nucleic Acids Res. 1998 Jun 15;26(12):2899-907
[
9611234.001
]
[Cites]
Genes Dev. 1998 Jul 1;12(13):1953-61
[
9649500.001
]
[Cites]
Mol Cell Biol. 2002 Mar;22(6):1804-18
[
11865059.001
]
[Cites]
Blood. 2002 Apr 1;99(7):2285-90
[
11895757.001
]
[Cites]
Blood. 2002 Apr 1;99(7):2562-8
[
11895794.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5757-9
[
11983876.001
]
[Cites]
J Clin Oncol. 2002 May 15;20(10):2453-63
[
12011122.001
]
[Cites]
Curr Opin Hematol. 2002 Jul;9(4):333-8
[
12042708.001
]
[Cites]
Mol Cell Biol. 2002 Jul;22(13):4771-80
[
12052884.001
]
[Cites]
N Engl J Med. 2002 Jun 20;346(25):1937-47
[
12075054.001
]
[Cites]
Nat Immunol. 2002 Jul;3(7):611-8
[
12087419.001
]
[Cites]
Nat Rev Immunol. 2002 Dec;2(12):920-32
[
12461565.001
]
[Cites]
Genes Dev. 2002 Dec 1;16(23):2991-3003
[
12464630.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):243-53
[
12507907.001
]
[Cites]
Blood. 2003 Jan 15;101(2):433-40
[
12509382.001
]
[Cites]
J Biol Chem. 2003 Feb 14;278(7):5205-13
[
12435740.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2639-44
[
12604779.001
]
[Cites]
Cancer Cell. 2003 Feb;3(2):185-97
[
12620412.001
]
[Cites]
J Biol Chem. 2003 Apr 4;278(14):12563-73
[
12529326.001
]
[Cites]
Blood. 2003 Apr 15;101(8):3181-7
[
12515730.001
]
[Cites]
Cell. 2003 Apr 18;113(2):207-19
[
12705869.001
]
[Cites]
Biochem Biophys Res Commun. 2003 May 2;304(2):393-8
[
12711328.001
]
[Cites]
N Engl J Med. 2003 May 1;348(18):1777-85
[
12724484.001
]
[Cites]
Nat Med. 2003 May;9(5):562-7
[
12704383.001
]
[Cites]
Blood. 2003 Jun 1;101(11):4464-71
[
12531790.001
]
(PMID = 16102574.001).
[ISSN]
0065-2776
[Journal-full-title]
Advances in immunology
[ISO-abbreviation]
Adv. Immunol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / SC / Z01 SC004024-18
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
165
[Other-IDs]
NLM/ NIHMS5150; NLM/ PMC1351148
58.
Dzhumabaeva BT, Kremenetskaia AM, Gotman LN, Shavlokhov VS, Kaplanskaia IB, Kravchenko SK, Vishnevskaia ES, Gemdzhian EG, Frank GA:
[Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in primary mediastinal B-cell lymphosarcoma].
Ter Arkh
; 2005;77(8):78-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in
primary mediastinal
B-
cell
lymphosarcoma].
AIM: To evaluate efficacy of treatment of
primary mediastinal
B-
cell
lymphosarcoma (
PMBLS
).
Group 3 (n = 36)--2 courses of CHOP and 2-3 courses of ESHAP or 3 courses of DexaBEAM, surgical removal of residual
mediastinal
tumor (RMT), RT.
CONCLUSION: CHOP program is ineffective in
PMBLS
.
[MeSH-major]
Lymphoma
, B-
Cell
/ radiotherapy.
Lymphoma
, B-
Cell
/ surgery.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ radiotherapy.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ surgery.
Lymphoma
, Non-Hodgkin / radiotherapy.
Lymphoma
, Non-Hodgkin / surgery.
Mediastinal
Neoplasms / radiotherapy.
Mediastinal
Neoplasms / surgery
Genetic Alliance.
consumer health - Lymphosarcoma
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
Hazardous Substances Data Bank.
METHOTREXATE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16206611.001).
[ISSN]
0040-3660
[Journal-full-title]
Terapevticheskiĭ arkhiv
[ISO-abbreviation]
Ter. Arkh.
[Language]
rus
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Russia (Federation)
[Chemical-registry-number]
11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MACOP-B protocol
59.
Rózańska-Kudelska M, Maksimowicz T, Sieśkiewicz A:
[B-cell lymphoma of the nose cavity--case report].
Otolaryngol Pol
; 2008;62(4):496-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[B-
cell lymphoma
of the nose cavity--case report].
INTRODUCTION: Non-Hodgkin's
lymphoma of
the nose and sinuses accounts for 5,8-8% of the tumors in that localisation.
Large B
-
cell lymphoma
(DLBCL) are frequent in
mediastinum
, nasopharynx, stomach and retroperitoneal space.
AIM: The aim of the study was to show a case of the female patient presented DLBCL-
lymphoma of
the right nose cavity and cutaneous
lymphoma of
the right lower leg.
MATERIAL AND METHODS: We described a case of the 68-year-old female diagnosed in Otolaryngology Clinic of the Medical University in Bialystok with DLBCL-
lymphoma of
the right nose cavity.
One month later two tumors on the skin of the right lower leg was appeared (histological: DLBCL-
lymphoma
).
CONCLUSIONS: We present the case of the rare occurrence of a DLBCL-
lymphoma of
the nose cavity and the skin of the lower leg.
Chemotherapy, immunochemotherapy and radiotherapy are suitable treatment fort that
type
of lymphoma
.
[MeSH-major]
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ therapy. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18837234.001).
[ISSN]
0030-6657
[Journal-full-title]
Otolaryngologia polska = The Polish otolaryngology
[ISO-abbreviation]
Otolaryngol Pol
[Language]
pol
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Poland
60.
Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, Alonso MA, Pohlman B:
MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.
Am J Clin Pathol
; 2006 May;125(5):776-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
MAL is expressed in a subset of Hodgkin
lymphoma
and identifies a population of patients with poor prognosis.
Classical Hodgkin
lymphoma
(cHL) and
mediastinal
(
thymic
)
large B
-
cell lymphoma
(MLBL) have clinical, histopathologic, and molecular genetic similarities.
Expression correlated with nodular sclerosis
subtype
, and within this
subtype
, with grade 2 histology.
[MeSH-major]
Hodgkin Disease /
diagnosis
. Hodgkin Disease / metabolism. Membrane Transport Proteins / metabolism. Myelin Proteins / metabolism. Proteolipids / metabolism
[MeSH-minor]
Adult. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry.
Lymphoma
, B-
Cell
/
diagnosis
.
Lymphoma
, B-
Cell
/ metabolism.
Lymphoma
, B-
Cell
/ therapy.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ metabolism.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ therapy. Male.
Mediastinal
Neoplasms /
diagnosis
.
Mediastinal
Neoplasms / metabolism.
Mediastinal
Neoplasms / therapy. Middle Aged. Myelin and Lymphocyte-Associated Proteolipid Proteins. Neoplasm Staging. Survival Rate. Tissue Array Analysis
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16707382.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
61.
Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M:
Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
Leuk Lymphoma
; 2008 Jul;49(7):1329-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Salvage chemotherapy and autologous stem
cell
transplantation are inferior for relapsed or refractory
primary mediastinal
large B
-
cell lymphoma
compared with
diffuse large
B-
cell lymphoma
.
Primary mediastinal
large B
-
cell lymphoma
(
PMLCL
) is an aggressive non-Hodgkin
lymphoma
with distinct clinical and gene expression profiles.
Outcomes of salvage chemotherapy and autologous stem
cell
transplantation (ASCT) for relapsed or refractory disease (RR) have not been well characterised.
We retrospectively identified 180 consecutive RR patients (37
PMLCL
and a control group of 143 DLBCL) that underwent salvage chemotherapy.
The overall response rate (ORR) to salvage chemotherapy (25% vs. 48%, p = 0.01) and 2-year OS after
diagnosis
of RR disease (15% vs. 34%, p = 0.018) was inferior in
PMLCL
patients.
The 2-year post-ASCT OS (67%
PMLCL
vs. 53%, p = 0.78) and PFS (57%
PMLCL
vs. 36%, p = 0.64) were similar.
RR
PMLCL
had an inferior ORR and survival compared with DLBCL but chemosensitive
PMLCL
and DLBCL patients have similar outcomes post-ASCT.
Strategies for
PMLCL
should focus on identifying poor risk patients to test novel induction and salvage strategies.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem
Cell
Transplantation / methods.
Lymphoma
, B-
Cell
/ therapy.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ therapy.
Mediastinal
Neoplasms / therapy. Salvage Therapy / methods
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Genetic Alliance.
consumer health - Transplantation
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18604722.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
62.
Ríos A, Torres J, Roca MJ, Galindo PJ, Alonso JL, Parrilla P:
[Primary thymic lymphomas].
Rev Clin Esp
; 2006 Jul-Aug;206(7):326-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Primary thymic lymphomas
].
[Transliterated title]
Linfomas primarios
del timo.
INTRODUCTION:
Primary thymic lymphomas
(PTLs) are uncommon, and their prognosis is linked with early treatment.
MATERIAL AND METHODS: Ten LPTs--four Hodgkin's and six non-Hodgkin's (4
primary mediastinal
B
lymphomas
[
PMBLs
] and 2 lymphoblastic
T lymphomas
[LTLs]--were reviewed.
RESULTS: The initial diagnostic suspicion in the Hodgkin's
lymphomas
was thymoma in two cases and
lymphoma
in the other 2.
The non-Hodgkin's
lymphomas
had
large
tumors and short evolution.
CONCLUSIONS: In a patient with
thymic
tumour with a preoperative or intraoperative study suspected of having a
lymphoma
, it is necessary to do a biopsy and not resective surgery, to avoid unnecessary resections and morbidity.
PTLs are uncommon but aggressive, principally the non-Hodgkin's
lymphomas
.
[MeSH-major]
Hodgkin Disease / radiography.
Lymphoma
, Non-Hodgkin / radiography.
Thymus
Neoplasms / radiography
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16831379.001).
[ISSN]
0014-2565
[Journal-full-title]
Revista clínica española
[ISO-abbreviation]
Rev Clin Esp
[Language]
spa
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Spain
63.
Wu D, Dutra B, Lindeman N, Takahashi H, Takeyama K, Harris NL, Pinkus GS, Longtine J, Shipp M, Kutok JL:
No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma.
Diagn Mol Pathol
; 2009 Sep;18(3):144-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in
primary mediastinal
large B
-
cell lymphoma
.
Recently, our work comparing gene expression signatures of
primary mediastinal
large B
-
cell
lymphomas
(PMLBCL) versus nodal
diffuse large
B-
cell
lymphomas
revealed a relative increase in JAK2 transcripts in the former, suggesting a role for increased JAK2 signaling in a subset of these tumors.
Analysis using
cell
lines derived from PMLBCLs (n = 1) and from the molecularly similar classic Hodgkin
lymphoma
(n = 4) also failed to reveal involvement of a mutant JAK2 allele.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Surg Pathol. 1986 Mar;10(3):176-91
[
3953939.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Nature. 1997 Jun 26;387(6636):917-21
[
9202125.001
]
[Cites]
Nature. 1997 Jun 26;387(6636):921-4
[
9202126.001
]
[Cites]
Blood. 2005 Mar 15;105(6):2535-42
[
15572583.001
]
[Cites]
Blood. 2005 Sep 15;106(6):2162-8
[
15920007.001
]
[Cites]
Leukemia. 2006 Jan;20(1):157-8
[
16331280.001
]
[Cites]
J Clin Invest. 2006 Oct;116(10):2695-706
[
16906227.001
]
[Cites]
N Engl J Med. 2007 Feb 1;356(5):459-68
[
17267906.001
]
[Cites]
Blood. 2008 Feb 1;111(3):1686-9
[
17984312.001
]
[Cites]
J Leukoc Biol. 1999 Oct;66(4):588-92
[
10534114.001
]
[Cites]
Jpn J Cancer Res. 1999 Sep;90(9):951-6
[
10551323.001
]
[Cites]
Cancer Res. 2000 Feb 1;60(3):549-52
[
10676635.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Apr;30(4):393-401
[
11241792.001
]
[Cites]
Nat Genet. 2001 May;28(1):29-35
[
11326271.001
]
[Cites]
Ann Hematol. 2001;80 Suppl 3:B49-53
[
11757707.001
]
[Cites]
Blood. 2002 Jun 15;99(12):4283-97
[
12036854.001
]
[Cites]
Lancet Oncol. 2002 Apr;3(4):229-34
[
12067685.001
]
[Cites]
Int J Cancer. 2003 Feb 10;103(4):489-95
[
12478664.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Am J Surg Pathol. 1989 Sep;13(9):730-9
[
2788371.001
]
(PMID = 19704259.001).
[ISSN]
1533-4066
[Journal-full-title]
Diagnostic molecular pathology : the American journal of surgical pathology, part B
[ISO-abbreviation]
Diagn. Mol. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA092625-08; United States / NCI NIH HHS / CA / P01 CA092625; United States / NCI NIH HHS / CA / P01 CA092625-08; United States / NCI NIH HHS / CA / P01CA092625-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
[Other-IDs]
NLM/ NIHMS80972; NLM/ PMC2732663
64.
Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM:
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
J Exp Med
; 2007 Mar 19;204(3):633-43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant immunoglobulin class switch recombination and switch translocations in activated
B cell
-like
diffuse large B cell lymphoma
.
To elucidate the mechanisms underlying chromosomal translocations in
diffuse large B cell lymphoma
(DLBCL), we investigated the nature and extent of immunoglobulin class switch recombination (CSR) in these tumors.
We used Southern blotting to detect legitimate and illegitimate CSR events in tumor samples of the activated
B cell
-like (ABC), germinal center
B cell
-like (GCB), and
primary mediastinal
B cell lymphoma
(
PMBL
) subgroups of DLBCL.
The frequency of legitimate CSR was lower in ABC DLBCL than in GCB DLBCL and
PMBL
.
In contrast, ABC DLBCL had a higher frequency of internal deletions within the switch mu (Smu) region compared with GCB DLBCL and
PMBL
.
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Immunol. 2007 Jan;37(1):235-9
[
17183606.001
]
[Cites]
Immunity. 2006 Aug;25(2):225-36
[
16919487.001
]
[Cites]
Blood. 2000 Feb 1;95(3):1032-8
[
10648419.001
]
[Cites]
Nature. 2000 Feb 3;403(6769):503-11
[
10676951.001
]
[Cites]
Immunity. 2000 Aug;13(2):199-212
[
10981963.001
]
[Cites]
Cell. 2000 Sep 1;102(5):553-63
[
11007474.001
]
[Cites]
Cell. 2000 Sep 1;102(5):565-75
[
11007475.001
]
[Cites]
Cold Spring Harb Symp Quant Biol. 1999;64:71-8
[
11232339.001
]
[Cites]
Curr Opin Oncol. 2001 Sep;13(5):325-34
[
11555708.001
]
[Cites]
Nature. 2001 Dec 6;414(6864):660-5
[
11740565.001
]
[Cites]
J Exp Med. 2001 Dec 17;194(12):1861-74
[
11748286.001
]
[Cites]
Trends Immunol. 2002 Jan;23(1):31-9
[
11801452.001
]
[Cites]
Science. 2002 Feb 15;295(5558):1301-6
[
11847344.001
]
[Cites]
N Engl J Med. 2002 Jun 20;346(25):1937-47
[
12075054.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9984-9
[
12114543.001
]
[Cites]
Immunity. 2002 Jul;17(1):51-62
[
12150891.001
]
[Cites]
Am J Pathol. 2002 Aug;161(2):413-20
[
12163366.001
]
[Cites]
Mod Pathol. 2002 Nov;15(11):1172-80
[
12429796.001
]
[Cites]
Blood. 2003 Feb 1;101(3):1015-23
[
12393575.001
]
[Cites]
J Exp Med. 2003 Jun 16;197(12):1767-78
[
12810694.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
[
12900505.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Nat Immunol. 2004 May;5(5):481-7
[
15077110.001
]
[Cites]
Nat Rev Immunol. 2004 Jul;4(7):541-52
[
15229473.001
]
[Cites]
Cell. 2004 Aug 20;118(4):431-8
[
15315756.001
]
[Cites]
Immunity. 2004 Jul;21(1):81-93
[
15345222.001
]
[Cites]
Blood. 1996 Jul 15;88(2):674-81
[
8695815.001
]
[Cites]
J Exp Med. 1996 Jul 1;184(1):203-14
[
8691135.001
]
[Cites]
Blood. 1996 Aug 1;88(3):985-94
[
8704258.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6
[
8943038.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3909-18
[
9166827.001
]
[Cites]
EMBO J. 1997 Dec 1;16(23):7118-29
[
9384589.001
]
[Cites]
J Biol Chem. 1999 Jun 25;274(26):18470-6
[
10373455.001
]
[Cites]
J Exp Med. 2004 Nov 1;200(9):1111-21
[
15504820.001
]
[Cites]
J Exp Med. 2004 Nov 1;200(9):1103-10
[
15520243.001
]
[Cites]
Blood. 2004 Nov 15;104(10):3318-25
[
15304391.001
]
[Cites]
Leukemia. 2004 Dec;18(12):2026-31
[
15496980.001
]
[Cites]
Nature. 2004 Dec 2;432(7017):635-9
[
15577913.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):28-40
[
15671525.001
]
[Cites]
Nat Immunol. 2005 Jul;6(7):655-61
[
15970938.001
]
[Cites]
Adv Immunol. 2005;87:163-208
[
16102574.001
]
[Cites]
J Exp Med. 2005 Aug 15;202(4):561-8
[
16103411.001
]
[Cites]
Mol Cell. 2006 Jan 20;21(2):201-14
[
16427010.001
]
[Cites]
J Exp Med. 2006 Feb 20;203(2):311-7
[
16492805.001
]
[Cites]
Nature. 2006 Mar 2;440(7080):105-9
[
16400328.001
]
[Cites]
Curr Opin Immunol. 2006 Apr;18(2):164-74
[
16464563.001
]
[Cites]
Blood. 2006 May 15;107(10):4090-100
[
16424392.001
]
[Cites]
N Engl J Med. 2006 Jun 8;354(23):2431-42
[
16760443.001
]
[Cites]
Nat Immunol. 2006 Jul;7(7):773-82
[
16767092.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33
[
10618400.001
]
(PMID = 17353367.001).
[ISSN]
0022-1007
[Journal-full-title]
The Journal of experimental medicine
[ISO-abbreviation]
J. Exp. Med.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA114778-01; United States / NCI NIH HHS / CA / U01 CA084967; United States / NCI NIH HHS / CA / U01 CA114778-01; United States / NCI NIH HHS / CA / U01-CA84967
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2137913
65.
Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, Stanelle J, Siebert R, Küppers R:
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
J Exp Med
; 2009 May 11;206(5):981-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin
lymphoma
and
primary mediastinal
B cell lymphoma
.
Proliferation and survival of Hodgkin and Reed/Sternberg (HRS) cells, the
malignant
cells of classical Hodgkin
lymphoma
(cHL), are dependent on constitutive activation of nuclear factor kappaB (NF-kappaB).
To determine whether A20 contributes to the pathogenesis of cHL, we sequenced TNFAIP3, encoding A20, in HL
cell
lines and laser-microdissected HRS cells from cHL biopsies.
Reconstitution of wild-
type
TNFAIP3 in A20-deficient cHL
cell
lines revealed a significant decrease in transcripts of selected NF-kappaB target genes and caused cytotoxicity.
Extending the mutation analysis to
primary mediastinal
B cell lymphoma
(
PMBL
), another
lymphoma
with constitutive NF-kappaB activity, revealed destructive mutations in 5 out of 14
PMBLs
(36%).
This report identifies TNFAIP3 (A20), a key regulator of NF-kappaB activity, as a novel tumor suppressor gene in cHL and
PMBL
.
[MeSH-major]
Chromosome Deletion. Genes, Tumor Suppressor. Hodgkin Disease / genetics. Intracellular Signaling Peptides and Proteins / genetics.
Lymphoma
, B-
Cell
/ genetics. Mutation. Nuclear Proteins / genetics
[MeSH-minor]
Cell
Line, Tumor. DNA Transposable Elements. DNA-Binding Proteins. Epstein-Barr Virus Infections / genetics. Frameshift Mutation. Humans. Mutation, Missense. Polymorphism, Single Nucleotide. Transcription, Genetic
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
SciCrunch.
OMIM: Data: Gene Annotation
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1999 Nov 1;94(9):3129-34
[
10556199.001
]
[Cites]
Genes Chromosomes Cancer. 2000 Jan;27(1):52-8
[
10564586.001
]
[Cites]
J Exp Med. 2000 Jan 17;191(2):395-402
[
10637284.001
]
[Cites]
Science. 2000 Sep 29;289(5488):2350-4
[
11009421.001
]
[Cites]
Am J Pathol. 2002 Aug;161(2):413-20
[
12163366.001
]
[Cites]
J Exp Med. 2002 Sep 2;196(5):605-17
[
12208876.001
]
[Cites]
J Pathol. 2003 Jun;200(2):229-39
[
12754742.001
]
[Cites]
J Pathol. 2003 Nov;201(3):413-20
[
14595753.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Nat Biotechnol. 2004 May;22(5):589-94
[
15064769.001
]
[Cites]
Nature. 2004 Aug 5;430(7000):694-9
[
15258597.001
]
[Cites]
Nat Immunol. 2004 Oct;5(10):1052-60
[
15334086.001
]
[Cites]
EMBO J. 1995 Jun 15;14(12):2876-83
[
7796813.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6721-5
[
8692885.001
]
[Cites]
Genes Chromosomes Cancer. 1997 Apr;18(4):310-3
[
9087572.001
]
[Cites]
J Clin Invest. 1997 Dec 15;100(12):2961-9
[
9399941.001
]
[Cites]
Oncogene. 1999 May 20;18(20):3063-70
[
10340377.001
]
[Cites]
Blood. 2005 Aug 15;106(4):1392-9
[
15870177.001
]
[Cites]
Blood. 2006 Jan 15;107(2):844-5
[
16401828.001
]
[Cites]
Nat Cell Biol. 2006 Apr;8(4):398-406
[
16547522.001
]
[Cites]
Mol Cell. 2006 Apr 21;22(2):245-57
[
16603398.001
]
[Cites]
Oncogene. 2006 Oct 30;25(51):6831-43
[
17072331.001
]
[Cites]
Clin Cancer Res. 2007 Aug 15;13(16):4777-85
[
17699855.001
]
[Cites]
Genes Chromosomes Cancer. 2007 Dec;46(12):1090-7
[
17823928.001
]
[Cites]
Genes Chromosomes Cancer. 2008 Jan;47(1):1-7
[
17886247.001
]
[Cites]
Leukemia. 2007 Dec;21(12):2463-9
[
17728785.001
]
[Cites]
Cytogenet Genome Res. 2007;119(3-4):204-10
[
18253030.001
]
[Cites]
Cell. 2008 Feb 8;132(3):344-62
[
18267068.001
]
[Cites]
Nat Immunol. 2008 Mar;9(3):263-71
[
18223652.001
]
[Cites]
Immunity. 2008 Mar;28(3):381-90
[
18342009.001
]
[Cites]
Haematologica. 2008 Sep;93(9):1318-26
[
18641027.001
]
[Cites]
Br J Haematol. 2008 Sep;142(6):916-24
[
18671701.001
]
[Cites]
J Pathol. 2009 Feb;217(3):420-30
[
19006194.001
]
[Cites]
Blood. 2009 May 14;113(20):4918-21
[
19258598.001
]
(PMID = 19380639.001).
[ISSN]
1540-9538
[Journal-full-title]
The Journal of experimental medicine
[ISO-abbreviation]
J. Exp. Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA Transposable Elements; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; EC 6.3.2.19 / TNFAIP3 protein, human
[Other-IDs]
NLM/ PMC2715030
66.
Savage KJ:
Primary mediastinal large B-cell lymphoma.
Oncologist
; 2006 May;11(5):488-95
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell lymphoma
.
Primary mediastinal
large B
-
cell lymphoma
represents a distinct entity with unique clinicopathologic features and a molecular gene-expression signature reminiscent of nodular sclerosis
subtype
of classical Hodgkin's
lymphoma
.
Recent studies, including those using a refined molecular signature, suggest that the outcome is more favorable than that
of diffuse large B
-
cell lymphoma
.
[MeSH-major]
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16720849.001).
[ISSN]
1083-7159
[Journal-full-title]
The oncologist
[ISO-abbreviation]
Oncologist
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Number-of-references]
47
67.
Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M:
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Clin Lymphoma Myeloma
; 2009 Oct;9(5):381-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in
primary mediastinal
large B
-
cell lymphoma
: a retrospective study.
BACKGROUND: Third-generation regimens (MACOP-B [methotrexate/leucovorin (LV)/doxorubicin/cyclophosphamide/vincristine/ prednisone/bleomycin] or VACOP-B [etoposide/LV/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin]) in combination with local radiation therapy seem to improve
lymphoma
-free survival of
primary mediastinal
large B
-
cell lymphoma
(PMLBCL).
Recently, the superiority of R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone) over CHOP-like regimens has been demonstrated in elderly and younger patients with low-risk
diffuse large
B-
cell lymphoma
.
PATIENTS AND METHODS: Retrospectively, between February 2002 and July 2006, 45 previously untreated patients with PMLBCL were treated with a combination of a third-generation chemotherapy regimen (MACOP-B or VACOP-B), concurrent rituximab, and
mediastinal
radiation therapy.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ drug therapy.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ radiotherapy.
Mediastinal
Neoplasms / drug therapy.
Mediastinal
Neoplasms / radiotherapy
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
Hazardous Substances Data Bank.
METHOTREXATE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19858058.001).
[ISSN]
1938-0712
[Journal-full-title]
Clinical lymphoma & myeloma
[ISO-abbreviation]
Clin Lymphoma Myeloma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MACOP-B protocol; VACOP-B protocol
68.
Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM:
Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Ann Oncol
; 2006 Jan;17(1):123-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Favorable outcome of
primary mediastinal
large B
-
cell lymphoma
in a single institution: the British Columbia experience.
BACKGROUND:
Primary mediastinal
large B
-
cell lymphoma
(PMBCL) is a distinct clinico-pathological
subtype
of diffuse large B
-
cell lymphoma
(DLBCL).
PATIENTS AND METHODS: The British Columbia Cancer Agency
lymphoma
database was searched and records reviewed to identify those patients presenting with a prominent
mediastinal
mass and considered to be PMBCL based on the current REAL/WHO classifications.
Patients were treated based on era-specific BCCA guidelines (1980-1992 MACOPB/VACOPB; 1992-2001 CHOP-
type
; 2001-present CHOP-R).
The median age was 37 years (range 13-82) and the majority had stage I/II (74%), bulky
mediastinal
disease (75%).
Five-year OS in patients < 65 years old treated with MACOPB/VACOPB, CHOP-R and CHOP-
type
was 87%, 81% and 71% respectively (P = 0.048).
In pair-wise survival comparisons, only MACOPB/VACOPB and CHOP-
type
treated patients were significantly different (P = 0.016).
In Cox multiple regression analysis, poor performance status remained the only predictor of survival, with treatment received demonstrating a trend to worse outcome for patients treated with CHOP-
type
regimens (P = 0.09).
Dose-intensified chemotherapy with MACOPB or VACOPB demonstrated a trend to superior outcome over CHOP-
type
chemotherapy.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
Hazardous Substances Data Bank.
METHOTREXATE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16236753.001).
[ISSN]
0923-7534
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
69.
Brien G, Trescol-Biemont MC, Bonnefoy-Bérard N:
Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.
Oncogene
; 2007 Aug 23;26(39):5828-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Downregulation of Bfl-1 protein expression sensitizes
malignant
B cells to apoptosis.
Elevated expression of the antiapoptotic protein Bfl-1 (A1) was previously reported in several cancer
cell
lines.
Recently, molecular profiling
of large
B-
cell lymphoma
identified Bfl-1 as a gene signature in 'OxPhos'
diffuse large
B-
cell lymphoma
subtype
and in
primary mediastinal
large B
-
cell lymphoma
, suggesting that in addition to Bcl-2, Bcl-xL and Mcl-1, Bfl-1 may be a relevant target in the design of new strategies for cancer therapy.
Using short hairpin RNA strategy, we show here that Bfl-1 silencing in one lymphoblastoid B-
cell
line and in two
diffuse large
B-
cell lymphoma cell
lines potently induces their apoptosis and sensitizes those
cell
lines to anti-CD20 (Rituximab)-mediated
cell
death as well as to apoptosis induced by chemotherapeutic molecules such as doxorubicin, vincristine, cisplatin and fludarabine.
These results demonstrate for the first time that Bfl-1 is an essential protein for survival of
malignant
B cells and suggest Bfl-1 may represent a potential target for future drug development against
B cell lymphoma
.
[MeSH-major]
Apoptosis / drug effects. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic / physiology.
Lymphoma
, B-
Cell
/ pathology. Proto-Oncogene Proteins c-bcl-2 / genetics
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
VIDARABINE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17353899.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / BCL2-related protein A1; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; EC 3.4.22.- / Caspases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q20Q21Q62J / Cisplatin
70.
Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS:
Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.
Int J Hematol
; 2010 Apr;91(3):456-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Improved treatment outcome of
primary mediastinal
large B
-
cell lymphoma
after introduction of rituximab in Korean patients.
The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with
diffuse large
B-
cell lymphoma
(DLBCL).
However, the impact of rituximab (R-CHOP) is still not determined in
primary mediastinal
large B
-
cell lymphoma
(PMBCL),
a subtype
of DLBCL, especially in Asian patients.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ drug therapy.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ mortality.
Mediastinal
Neoplasms / drug therapy
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leuk Lymphoma. 1999 Sep;35(1-2):139-46
[
10512171.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
Adv Anat Pathol. 2004 Sep;11(5):227-38
[
15322489.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Int J Hematol. 2004 Jun;79(5):465-71
[
15239397.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):823-9
[
17379431.001
]
[Cites]
Br J Haematol. 2005 Sep;130(5):691-9
[
16115124.001
]
[Cites]
Control Clin Trials. 1996 Aug;17(4):343-6
[
8889347.001
]
[Cites]
Hum Pathol. 1988 Nov;19(11):1280-7
[
3263309.001
]
[Cites]
Ann Oncol. 2006 Jan;17(1):123-30
[
16236753.001
]
[Cites]
Blood. 1999 Nov 15;94(10 ):3289-93
[
10552937.001
]
[Cites]
J Clin Oncol. 1999 Mar;17(3):784-90
[
10071267.001
]
[Cites]
Haematologica. 2008 Sep;93(9):1364-71
[
18603558.001
]
[Cites]
Haematologica. 2001 Feb;86(2):187-91
[
11224489.001
]
[Cites]
J Clin Oncol. 1997 Apr;15(4):1646-53
[
9193365.001
]
[Cites]
Haematologica. 2002 Dec;87(12):1258-64
[
12495899.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3909-18
[
9166827.001
]
[Cites]
Am J Surg Pathol. 1996 Jul;20(7):877-88
[
8669537.001
]
[Cites]
Br J Cancer. 2004 Jan 26;90(2):372-6
[
14735179.001
]
[Cites]
Lancet Oncol. 2006 May;7(5):379-91
[
16648042.001
]
(PMID = 20198460.001).
[ISSN]
1865-3774
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
71.
Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC:
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
Clin Cancer Res
; 2009 Sep 1;15(17):5494-502
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A new immunostain algorithm classifies
diffuse large
B-
cell lymphoma
into molecular subtypes with high accuracy.
PURPOSE: Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification
of diffuse large B
-
cell lymphoma
(DLBCL) into the germinal center B-
cell
-like (GCB) and activated B-
cell
-like (ABC) subtypes.
For a group of seven
primary mediastinal
large B
-
cell lymphoma
, the new algorithm is a better prognostic classifier (all "GCB") than the Hans' algorithm (two GCB, five non-GCB).
[MeSH-major]
Biomarkers, Tumor / metabolism. Immunohistochemistry / methods.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ classification
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Clin Cancer Res. 2009 Sep 1;15(17):5291-3
[
19706818.001
]
[CommentIn]
Clin Cancer Res. 2010 Jul 15;16(14):3805-6
[
20628029.001
]
(PMID = 19706817.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA36727; United States / NCI NIH HHS / CA / U01CA114778
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
72.
Macchi A, Vecchia LD:
Open comparative, randomized controlled clinical study of a new immunostimulating bacterial lysate in the prophylaxis of upper respiratory tract infections.
Arzneimittelforschung
; 2005;55(5):276-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The first group received, by sublingual route, Ismigen, a new immunostimulating lysate (Polivalent Mechanical Bacterial Lysate,
PMBL
) obtained by mechanical lysis of 48 billion bacteria commonly responsible for upper respiratory tract infections; the second group received an oral immunostimulating lysate (CLBL) obtained by chemical lysis of 36 billion bacteria.
One tablet a day of
PMBL
was given to the first group for the first ten days during three consecutive months; the patients of the second group received one capsule a day of CLBL with the same treatment schedule.
The
primary
end point was the number of acute upper respiratory tract infections (URTIs) that occurred during the three months of treatment and three months of follow-up.
During the treatment period the mean number (+/- SD) of URTIs per patient was 0.34 (0.48) in the
PMBL
group, 1.0 (0.83) and 1.23 (0.77) in the CLBL and Control NT groups, respectively.
Results of
PMBL
treatment were significantly better (p < 0.05) than the results in the other two groups; CLBL was not significantly different from the control group.
In the three months of follow-up, the mean number (+/- SD) of URTIs per patient was: 0.42 (0.55) in the
PMBL
group, 0.92 (0.67) in the CLBL group, and 1.55 (0.88) in the Control NT group.
The
PMBL
group was significantly better than the other two (p < 0.05).
During the 6-month study, significantly more patients of the
PMBL
group remained free from respiratory infections in comparison to the other two groups.
As regards other secondary end points (duration of infectious episodes and number of working days lost), the mean values of the
PMBL
group were statistically significantly lower than those of the other two groups, in both the treatment and follow-up periods.
No
PMBL
treated patient needed concomitant administration of an antibiotic, while 9 patients of the CLBL group received such treatment (p < 0.05).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15960427.001).
[ISSN]
0004-4172
[Journal-full-title]
Arzneimittel-Forschung
[ISO-abbreviation]
Arzneimittelforschung
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
[Publication-country]
Germany
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Anti-Bacterial Agents; 0 / Bacterial Vaccines
73.
Ioannou S, Vlahadami I, Voulgarelis M:
Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma.
Leuk Res
; 2010 Jan;34(1):116-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with
primary mediastinal
large B
-
cell lymphoma
.
[MeSH-major]
Bone Marrow / pathology. Embolism, Fat / pathology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ pathology.
Mediastinal
Neoplasms / pathology. Spinal Cord Compression / pathology
Genetic Alliance.
consumer health - Embolism
.
Genetic Alliance.
consumer health - Bone marrow necrosis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19540591.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
74.
Hoeller S, Zihler D, Zlobec I, Obermann EC, Pileri SA, Dirnhofer S, Tzankov A:
BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.
Histopathology
; 2010 Jan;56(2):217-28
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's
lymphoma
from
primary mediastinal
large B
-
cell lymphoma
.
AIMS: To clarify which immunohistochemical markers could be helpful in distinguishing between classical Hodgkin's
lymphoma
(cHL) and
primary mediastinal
B-
cell lymphoma
(PMBCL) to more narrowly define 'B-
cell lymphoma
, unclassifiable, with features intermediate between
diffuse large
B-
cell lymphoma
and cHL'.
CONCLUSIONS: The use of at least three of the most accurate immunohistochemical markers, cyclin E, CD79a and BOB.1, may be helpful in the differential
diagnosis
of cHL and PMBCL.
[MeSH-major]
Antigens, CD79 / analysis. Biomarkers, Tumor. Cyclin E / analysis. Hodgkin Disease /
diagnosis
.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
. Trans-Activators / analysis
[MeSH-minor]
Antibodies, Neoplasm / immunology.
Diagnosis
, Differential. Humans. Immunohistochemistry. Predictive Value of Tests. ROC Curve
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20102401.001).
[ISSN]
1365-2559
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Neoplasm; 0 / Antigens, CD79; 0 / Biomarkers, Tumor; 0 / Cyclin E; 0 / POU2AF1 protein, human; 0 / Trans-Activators
75.
Eldar AH, Futerman B, Abrahami G, Attias D, Barak AB, Burstein Y, Dvir R, Gabriel H, Horovitz J, Kapelushnik J, Kaplinsky H, Miskin H, Sthoeger D, Toren A, Vilk-Revel S, Weintraub M, Yaniv I, Linn S, Arush MB:
Burkitt lymphoma in children: the Israeli experience.
J Pediatr Hematol Oncol
; 2009 Jun;31(6):428-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Burkitt
lymphoma
in children: the Israeli experience.
BACKGROUND: We analyzed the results of the French-American-British-LMB 96 protocol performed in 9 centers in Israel on 88 patients with B-
cell
non-Hodgkin
lymphoma
treated from 2000 to 2005.
Fifty (57%) patients were classified as Burkitt
lymphoma
, 5 (5.7%) as Burkitt-like
lymphoma
, 22 (25%) as
diffuse large B cell
(DLBC), and 9 (10.2%) as Burkitt leukemia with over 25% of their bone marrow (BM) involved.
Initial disease sites included the abdomen in 43%, head and neck in 45%, and
mediastinum
in 7%.
OS according to
primary
site: bone and ovary: 100%; head and neck: 95%; abdomen: 92%;
mediastinum
: 50%.
The difference between the
mediastinal primary
site to all other
primary
sites was statistically significant with P=0.003.
All the
mediastinal
tumors were of DLBC origin but no significant differences in outcome were found when DLBC was compared with other histologies (DLBC: 81.8%, other B line: 90.9%).
CONCLUSIONS: In nonresected mature B-
cell lymphoma
of childhood and adolescence with no BM or CNS involvement, a 93% cure rate can be achieved, similar to the French-American-British/LMB 96 trial.
Patients with
primary
DLBC
mediastinal
mass had a significantly reduced OS, indicating the need for a different therapeutic approach.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt
Lymphoma
/ drug therapy. Burkitt
Lymphoma
/ mortality
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19648792.001).
[ISSN]
1536-3678
[Journal-full-title]
Journal of pediatric hematology/oncology
[ISO-abbreviation]
J. Pediatr. Hematol. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
76.
Lau G:
Post-anaesthetic maternal death in a patient with mediastinal large B-cell lymphoma: a case report.
Med Sci Law
; 2007 Jan;47(1):74-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Post-anaesthetic maternal death in a patient with
mediastinal
large B
-
cell lymphoma
: a case report.
Autopsy demonstrated the presence of a
large
mediastinal
tumour, whose existence was apparently unsuspected preoperatively, encasing the ascending thoracic aorta, aortic arch and the proximal segments of the brachiocephalic and subclavian arteries, and causing extrinsic airway compression.
Subsequent microscopic examination showed histological and immunohistochemical features of
a mediastinal
large B
-
cell lymphoma
.
It is thought that the mechanical effects exerted by the advanced
mediastinal
tumour upon the airways and the thoracic cage, coupled with the pathophysiological effects of general anaesthesia on respiratory movement and airway patency, had led to the patient's unfortunate demise in early pregnancy.
[MeSH-major]
Anesthesia.
Lymphoma
, B-
Cell
/ pathology. Maternal Mortality.
Mediastinal
Neoplasms / physiopathology
MedlinePlus Health Information.
consumer health - Anesthesia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17345895.001).
[ISSN]
0025-8024
[Journal-full-title]
Medicine, science, and the law
[ISO-abbreviation]
Med Sci Law
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
77.
Renné C, Willenbrock K, Martin-Subero JI, Hinsch N, Döring C, Tiacci E, Klapper W, Möller P, Küppers R, Hansmann ML, Siebert R, Bräuninger A:
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma.
Leukemia
; 2007 Apr;21(4):780-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in
mediastinal
large B cell lymphoma
reveals further similarities to Hodgkin
lymphoma
.
Mediastinal
large B
-
cell
(MBL) and classical Hodgkin
lymphoma
(HL) have several pathogenic mechanisms in common.
Indeed, MBL and HL were the only B-
cell
lymphomas
where elevated cellular phospho-tyrosine contents were typical features.
Among the intracellular pathways frequently triggered by TKs, the PI3K/AKT pathway was activated in about 40% of MBLs and essential for survival of MBL
cell
lines, whereas the RAF/mitogen-activated protein kinase pathway seemed to be inhibited.
No activating mutations were detected in the three TKs in MBL
cell
lines and
primary
cases.
[MeSH-major]
Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics.
Lymphoma
, B-
Cell
/ genetics. Oncogene Protein v-akt / genetics. Phosphatidylinositol 3-Kinases / genetics. Protein-Tyrosine Kinases / genetics
[MeSH-minor]
Enzyme Activation. Gene Expression Regulation, Enzymologic. Humans.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ enzymology.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ genetics
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17375124.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Oncogene Protein v-akt
78.
Quintanilla-Martinez L, de Jong D, de Mascarel A, Hsi ED, Kluin P, Natkunam Y, Parrens M, Pileri S, Ott G:
Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.
J Hematop
; 2009;2(4):211-36
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gray zones around
diffuse large B cell lymphoma
. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.
The term "gray-zone"
lymphoma
has been used to denote a group of
lymphomas
with overlapping histological, biological, and clinical features between various types of
lymphomas
.
It has been used in the context of Hodgkin
lymphomas
(HL) and non-Hodgkin
lymphomas
(NHL), including classical HL (CHL), and
primary mediastinal
large B cell lymphoma
, cases with overlapping features between nodular lymphocyte predominant Hodgkin
lymphoma
and T-
cell
/histiocyte-rich
large B cell lymphoma
, CHL, and Epstein-Barr-virus-positive lymphoproliferative disorders, and peripheral T
cell
lymphomas
simulating CHL.
A second group of gray-zone
lymphomas
includes
B cell
NHL with intermediate features between
diffuse large B cell lymphoma
and classical Burkitt
lymphoma
.
In order to review controversial issues in gray-zone
lymphomas
, a joint Workshop of the European Association for Hematopathology and the Society for Hematopathology was held in Bordeaux, France, in September 2008.
This Workshop summary is focused on the most controversial aspects of gray-zone
lymphomas
and describes the panel's proposals regarding diagnostic criteria, terminology, and new prognostic and diagnostic parameters.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Sci. 2008 Jun;99(6):1085-91
[
18429953.001
]
[Cites]
Am J Clin Pathol. 2009 Apr;131(4):511-5
[
19289586.001
]
[Cites]
Intern Med. 2009;48(7):559-62
[
19336959.001
]
[Cites]
Ther Clin Risk Manag. 2009 Feb;5(1):187-207
[
19436622.001
]
[Cites]
Blood. 2009 Sep 10;114(11):2273-9
[
19597184.001
]
[Cites]
Blood. 2009 Oct 22;114(17):3533-7
[
19704118.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1558-67
[
10334544.001
]
[Cites]
Hum Pathol. 1972 Dec;3(4):457-558
[
4638966.001
]
[Cites]
Am J Med. 1980 Apr;68(4):509-14
[
6892753.001
]
[Cites]
Ann Oncol. 1994;5 Suppl 1:7-11
[
8172822.001
]
[Cites]
Am J Surg Pathol. 1996 Feb;20(2):193-201
[
8554109.001
]
[Cites]
Blood. 1996 Feb 15;87(4):1571-8
[
8608249.001
]
[Cites]
Blood. 1997 Sep 15;90(6):2445-50
[
9310496.001
]
[Cites]
Genes Chromosomes Cancer. 2004 May;40(1):10-8
[
15034863.001
]
[Cites]
Am J Clin Pathol. 1999 Aug;112(2):241-7
[
10439805.001
]
[Cites]
Blood. 1999 Nov 15;94(10):3567-75
[
10552968.001
]
[Cites]
Cancer Res. 2000 Feb 1;60(3):549-52
[
10676635.001
]
[Cites]
Mod Pathol. 2000 Mar;13(3):223-8
[
10757332.001
]
[Cites]
Blood. 2000 May 15;95(10):3020-4
[
10807764.001
]
[Cites]
Blood. 2000 Jul 15;96(2):398-404
[
10887098.001
]
[Cites]
Blood. 2000 Sep 1;96(5):1889-99
[
10961891.001
]
[Cites]
Pathol Int. 2001 Apr;51(4):293-300
[
11350613.001
]
[Cites]
Am J Surg Pathol. 2004 Apr;28(4):464-70
[
15087665.001
]
[Cites]
Am J Surg Pathol. 2004 May;28(5):679-86
[
15105659.001
]
[Cites]
Leuk Lymphoma. 2003;44 Suppl 3:S21-6
[
15202521.001
]
[Cites]
Blood. 2004 Nov 15;104(10):3009-20
[
15265787.001
]
[Cites]
Ann Oncol. 2004 Nov;15(11):1673-9
[
15520070.001
]
[Cites]
Histopathology. 2004 Dec;45(6):619-24
[
15569053.001
]
[Cites]
Leuk Res. 2005 Apr;29(4):389-95
[
15725472.001
]
[Cites]
Br J Haematol. 2005 Apr;129(2):199-205
[
15813847.001
]
[Cites]
Histopathology. 2005 Jul;47(1):101-10
[
15982329.001
]
[Cites]
Am J Surg Pathol. 2005 Aug;29(8):1086-94
[
16006805.001
]
[Cites]
Eur J Haematol Suppl. 2005 Jul;(66):45-52
[
16007868.001
]
[Cites]
Blood. 2005 Nov 1;106(9):3183-90
[
16046532.001
]
[Cites]
Hematol Oncol. 2004 Dec;22(4):169-77
[
16134192.001
]
[Cites]
Am J Surg Pathol. 2005 Nov;29(11):1411-21
[
16224207.001
]
[Cites]
Mod Pathol. 2006 Jan;19(1):25-33
[
16258503.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2005 Dec;17(8):636-8
[
16372490.001
]
[Cites]
Am J Surg Pathol. 2006 May;30(5):585-92
[
16699312.001
]
[Cites]
Am J Clin Pathol. 2006 May;125(5):776-82
[
16707382.001
]
[Cites]
N Engl J Med. 2006 Jun 8;354(23):2419-30
[
16760442.001
]
[Cites]
N Engl J Med. 2006 Jun 8;354(23):2431-42
[
16760443.001
]
[Cites]
Leuk Lymphoma. 2006 Sep;47(9):1885-93
[
17065002.001
]
[Cites]
Am J Surg Pathol. 2007 Jan;31(1):106-12
[
17197926.001
]
[Cites]
Blood. 2007 Aug 1;110(3):972-8
[
17400912.001
]
[Cites]
Br J Haematol. 2007 Jul;138(1):44-53
[
17555446.001
]
[Cites]
Genes Chromosomes Cancer. 2007 Dec;46(12):1090-7
[
17823928.001
]
[Cites]
Am J Surg Pathol. 2007 Oct;31(10):1605-14
[
17895764.001
]
[Cites]
Blood. 2008 Jan 1;111(1):351-8
[
17898315.001
]
[Cites]
Am J Clin Pathol. 2007 Dec;128(6):981-91
[
18024324.001
]
[Cites]
Haematologica. 2007 Oct;92(10):1297-301
[
18024366.001
]
[Cites]
Haematologica. 2007 Oct;92(10):1335-42
[
18024371.001
]
[Cites]
Am J Clin Pathol. 2008 Apr;129(4):630-8
[
18343791.001
]
[Cites]
J Immunol. 2008 Apr 1;180(7):4805-15
[
18354204.001
]
[Cites]
Eur J Haematol. 2008 Aug;81(2):154-6
[
18462255.001
]
[Cites]
Histopathology. 2008 Jun;52(7):900-3
[
18494615.001
]
[Cites]
Int J Surg Pathol. 2009 Apr;17(2):163-6
[
18508845.001
]
[Cites]
Am J Surg Pathol. 2008 Aug;32(8):1252-7
[
18594468.001
]
[Cites]
Blood. 2008 Sep 15;112(6):2248-60
[
18612102.001
]
[Cites]
Haematologica. 2008 Sep;93(9):1327-34
[
18698080.001
]
[Cites]
Leukemia. 2008 Dec;22(12):2226-9
[
18754028.001
]
[Cites]
J Pathol. 2008 Dec;216(4):440-50
[
18802929.001
]
[Cites]
Leukemia. 2009 Feb;23(2):225-34
[
18923440.001
]
[Cites]
Blood. 2009 Mar 19;113(12):2629-36
[
19075188.001
]
[Cites]
Hum Pathol. 2009 May;40(5):653-61
[
19144386.001
]
[Cites]
Blood. 2009 May 7;113(19):4771-9
[
19211934.001
]
[Cites]
Leuk Lymphoma. 2009 Mar;50(3):335-40
[
19255922.001
]
[Cites]
Am J Pathol. 1997 Oct;151(4):1123-30
[
9327746.001
]
[Cites]
Ann Oncol. 1997 Nov;8(11):1133-8
[
9426333.001
]
[Cites]
Ann Oncol. 1998;9 Suppl 5:S31-8
[
9926235.001
]
[Cites]
Hum Pathol. 1999 Feb;30(2):178-87
[
10029446.001
]
[Cites]
Semin Diagn Pathol. 1992 Nov;9(4):297-303
[
1480852.001
]
[Cites]
Leukemia. 1991 Jun;5(6):473-8
[
1711639.001
]
[Cites]
Adv Cancer Res. 1990;55:133-270
[
2166998.001
]
[Cites]
Am J Med. 1985 May;78(5):885-90
[
2859806.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1986;409(1):79-92
[
3085342.001
]
[Cites]
Blood. 1987 Apr;69(4):1087-95
[
3103712.001
]
[Cites]
Am J Surg Pathol. 1987 Feb;11(2):122-32
[
3812872.001
]
[Cites]
Am J Surg Pathol. 1986 Mar;10(3):176-91
[
3953939.001
]
[Cites]
Am J Surg Pathol. 2002 May;26(5):630-6
[
11979093.001
]
[Cites]
Leuk Lymphoma. 2002 Mar;43(3):595-601
[
12002764.001
]
[Cites]
Am J Surg Pathol. 2002 Jun;26(6):724-32
[
12023576.001
]
[Cites]
Am J Surg Pathol. 2002 Nov;26(11):1458-66
[
12409722.001
]
[Cites]
Am J Pathol. 2002 Nov;161(5):1861-7
[
12414532.001
]
[Cites]
Mod Pathol. 2002 Nov;15(11):1172-80
[
12429796.001
]
[Cites]
Mod Pathol. 2002 Nov;15(11):1221-6
[
12429802.001
]
[Cites]
Am J Surg Pathol. 2003 Jan;27(1):16-26
[
12502924.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):243-53
[
12507907.001
]
[Cites]
Lancet Infect Dis. 2003 Mar;3(3):131-40
[
12614729.001
]
[Cites]
Am J Surg Pathol. 2003 Jul;27(7):903-11
[
12826882.001
]
[Cites]
Blood. 2003 Nov 15;102(10):3753-8
[
12881319.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Br J Surg. 1958 Nov;46(197):218-23
[
13628987.001
]
[Cites]
Am J Surg Pathol. 2003 Oct;27(10):1346-56
[
14508396.001
]
[Cites]
Am J Surg Pathol. 2003 Dec;27(12):1513-22
[
14657710.001
]
(PMID = 20309430.001).
[ISSN]
1865-5785
[Journal-full-title]
Journal of hematopathology
[ISO-abbreviation]
J Hematop
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC2798939
[Keywords]
NOTNLM ; European Association for Hematopathology / Gray zone lymphoma / Society for Hematopathology / Workshop
79.
Takahashi H, Feuerhake F, Monti S, Kutok JL, Aster JC, Shipp MA:
Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma.
Blood
; 2006 Jan 15;107(2):844-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lack of IKBA coding region mutations in
primary mediastinal
large B
-
cell lymphoma
and the host response
subtype
of diffuse large B
-
cell lymphoma
.
[MeSH-major]
Gene Expression Regulation, Neoplastic. I-kappa B Proteins / genetics.
Lymphoma
, B-
Cell
/ genetics.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ genetics.
Mediastinal
Neoplasms / genetics. Mutation / genetics
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16401828.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-rel; 139874-52-5 / NF-kappaB inhibitor alpha
80.
Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D:
Primary mediastinal large B-cell lymphoma in HIV: report of two cases.
J Hematop
; 2009 Mar;2(1):45-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
large B
-
cell lymphoma
in HIV: report of two cases.
Primary mediastinal
large B cell lymphoma
(PMLBCL) is
a subtype
of diffuse large B cell lymphoma
arising in
the mediastinum
with distinctive clinical and morphological features.
Though
diffuse large B cell lymphoma
is one of the most common non-Hodgkin
lymphoma
associated with AIDS, there are no data available regarding the association of HIV and PMLBCL.
In both cases, PMLBCL presented in a setting of low CD4 T-
cell
count as rapidly enlarging
mediastinal
mass.
The
morphologic
and immunophenotypic findings are characteristic of PMLBCL.
One of the two patients, a 25-year-old woman who had localized disease and evidence of Epstein-Barr virus in
lymphoma
cells, did not respond to chemotherapy and died of disease progression 5 months after
diagnosis
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54
[
8465656.001
]
[Cites]
J Pathol. 1992 Aug;167(4):381-4
[
1328576.001
]
[Cites]
Blood. 1991 Aug 1;78(3):780-8
[
1713514.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
J Clin Oncol. 2001 Apr 15;19(8):2171-8
[
11304769.001
]
[Cites]
J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97
[
8350362.001
]
[Cites]
Blood. 2007 Aug 1;110(3):972-8
[
17400912.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3786-91
[
16917006.001
]
[Cites]
Am J Med Sci. 2005 Mar;329(3):136-8
[
15767818.001
]
[Cites]
Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48
[
8880201.001
]
[Cites]
Br J Haematol. 1995 Jun;90(2):235-43
[
7794745.001
]
[Cites]
Blood. 2000 Oct 15;96(8):2730-4
[
11023505.001
]
(PMID = 19669223.001).
[ISSN]
1868-9256
[Journal-full-title]
Journal of hematopathology
[ISO-abbreviation]
J Hematop
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC2713493
81.
Lekovic D, Miljic P, Mihaljevic B:
Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma.
Thromb Res
; 2010 Dec;126(6):477-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Increased risk of venous thromboembolism in patients with
primary mediastinal
large B
-
cell lymphoma
.
BACKGROUND:
Primary mediastinal
large B
-
cell lymphoma
(PMBCL) is a rare
subtype
of diffuse large B
-
cell lymphoma
, arising in
the mediastinum
.
Compression
of large
mediastinal
vessels is common in patients with PMBCL, predisposing these patients to venous thrombosis.
Ten patients had a thrombosis at the moment of
diagnosis
PMBCL, while in five thrombosis occurred during the course of the disease.
Also, patients in the VTE subgroup had significantly larger diameter of
mediastinal
tumor mass (P=0.01) and the incidence of syndrome venae cava superior (P=0.009).
Use of antithrombotic prophylaxis may be considered together with chemotherapy, especially in those with bulky
mediastinal
tumor mass.
[MeSH-major]
Lymphoma
, B-
Cell
/ blood. Venous Thromboembolism / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010. Published by Elsevier Ltd.
(PMID = 21126629.001).
[ISSN]
1879-2472
[Journal-full-title]
Thrombosis research
[ISO-abbreviation]
Thromb. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
82.
Oura H, Watanabe Y, Sawada T, Handa M, Tomichi N:
[Surgical approach for histopathological determination of anterior mediastinal malignant lymphoma].
Kyobu Geka
; 2008 Aug;61(9):754-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Surgical approach for histopathological determination of anterior
mediastinal malignant
lymphoma
].
In a retrospective review of all patients who admitted our hospital between January 1992 and December 2006, we identified 9 with anterior
mediastinal malignant
lymphoma
.
They represented 6.8% of the 133 patients with
mediastinal
tumor.
Histology revealed 3 cases of
primary mediastinal
large B
-
cell lymphoma
, 2 of Hodgkin
lymphoma
, 2 of precursor T-lymphoblastic
lymphoma
and 2 of
thymic
extranodal marginal zone B-
cell lymphoma
of mucosa-associated lymphoid tissue (MALT)
lymphoma
.
Careful attention should be paid to the relatively high incidence of
malignant
lymphoma
in the anterior
mediastinal
tumors.
It is highly important to differentiate of
malignant
lymphoma
from other diseases that shape anterior
mediastinal
tumor to avoid unnecessary operation.
Early and accurate
diagnosis
of these tumors is also important because some of these patients require immediate treatment by hematology specialists.
[MeSH-major]
Lymphoma
/ pathology.
Mediastinal
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18697455.001).
[ISSN]
0021-5252
[Journal-full-title]
Kyobu geka. The Japanese journal of thoracic surgery
[ISO-abbreviation]
Kyobu Geka
[Language]
jpn
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Japan
83.
Rajagopalan R, Salvi VP, Jensenius JC, Rawal N:
New insights on the structural/functional properties of recombinant human mannan-binding lectin and its variants.
Immunol Lett
; 2009 Apr 27;123(2):114-24
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
But recent studies have shown the presence
of large
oligomers of MBL (approximately 450 kDa) in serum of individuals with variant MBL alleles.
In the present study, structural/functional properties of recombinant forms of wild
type
MBL (rMBL/A) and its three structural variants, rMBL/B, C, and D generated in insect cells were examined.
Comparison of rMBL/A to MBL purified from plasma (
pMBL
/A) indicated 8- and 24-fold weaker binding to mannan by BIAcore analysis and ELISA and about 5-fold lesser efficiency in activating complement.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19428558.001).
[ISSN]
1879-0542
[Journal-full-title]
Immunology letters
[ISO-abbreviation]
Immunol. Lett.
[Language]
eng
[Grant]
United States / NHLBI NIH HHS / HL / HL-073804
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Mannose-Binding Lectin; 0 / Recombinant Proteins
84.
Minami J, Dobashi N, Asai O, Yano S, Osawa H, Takei Y, Yahagi Y, Takahara S, Ogasawara Y, Yamaguchi Y, Kobayashi T, Morikawa N, Nikaido T, Aiba K, Usui N:
Two cases of mediastinal gray zone lymphoma.
J Clin Exp Hematop
; 2010;50(2):143-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Two cases of
mediastinal
gray zone
lymphoma
.
Mediastinal
gray zone
lymphoma
(MGZL) represents a range of tumors possessing characteristics of both nodular sclerosis classical Hodgkin
lymphoma
(NSHL) and
mediastinal
large B
-
cell lymphoma
(MLBCL).
Both patients had
a mediastinal
mass, were initially diagnosed with NSHL and exhibited resistance to first-line chemotherapy.
In patient 2, the tumor was a composite
lymphoma
with both NSHL and MLBCL components.
Both the patients received high-dose chemotherapy followed by autologous peripheral-blood stem-
cell
transplantation.
[MeSH-major]
Lymphoma
/ pathology.
Mediastinal
Neoplasms / pathology
[MeSH-minor]
Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Peripheral Blood Stem
Cell
Transplantation. Radiotherapy. Young Adult
Genetic Alliance.
consumer health - Gray zone lymphoma
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21123972.001).
[ISSN]
1880-9952
[Journal-full-title]
Journal of clinical and experimental hematopathology : JCEH
[ISO-abbreviation]
J Clin Exp Hematop
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antineoplastic Agents
85.
Fietz T, Knauf WU, Hänel M, Franke A, Freund M, Thiel E, East German Study Group on Hematology and Oncology-OSHO:
Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate.
Ann Hematol
; 2009 May;88(5):433-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment of
primary mediastinal
large B cell lymphoma
with an alternating chemotherapy regimen based on high-dose methotrexate.
Primary mediastinal
large B cell
lymphomas
(MLCL) differ from other
diffuse large cell
lymphomas
, leading to a description as a separate entity in the current World Health Organization classification.
We investigated the use of a high-dose methotrexate-based alternating chemotherapy regimen (B-ALL protocol of the German ALL study group) followed by consolidative
mediastinal
radiotherapy first as a single-center trial, then later as a prospective multicenter trial in 44 patients with a median age of 33 years.
No relapse occurred more than 2 years after
diagnosis
and initiation of treatment, but unfortunately, no patient with overt progression or relapse within these 2 years could be salvaged.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, B-
Cell
/ drug therapy.
Mediastinal
Neoplasms /
diagnosis
.
Mediastinal
Neoplasms / drug therapy. Methotrexate / administration & dosage
[MeSH-minor]
Adolescent. Adult. Aged.
Diagnosis
, Differential. Drug-Related Side Effects and Adverse Reactions. Female. Humans.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
. Male. Middle Aged. Recurrence. Survival Rate. Treatment Outcome. Young Adult
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18853160.001).
[ISSN]
1432-0584
[Journal-full-title]
Annals of hematology
[ISO-abbreviation]
Ann. Hematol.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Multicenter Study
[Publication-country]
Germany
[Chemical-registry-number]
YL5FZ2Y5U1 / Methotrexate
86.
Toubai T, Tanaka J, Ota S, Mori A, Ibata M, Shono Y, Mashiko S, Sugita J, Miura Y, Kato N, Umehara S, Kahata K, Toyoshima N, Asaka M, Imamura M:
Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy.
Intern Med
; 2005 May;44(5):476-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Successful reduced-intensity stem
cell
transplantation (RIST) for a patient with
malignant
lymphoma
and an ileostomy.
A 56-year-old man was admitted for treatment of non-Hodgkin's
lymphoma
(NHL).
After the operation, his disease status was in partial remission (PR), and reduced-intensity allogeneic stem
cell
transplantation (RIST) was therefore performed for further improvement of disease status.
[MeSH-major]
Ileostomy. Intestinal Perforation / surgery.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/ therapy. Stem
Cell
Transplantation / methods
[MeSH-minor]
Antineoplastic Agents / adverse effects. Biopsy. Colon / radiography. Colon / radionuclide imaging. Colon / surgery. Follow-Up Studies. Humans. Male.
Mediastinum
/ pathology.
Mediastinum
/ radiography.
Mediastinum
/ radionuclide imaging. Middle Aged. Positron-Emission Tomography. Rupture, Spontaneous. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15942098.001).
[ISSN]
0918-2918
[Journal-full-title]
Internal medicine (Tokyo, Japan)
[ISO-abbreviation]
Intern. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antineoplastic Agents
87.
Lanzilli G, Falchetti R, Cottarelli A, Macchi A, Ungheri D, Fuggetta MP:
In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes.
Int J Immunopathol Pharmacol
; 2006 Jul-Sep;19(3):551-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The aim of the present study is to investigate in humans the mechanism by which the oral vaccine Polyvalent Mechanical Bacterial Lysate (
PMBL
) can rapidly mobilize specific immune response and evaluate the efficacy of its immunostimulating activity in preventing recurrent infections of the upper respiratory tract (URTIs) in a group of patients with a medical history of URTI recurrence.
The results showed that
PMBL
exerts a therapeutic and preventing effect in acute and recurrent infections of the upper respiratory tract and that this effect correlated with the activation and enhancement of both IgM memory B lymphocytes (CD24+/CD27+ cells) and IL2 receptor-expressing lymphocytes (CD25+ cells) involved either in humoral or cellular immunity.
[MeSH-major]
Adjuvants, Immunologic / pharmacology. B-Lymphocytes / drug effects.
Cell
Extracts / pharmacology. Urinary Tract Infections / drug therapy
MedlinePlus Health Information.
consumer health - Urinary Tract Infections
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17026840.001).
[ISSN]
0394-6320
[Journal-full-title]
International journal of immunopathology and pharmacology
[ISO-abbreviation]
Int J Immunopathol Pharmacol
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Broncho-Vaxom; 0 / Cell Extracts; 0 / Immunoglobulin M; 0 / Interleukin-2 Receptor alpha Subunit
88.
Salama ME, Rajan Mariappan M, Inamdar K, Tripp SR, Perkins SL:
The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma.
Int J Surg Pathol
; 2010 Apr;18(2):121-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The value of CD23 expression as an additional marker in distinguishing
mediastinal
(
thymic
)
large B
-
cell lymphoma
from Hodgkin
lymphoma
.
Mediastinal
diffuse large
B-
cell lymphoma
(Med-DLBCL) is
a subtype
of DLBCL that has
morphologic
and clinical similarities and phenotypic overlaps with classical Hodgkin
lymphoma
(CHL) involving
the mediastinum
.
CD23 is a marker that has been previously reported in Med-DLBCI and is proposed in the differential
diagnosis
of M-DLBCL and CHL.
In conclusion CD23 is a useful marker in distinguishing Med-DLBCL and CHL in
mediastinal
biopsies and may be helpful as an adjunct to histomorphology and other markers in the
diagnosis
and appropriate clinical management of these lesions.
[MeSH-major]
Hodgkin Disease /
diagnosis
.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
.
Mediastinal
Neoplasms /
diagnosis
. Receptors, IgE / metabolism.
Thymus
Neoplasms /
diagnosis
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child.
Diagnosis
, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reed-Sternberg Cells / pathology. Retrospective Studies. Young Adult
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19223373.001).
[ISSN]
1940-2465
[Journal-full-title]
International journal of surgical pathology
[ISO-abbreviation]
Int. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Receptors, IgE
89.
Boulland ML, Marquet J, Molinier-Frenkel V, Möller P, Guiter C, Lasoudris F, Copie-Bergman C, Baia M, Gaulard P, Leroy K, Castellano F:
Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation.
Blood
; 2007 Jul 1;110(1):220-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Interleukin-4-induced gene 1 (IL4I1) was first described as a B-
cell
IL4-inducible gene and is highly expressed in
primary mediastinal
B-
cell
lymphomas
.
Both proteins were secreted into the culture medium, and we observed the secretion of endogenous human IL4I1 (hIL4I1) protein in
a mediastinal
lymphoma B
-
cell
line, MedB-1.
In vitro, functional enzyme was highest in mature dendritic cells (DCs), suggesting a role in antigen-presenting
cell
/T-lymphocyte cross-talk.
[MeSH-major]
Amino Acid Oxidoreductases / immunology.
Cell
Proliferation. Dendritic Cells / chemistry. L-Amino Acid Oxidase / immunology. T-Lymphocytes / cytology
[MeSH-minor]
Animals.
Cell
Line.
Cell
Line, Tumor. Humans. Hydrogen Peroxide / metabolism. Immunohistochemistry.
Lymphoma
, B-
Cell
/ pathology. Macrophages / chemistry. Mice. Myeloid Cells / chemistry
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
Hazardous Substances Data Bank.
HYDROGEN PEROXIDE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17356132.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
BBX060AN9V / Hydrogen Peroxide; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / phenylalanine oxidase; EC 1.4.3.2 / IL4I1 protein, human; EC 1.4.3.2 / L-Amino Acid Oxidase
90.
Mangasarova IaK, Magomedova AU, Kravchenko SK, Zvonkov EE, Kremenetskaia AM, Vorob'ev VI, Mar'in DS, Gubkin AV, Skidan NI, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Vorob'ev AI:
[Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment].
Ter Arkh
; 2010;82(7):61-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Diffuse large
B-
cell lymphoma
with
primary
involvement of
mediastinal
lymph nodes:
diagnosis
and treatment].
AIM: To diagnose
diffuse large
B-
cell
lymphosarcoma (DLBCLS) with
primary
involvement of the
mediastinal
lymph nodes (
LN
) and to evaluate the efficiency of aggressive polychemotherapy (PCT).
There were no signs of involvement of extranodal organs at the moment of
diagnosis
.
All the 15 patients received PCT according to the modified NHL-BFM-90 program: 4 to 6 courses depending on the response to the therapy; 10 (66.6%) and 5 (33.3%) patients had 4 and 6 courses, respectively; for consolidating purpose, 11 (78.5%) patients were prescribed radiotherapy applied to
the mediastinum
in a cumulative dose of 36 Gy due to the fact that they had a residual mass.
Primary
PCT resistance was confirmed in one case.
CONCLUSION: DLBCLS with
primary LN
involvement is an individual nosological entity to be differentiated from
primary mediastinal
large B
-
cell
lymphosarcoma.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes.
Lymphoma
,
Large B
-
Cell
,
Diffuse
/
diagnosis
.
Mediastinal
Neoplasms /
diagnosis
.
Mediastinum
[MeSH-minor]
Adolescent. Adult. Aged. Antigens, CD / immunology.
Diagnosis
, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Young Adult
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20853612.001).
[ISSN]
0040-3660
[Journal-full-title]
Terapevticheskiĭ arkhiv
[ISO-abbreviation]
Ter. Arkh.
[Language]
rus
[Publication-type]
Clinical Trial; English Abstract; Journal Article
[Publication-country]
Russia (Federation)
[Chemical-registry-number]
0 / Antigens, CD
91.
Melzner I, Weniger MA, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Leithäuser F, Ritz O, Dyer MJ, Barth TF, Möller P:
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.
Int J Cancer
; 2006 Apr 15;118(8):1941-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P
mediastinal
B-
cell lymphoma
line is associated with delayed degradation of JAK2 protein.
We have previously shown that SOCS-1 is biallelically mutated in the
primary mediastinal
B-
cell lymphoma
(
PMBL
)
cell
line MedB-1, resulting in impaired JAK2 degradation and sustained phospho-JAK2 action.
SOCS-1 is frequently mutated in
PMBL
tumor primaries.
Here, we report that the
PMBL
cell
line Karpas1106P has a biallelic deletion of the SOCS-1 region on chromosome 16p13.13.
In analogy to MedB-1 cells, Karpas1106P cells exhibited a retarded degradation of
de
novo synthesized JAK2 protein revealed by pulse/chase experiments.
Therefore, we conclude that loss of SOCS-1 function either by mutation or by the complete deletion of the gene plays an important role in the dysregulation of JAK/STAT signaling in Karpas1106P and
PMBL
.
[MeSH-major]
Chromosomes, Human, Pair 16. Gene Deletion. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / physiology.
Lymphoma
, B-
Cell
/ genetics.
Mediastinal
Neoplasms / genetics. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / genetics. Repressor Proteins / physiology. Suppressor of Cytokine Signaling Proteins / genetics. Suppressor of Cytokine Signaling Proteins / physiology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2005 Wiley-Liss, Inc.
(PMID = 16287070.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Grant]
United Kingdom / Medical Research Council / / MC/ U132670597
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling 1 Protein; 0 / Suppressor of Cytokine Signaling Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
92.
Stejskalova E, Jarosova M, Kabickova E, Smelhaus V, Mrhalova M, Kodet R:
Primary mediastinal (thymic) large B-cell lymphoma with a der(14)t(8;14)(q24;q32) and a translocation of MYC to the derivative chromosome 14 with a deleted IgH locus.
Cancer Genet Cytogenet
; 2006 Oct 15;170(2):158-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mediastinal
(
thymic
)
large B
-
cell lymphoma
with a der(14)t(8;14)(q24;q32) and a translocation of MYC to the derivative chromosome 14 with a deleted IgH locus.
We report a case of
primary mediastinal
(
thymic
)
large B
-
cell lymphoma
(
PMBL
) with an initial karyotype containing numerical chromosomal aberrations: +X, +9, +12, +21, and a novel translocation t(2;11)(q?31; q23 approximately 24) with a duplication of the derivative chromosome 11.
Our data show definitively the existence of the t(8;14) in
PMBL
, previously only suspected.
This finding supplies additional evidence that a translocation-mediated MYC activation may be an important event in the pathogenesis of this unique
lymphoma
.
[MeSH-major]
Chromosome Deletion. Chromosomes, Human, Pair 14. Genes, Immunoglobulin Heavy Chain. Genes, myc.
Lymphoma
, B-
Cell
/ genetics.
Mediastinal
Neoplasms / genetics. Translocation, Genetic
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17011988.001).
[ISSN]
0165-4608
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
93.
Hara S, Yokote T, Oka S, Akioka T, Kobayashi K, Tsuji M, Hanafusa T:
Bronchial infiltration with diffuse large B-cell lymphoma.
Leuk Res
; 2006 Oct;30(10):1319-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Bronchial infiltration with
diffuse large
B-
cell lymphoma
.
Non-Hodgkin's
lymphoma
(NHL) refers to a heterogeneous group of lymphoproliferative diseases with a diversity of clinical courses, including involvement in another organs.
NHL frequently involves the thoracic structures, and particularly
the mediastinum
and lung parenchyma.
Several clinical reports have described bronchial-associated lymphoid tissue (BALT)
lymphoma
as an endobronchial lesion, but endobronchial infiltration with
diffuse large
B-
cell lymphoma
is extremely rare.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / pathology.
Lymphoma
, B-
Cell
/ pathology
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
IFOSFAMIDE
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16533528.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / DNA Primers; 0 / Immunoglobulin Heavy Chains; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
94.
Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL:
AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Clin Cancer Res
; 2008 Jun 1;14(11):3338-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic
large cell
lymphomas
from other lymphoid malignancies with shared molecular features.
We recently found that Reed-Sternberg
cell
Gal1 promotes the immunosuppressive T-helper 2/T-regulatory
cell
-skewed microenvironment in classical Hodgkin
lymphoma
(cHL).
In addition, because there are common signaling and survival pathways in cHL and additional non-Hodgkin
lymphomas
, we also evaluated whether the AP1/Gal1 signature is shared by other molecularly or morphologically related
lymphomas
.
EXPERIMENTAL DESIGN: We evaluated 225 cases of
primary
cHL and non-Hodgkin
lymphoma
for evidence of a functional AP1/Gal1 signature by immunohistochemical techniques.
RESULTS: Gal1 is selectively expressed by
malignant
Reed-Sternberg cells in >90% of
primary
cHLs, and Gal1 expression is concordant with the activated AP1 component, c-Jun.
In contrast,
diffuse large
B-
cell lymphoma
,
primary mediastinal
large B
-
cell lymphoma
, and another Hodgkin-related entity, nodular lymphocyte-predominant Hodgkin
lymphoma
, do not express Gal1.
However, anaplastic
large cell lymphoma
(ALCL), consistently expresses both Gal1 and its transcriptional regulator, c-Jun.
In addition, the combination of Gal1 and c-Jun serve as diagnostic biomarkers that delineate cHL and ALCL from other
lymphomas
with shared
morphologic
and/or molecular features.
[MeSH-major]
Biomarkers, Tumor / analysis. Galectin 1 / biosynthesis. Hodgkin Disease / metabolism.
Lymphoma
,
Large
-
Cell
, Anaplastic / metabolism. Lymphoproliferative Disorders / metabolism. Transcription Factor AP-1 / metabolism
[MeSH-minor]
Diagnosis
, Differential. Gene Expression. Humans. Immunohistochemistry. Proto-Oncogene Proteins c-jun / metabolism. Reed-Sternberg Cells / metabolism
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18519761.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Proto-Oncogene Proteins c-jun; 0 / Transcription Factor AP-1
95.
Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM:
Cooperative epigenetic modulation by cancer amplicon genes.
Cancer Cell
; 2010 Dec 14;18(6):590-605
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Chromosome band 9p24 is frequently amplified in
primary mediastinal
B cell lymphoma
(
PMBL
) and Hodgkin
lymphoma
(HL).
To identify oncogenes in this amplicon, we screened an RNA interference library targeting amplicon genes and thereby identified JAK2 and the histone demethylase JMJD2C as essential genes in these
lymphomas
.
Inhibition of JAK2 and JMJD2C cooperated in killing these
lymphomas
by decreasing tyrosine 41 phosphorylation and increasing lysine 9 trimethylation of histone H3, promoting heterochromatin formation.
Hence, JAK2 and JMJD2C cooperatively remodel the
PMBL
and HL epigenome, offering a mechanistic rationale for the development of JAK2 and JMJD2C inhibitors in these diseases.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
SciCrunch.
ArrayExpress: Data: Microarray
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
[Cites]
Blood. 1999 Nov 1;94(9):3129-34
[
10556199.001
]
[Cites]
Cell. 2006 May 5;125(3):467-81
[
16603238.001
]
[Cites]
Cancer Res. 2000 Sep 1;60(17):4735-9
[
10987278.001
]
[Cites]
Blood. 2001 Jan 1;97(1):250-5
[
11133768.001
]
[Cites]
Nature. 2001 Mar 1;410(6824):116-20
[
11242053.001
]
[Cites]
Nature. 2001 Mar 1;410(6824):120-4
[
11242054.001
]
[Cites]
Genes Chromosomes Cancer. 2001 Apr;30(4):393-401
[
11241792.001
]
[Cites]
Nature. 2001 Aug 2;412(6846):561-5
[
11484059.001
]
[Cites]
Blood. 2002 Jan 15;99(2):618-26
[
11781246.001
]
[Cites]
J Biol Chem. 2002 Nov 29;277(48):46073-8
[
12354755.001
]
[Cites]
Int J Cancer. 2003 Feb 10;103(4):489-95
[
12478664.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Feb 7;301(2):287-92
[
12565857.001
]
[Cites]
N Engl J Med. 2003 Jun 12;348(24):2386-95
[
12802024.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Blood. 2004 Jul 15;104(2):543-9
[
15044251.001
]
[Cites]
Blood. 1996 Feb 15;87(4):1571-8
[
8608249.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):28-40
[
15671525.001
]
[Cites]
Blood. 2005 Mar 15;105(6):2535-42
[
15572583.001
]
[Cites]
Mol Cell Biol. 2005 Jun;25(11):4552-64
[
15899859.001
]
[Cites]
Leukemia. 2005 Jun;19(6):1082-4
[
15815722.001
]
[Cites]
Nature. 2006 Jan 19;439(7074):353-7
[
16273092.001
]
[Cites]
J Pathol. 2006 Mar;208(4):554-63
[
16400626.001
]
[Cites]
Immunol Rev. 2006 Apr;210:67-85
[
16623765.001
]
[Cites]
Leukemia. 2006 Jan;20(1):157-8
[
16331280.001
]
[Cites]
Oncogene. 2006 Apr 27;25(18):2679-84
[
16532038.001
]
[Cites]
Nature. 2006 May 4;441(7089):106-10
[
16572121.001
]
[Cites]
Cancer Res. 2000 Feb 1;60(3):549-52
[
10676635.001
]
[Cites]
Cancer Genet Cytogenet. 2006 Jun;167(2):122-30
[
16737911.001
]
[Cites]
Nature. 2006 Jul 20;442(7100):307-11
[
16732293.001
]
[Cites]
Nat Genet. 2006 Sep;38(9):1071-6
[
16892059.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17834-9
[
17093053.001
]
[Cites]
Mol Cell. 2007 Oct 12;28(1):1-13
[
17936700.001
]
[Cites]
Genes Dev. 2007 Oct 15;21(20):2545-57
[
17938240.001
]
[Cites]
Adv Cancer Res. 2008;99:113-333
[
18037408.001
]
[Cites]
Cell. 2008 Jan 25;132(2):259-72
[
18243101.001
]
[Cites]
Cytogenet Genome Res. 2007;119(3-4):204-10
[
18253030.001
]
[Cites]
Nat Cell Biol. 2008 Apr;10(4):489-96
[
18344984.001
]
[Cites]
Cancer Cell. 2008 Apr;13(4):311-20
[
18394554.001
]
[Cites]
Cancer Cell. 2008 Apr;13(4):321-30
[
18394555.001
]
[Cites]
Nature. 2008 Jul 10;454(7201):226-31
[
18568025.001
]
[Cites]
Leukemia. 2008 Sep;22(9):1790-2
[
18354492.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5
[
18765795.001
]
[Cites]
Clin Cancer Res. 2008 Oct 15;14(20):6426-31
[
18927281.001
]
[Cites]
Mod Pathol. 2009 Mar;22(3):476-87
[
19136931.001
]
[Cites]
Immunol Rev. 2009 Mar;228(1):273-87
[
19290934.001
]
[Cites]
Diagn Mol Pathol. 2009 Sep;18(3):144-9
[
19704259.001
]
[Cites]
Nature. 2009 Oct 8;461(7265):819-22
[
19783980.001
]
[Cites]
Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5
[
19858058.001
]
[Cites]
Blood. 2009 Nov 12;114(20):4503-6
[
19734449.001
]
[Cites]
Cancer Cell. 2009 Dec 8;16(6):487-97
[
19962667.001
]
[Cites]
Oncogene. 2009 Dec 17;28(50):4491-500
[
19784073.001
]
[Cites]
Blood. 2010 Feb 11;115(6):1131-6
[
20008298.001
]
[Cites]
Nat Cell Biol. 2007 Mar;9(3):347-53
[
17277772.001
]
[CommentIn]
Cancer Cell. 2010 Dec 14;18(6):539-41
[
21156276.001
]
(PMID = 21156283.001).
[ISSN]
1878-3686
[Journal-full-title]
Cancer cell
[ISO-abbreviation]
Cancer Cell
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA114778; United States / Intramural NIH HHS / / Z01 BC011008-01; Canada / Canadian Institutes of Health Research / / 178536; United States / NCI NIH HHS / CA / UO1-CA 114778
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Histones; 0 / KDM4C protein, human; EC 1.14.11.- / Jumonji Domain-Containing Histone Demethylases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
[Other-IDs]
NLM/ NIHMS253448; NLM/ PMC3049192
96.
Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM:
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Proc Natl Acad Sci U S A
; 2008 Sep 9;105(36):13520-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular subtypes
of diffuse large B
-
cell lymphoma
arise by distinct genetic pathways.
Gene-expression profiling has been used to define 3 molecular subtypes
of diffuse large B
-
cell lymphoma
(DLBCL), termed germinal center B-
cell
-like (GCB) DLBCL, activated B-
cell
-like (ABC) DLBCL, and
primary mediastinal
B-
cell lymphoma
(
PMBL
).
An amplicon on chromosome 19 was detected in 26% of ABC DLBCLs but in only 3% of GCB DLBCLs and
PMBLs
.
Knockdown of SPIB by RNA interference was toxic to ABC DLBCL
cell
lines but not to GCB DLBCL,
PMBL
, or myeloma
cell
lines, strongly implicating SPIB as an oncogene involved in the pathogenesis of ABC DLBCL.
Deletion of the INK4a/ARF tumor suppressor locus and trisomy 3 also occurred almost exclusively in ABC DLBCLs and was associated with inferior outcome within this
subtype
.
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
ArrayExpress: Data: Microarray
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30
[
15983384.001
]
[Cites]
Blood. 2005 Nov 1;106(9):3183-90
[
16046532.001
]
[Cites]
Adv Immunol. 2005;87:163-208
[
16102574.001
]
[Cites]
Blood. 2005 Sep 1;106(5):1770-7
[
15886317.001
]
[Cites]
Cancer Res. 2004 May 1;64(9):3087-95
[
15126345.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72
[
15199222.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3909-18
[
9166827.001
]
[Cites]
EMBO J. 1997 Dec 1;16(23):7118-29
[
9384589.001
]
[Cites]
Blood. 1998 Dec 1;92(11):4487-9
[
9882102.001
]
[Cites]
Cancer Res. 2000 Feb 1;60(3):549-52
[
10676635.001
]
[Cites]
Nature. 2000 Feb 3;403(6769):503-11
[
10676951.001
]
[Cites]
Curr Opin Oncol. 2001 Sep;13(5):325-34
[
11555708.001
]
[Cites]
J Exp Med. 2001 Dec 17;194(12):1861-74
[
11748286.001
]
[Cites]
N Engl J Med. 2002 Jun 20;346(25):1937-47
[
12075054.001
]
[Cites]
Nat Rev Immunol. 2002 Dec;2(12):920-32
[
12461565.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
[
12900505.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3871-9
[
12933571.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):28-40
[
15671525.001
]
[Cites]
J Biol Chem. 2005 Mar 4;280(9):7444-51
[
15618216.001
]
[Cites]
Leukemia. 2005 Apr;19(4):652-8
[
15703784.001
]
[Cites]
Nature. 2005 Jun 9;435(7043):839-43
[
15944709.001
]
[Cites]
Blood. 2006 Mar 15;107(6):2477-85
[
16317097.001
]
[Cites]
Nature. 2006 May 4;441(7089):106-10
[
16572121.001
]
[Cites]
N Engl J Med. 2006 Jun 8;354(23):2419-30
[
16760442.001
]
[Cites]
Leukemia. 2006 Jul;20(7):1300-3
[
16673020.001
]
[Cites]
Nature. 2006 Nov 23;444(7118):444-54
[
17122850.001
]
[Cites]
Nat Genet. 2007 Mar;39(3):347-51
[
17293865.001
]
[Cites]
J Exp Med. 2007 Mar 19;204(3):633-43
[
17353367.001
]
[Cites]
Trends Biochem Sci. 2007 Nov;32(11):509-19
[
17949986.001
]
[Cites]
Science. 2008 Mar 21;319(5870):1676-9
[
18323416.001
]
[Cites]
Blood. 2008 Apr 1;111(7):3701-13
[
18160665.001
]
[Cites]
Leukemia. 2005 Aug;19(8):1299-305
[
15944719.001
]
(PMID = 18765795.001).
[ISSN]
1091-6490
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / UO1-CA 114778; United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Oncogene Proteins; 0 / Tumor Suppressor Proteins
[Other-IDs]
NLM/ PMC2533222
97.
Chetaille B:
[Mediastinal lymphomas: histopathology].
Rev Pneumol Clin
; 2010 Feb;66(1):28-31
[Fulltext service]
Get downloadable